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Mitral regurgitation (MR) is a heterogeneous disease requiring accurate 
investigations to guide optimal management. Cardiovascular magnetic resonance 
(CMR) provides reference standard biventricular assessment and highly 
reproducible MR quantification. Exercise-CMR (Ex-CMR) combines CMR with 
physiological stress; further development may allow comprehensive MR 
assessment. Therefore CMR is ideal to assist clinical decision making and assess 
research outcomes.   
Aims 
The thesis aims were to: 1) Develop and validate an Ex-CMR protocol assessing 
biventricular volumes and great vessel flow in healthy volunteers, 2) Evaluate the 
validated Ex-CMR protocol in primary MR patients, 3) Compare cardiac reverse 
remodelling and residual MR post mitral valve repair (MVr) vs replacement (MVR) 
in primary MR patients 4) Assess cardiac reverse remodelling after percutaneous 
mitral valve intervention for primary MR. 
Methods 
1) Free-breathing, respiratory navigated Compressed-SENSE short-axis cines and 
aortic/pulmonary phase contrast magnetic resonance sequences were validated 
against clinical sequences at rest and used during Ex-CMR in 12 healthy 
volunteers, 2) 10 primary MR patients underwent the validated Ex-CMR protocol, 
3) Of 83 moderate-severe primary MR patients, 72 (30 MVr, 22 MVR, 20 controls) 
completed CMR imaging at baseline and 6 months after mitral surgery or 
observation (control group). 4) Of 11 primary MR patients, 10 completed CMR 
imaging at baseline and 6-months after percutaneous intervention. 
Findings 
1) Biventricular volumes and great vessel flow assessment during continuous 
supine Ex-CMR is feasible in healthy volunteers using the Compressed-SENSE 
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Ex-CMR protocol, demonstrating good/excellent intra/inter-observer reproducibility, 
2) The validated Ex-CMR protocol is feasible in asymptomatic primary MR patients 
demonstrating effective forward left ventricular ejection fraction is augmented by 
decreases in MR, 3) MVR results in comparable cardiac reverse remodelling to 
MVr with lower residual quantitated MR and better right ventricular ejection fraction 
(compared with controls) 4) In primary MR, percutaneous valve intervention results 
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Chapter 1 Introduction 
 
1.1 Mitral Regurgitation: aetiology, investigation and 
management 
 
Mitral regurgitation (MR) is the second commonest valve lesion in Europe after 
aortic stenosis (1) and is defined as the retrograde flow of blood from the left 
ventricle into the left atrium (2). MR occurs due to the dysfunction of one (or more) 
anatomical components of the complex mitral apparatus. As such, anatomical 
understanding and appropriate imaging are required to diagnose the aetiology of 
mitral regurgitation to guide optimal management (3).     
 
1.1.1 Mitral valve anatomy 
The mitral valve anatomy consists of the mitral annulus, anterior and posterior 
valve leaflets which meet at the commissures and are attached to anterolateral and 
posteromedial papillary muscles respectively by chordae tendinae (4). MR can 
occur as the result of dysfunction in any of these anatomical components therefore 
an accurate description and thorough understanding of these components is 
important (3).   
 
1.1.1.1 Mitral annulus 
The mitral annulus is the anatomical junction between the endocardium of the left 
atrium, the valve proper and the left ventricular endocardium and myocardium (5). 
The mitral annulus is divided into anterior and posterior sections and serves as the 
insertion point for the 2 leaflets. The anterior annulus attaches to the fibrous 
trigone, however the posterior annulus is less supported with fibrous tissues, as 
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such the posterior annulus is prone to enlarge with left ventricular (LV) or left atrial 
(LA) dilatation (6). The mitral annulus forms a 3D saddle shape, during diastole the 
annulus moves with the posterior wall of the LV, creating a more circular shape for 
inflow. During systole, when the valve is closed, the annulus reverts back to an 
asymmetrical shape, with the long axis between the commissures and the short 
axis in the antero-posterior direction (5). 
 
1.1.1.2 Leaflets 
The mitral leaflet anatomy is illustrated in Figure 1-1 and has 2 leaflets; the anterior 
(AMVL) and posterior (PMVL) mitral valve leaflets. The AMVL has a semi-circular 
shape and attaches to 2/5 of the annular circumference and as per the Carpentier 
segmental leaflet classification, it is divided into 3 scallops: A1; anterior, A2, middle 
and A3 posterior (7). The PMVL is quadrangular in shape and attaches to 3/5 of 
the annular circumference and is divided into 3 scallops by 2 indentations: P1 the 
anteromedial scallop, P2 the middle scallop and P3 the posteromedial scallop (6). 
Unlike the PMVL that has indentations to demarcate the scallops, the AMVL does 
not, therefore scallops are defined by comparison to the opposing PMVL scallops. 
Identification of the differing scallops is important in describing pathology of the 
valve. In a normally functioning mitral valve the coaptation length of the leaflets is 
often several millimetres in length to ensure competency against high LV end-








Figure 1-1 Anatomy of the mitral valve leaflets  
An original illustration of a closed mitral valve (left) and short axis CMR image of an 
open mitral valve (right) depicting the mitral valve leaflets, anterolateral (AC) and 
posteromedial commissures (PC) and indentations in the posterior leaflet dividing it 
into the anteromedial scallop (P1), middle scallop (P2) and the posteromedial 
scallop (P3) thus allowing recognition of the opposing anterior (A1), middle A2 and 
posterior (A3) scallops of the anterior mitral valve leaflet.  
 
1.1.1.3 Commissures 
The commissures constitute the area where the AMVL and PMVL meet at the 
annular insertion point and are defined as the anterolateral commissure and 
posterolateral commissures. The commissures often overlap with millimetres of 
overlapping tissue between the leaflets (6).  
 
1.1.1.4 Chordae tendinae 
The chordae tendinae originate from the fibrous heads of the papillary muscles and 
are classified as either primary, if they insert into the free margins of the leaflets; 
secondary, if they insert into the body of the leaflets on the ventricular side or 
tertiary/basal if they connect the base of the PMVL and mitral annulus to the 
papillary muscle (4). The chordae tendinae control the positon of the leaflets at 
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end-systole with primary chordae preventing prolapse of the leaflet margins and 
secondary chordae preventing billowing (6). 
 
1.1.1.5 Papillary muscles 
Typically there are two papillary muscles which originate from between the apical 
and middle third of the LV free wall and provide chordae to both leaflets. The 
anterolateral papillary muscle consists of one body and head with a blood supply 
originating often from one or more left coronary branches. The posteromedial 
papillary muscle comprises two or more heads and more commonly receives blood 
supply from a single coronary artery (either the circumflex or right coronary artery 
depending on dominance) and is therefore more prone to injury in the event of 
myocardial infarction (8). As the papillary muscles attach in the LV, the LV can 
therefore directly affect MV anatomy. Changes in LV geometry can therefore result 
in poor coaptation of the MV by affecting papillary muscle position (6, 8). 
 
1.1.2 Classification of MR 
MR is commonly classified by the underlying aetiology and by using Carpentier 
functional classification. Classified by aetiology, MR is either primary/organic, a 
result of intrinsic disease of one or more valve components or can be 
secondary/functional, which is MR occurring as a result of alterations to LV or LA 
geometry (1). Carpentier’s functional classification classifies MR by the effect the 
underlying lesion(s) has upon the motion of the free margin of the leaflet in relation 
to the annular plane (3, 9). 
 
1.1.2.1 Carpentier’s functional classification 
Carpentier’s functional classification is useful to guide optimal repair techniques 
(Figure 1-2). MR can occur in the context of normal leaflet motion (Type I) 
secondary to annular dilatation, clefts, perforations; due to excessive leaflet motion 
(Type II) as a result of chordal rupture or elongation; due to restricted leaflet 
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movement predominantly in diastole (Type IIIa) for example secondary to 
rheumatic disease; or restricted leaflet motion in systole (Type IIIb) which can be 
secondary to ischaemic or non-ischaemic regional or global LV remodelling with 
leaflet tethering (3, 9). The underlying lesions and possible aetiologies attributable 




Figure 1-2 Original illustration depicting examples of Carpentier’s functional 
classification.  
Adapted from (3). Type I, normal leaflet motion; Type II, Increased leaflet motion; 







Table 1-1 Carpentier’s functional classification of mitral regurgitation, corresponding lesions and possible aetiologies  
 









Leaflet perforation  Endocarditis 
II 













Restricted leaflet motion 
(Diastole) 
 
Leaflet calcification Rheumatic heart disease 
Leaflet thickening/retraction Carcinoid heart disease 








Restricted leaflet motion 
(Systole)  
 
Left ventricular dilatation Ischaemic  cardiomyopathy 
Chordal tethering Dilated cardiomyopathy 
Papillary muscle displacement   




1.1.2.2 Classification by Aetiology: Primary MR 
Primary/Organic MR results from intrinsic disease of the mitral valve apparatus. 
Degenerative mitral valve disease is the commonest form, other causes include: 
rheumatic disease, infective endocarditis, drug-induced and MR associated with 
systemic disease (11). 
1.1.2.2.1 Degenerative MR 
Degenerative mitral valve disease constitutes a spectrum of conditions in which 
structural lesions of the mitral valve are caused by connective tissue changes 
preventing normal functioning of the valve. There are two major phenotypes of 
degenerative disease that lead to mitral valve prolapse; Barlow’s disease and 
fibroelastic deficiency (12).    
Barlow’s disease is the abnormal accumulation of mucopolysaccharides leading to 
mitral valve prolapse that occurs more commonly in younger (<60yrs), female 
patients. Pathologically there is myxoid infiltration which destroys the 3 layer leaflet 
architecture (myxomotous degeneration) and demonstrates collagen alterations on 
histological examination (12). Classically there is bi-leaflet thickening and 
redundancy (13), chordae are often thickened, fused or potentially calcified. The 
aetiology is unknown, however familial/genetic cases have been described (14). 
On echocardiography, Barlow’s disease will often show billowing of the body of one 
or more leaflets and prolapse of the margin of one or more leaflets, with the latter 
allowing MR. MR often occurs in mid to late systole, if as a result of chordal 
elongation (12).  
Fibroelastic deficiency is characterised by the loss of mechanical stability as the 
result of abnormalities in the connective tissue structure (15). There is a deficiency 
of fibroelastic tissue rather than an excess that occurs in Barlow’s disease. As a 
result leaflets are thin and the chordae are thin and friable. MR often occurs as a 
result of rupture of the thin, deficient chords and therefore, commonly is the result 
of prolapse of a single scallop (16). Often patients present with a short duration of 
symptoms that have occurred after rupture of thinned chordae. Typically on 
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echocardiography a single prolapsing scallop is seen, most commonly P2. 
Billowing is not seen, annular dilatation is less significant than in Barlow’s disease 
and annular calcification is rare. MR can occur throughout the entirety of systole, 
especially if as a result of chordal rupture (12).      
Degenerative MR can also result from a syndrome of connective tissue disease. 
Marfans syndrome, Ehlos-Danlos syndrome, osteogenesis imperfecta and 
pseudoxanthoma elasticum often create a Barlow-type mitral valve disease. 
Marfans syndrome, like Barlow’s, shows a high myxoid infiltration, but a tendency 
to more elastic fibre alterations (17).     
 
1.1.2.2.2 Rheumatic MR 
MR as a result of rheumatic heart disease is rare in the developed world, but still 
prevalent in developing counties (18). Mitral stenosis is more common in chronic 
rheumatic heart disease, however significant MR can also occur. In active/acute 
rheumatic heart disease, severe MR can occur as a result of annular dilatation, 
chordal elongation and anterior leaflet prolapse (19). Numerous studies 
demonstrate that rheumatic heart disease in young patients predominantly 
demonstrates isolated MR (often first decade of life), whilst mixed disease is more 
prominent in the second decade and isolated mitral stenosis occurs in later life (3rd 
decade onward) (20-22). It is therefore theorised that patients develop a varying 
degree of MR in the acute phase that remains and patients then develop mitral 
stenosis due to commissural fusion, leaflet thickening, and subvalvular disease. 
Similarly, it is theorised that pure mitral stenosis phenotypes of rheumatic heart 
disease potentially result from a milder carditis and thus minimal MR (23).     
1.1.2.2.3 Infective endocarditis 
Mitral valve infective endocarditis (IE) is the infection of a portion or the entirety of 
one or both mitral valve leaflets that can occur by a variety of pathogens including 
(but not limited to) bacterial, viral and fungal. Infective endocarditis is one of 
commonest causes of acute mitral regurgitation in the developed world (24). Mitral 
valve endocarditis can result in leaflet perforation, chordal rupture and even 
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complete leaflet destruction, therefore the resultant MR can vary in appearance 
and severity. Additional findings on echocardiography can include the presence of 
a vegetation, abscess or pseudoaneurysm and new dehiscence of a prosthetic 
valve, all of which are major criteria in the diagnosis of IE (25).    
 
1.1.2.3 Classification by Aetiology: Secondary MR 
In secondary MR the mitral valve is structurally normal, however its function is 
impaired as the result of either distorted LV geometry, most commonly by dilated or 
ischaemic cardiomyopathy, or as a result of annular dilatation caused by LA 
dilatation, most commonly in patients with chronic atrial fibrillation (AF) (1).  
1.1.2.3.1 Ischaemic MR 
The mitral valve is reliant on the papillary muscles for correct function (6). The 
anterolateral papillary muscle is supplied by the circumflex artery with secondary 
supply from the left anterior descending artery. The posteromedial papillary 
muscles coronary supply is variable, generally from the circumflex in a left 
dominant system and from the right coronary artery in a right dominant system 
(26). Ischaemia or infarction in the territory of the supplying arteries can therefore 
result in papillary muscle dysfunction and therefore MR of an otherwise structurally 
normal mitral valve. Often with a single coronary blood supply, the posteromedial 
papillary muscle is more susceptible to an ischaemic insult. In rare cases the 
papillary muscle can be directly affected by an infarct causing complete or partial 
papillary muscle rupture, often resulting in acute torrential MR (27). However, the 
majority of ischaemic MR cases are a result of papillary muscle dysfunction caused 
either by localised regional wall motion abnormalities adjacent to the papillary 
muscle or by papillary muscle displacement, which provokes increased tethering of 
the mitral valve leaflets (28). Ischaemic MR predominantly occurs post myocardial 
infarction (MI), one study demonstrating mild MR in 38% and moderate/severe MR 
in 12% within 30 days post infarction (29). It can occur as part of acute ischaemia 
creating intermittent ‘flash’ pulmonary oedema, however MR from intermittent 
single vessel occlusion is often mild without an underlying ventricular abnormality 
(30).     
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1.1.2.3.2 Functional MR 
Functional MR is the result of an imbalance between leaflet tethering forces and 
decreased closing forces (31). Increased leaflet tethering is principally caused by 
adverse left ventricular remodelling resulting in apical shift of the papillary muscle 
thus causing leaflet tethering and abnormal coaptation (32). Leaflet remodelling, in 
terms of increased leaflet thickness and length, is a common response, however 
insufficient leaflet remodelling, relative to the mitral annular and LV changes, is 
independently associated with the severity of functional MR (33). Decreased mitral 
valve closing forces can cause functional MR and occur due to reduced LV 
contractility and/or synchronicity (31). Functional MR is common in dilated 
cardiomyopathy (DCM) and the severity of functional MR is strongly associated 
with outcomes of heart failure (HF) patients independent of LV function (34). 
Recently, the concept of proportionate and disproportionate functional MR in 
patients with chronic HF with reduced ejection fraction has been described. 
Proportionate functional MR is where there is a linear relationship between the LV 
end-diastolic volume (LVEDV) and effective orifice area of the mitral valve. These 
patients respond well to treatments that reverse LV remodelling such as 
neurohormonal agonists and LV assist devices. Disproportionate MR occurs when 
ventricular dyssynchrony causes unequal contraction of the papillary muscles and 
thus functional MR greater than expected for the patient’s LVEDV. HF with reduced 
ejection fraction patients with disproportionate MR respond well to treatments of 
any underlying dyssynchrony (e.g. cardiac resynchronisation) and/or the mitral 
valve leaflets (e.g. transcather mitral valve repair) (35). 
1.1.2.3.3 Atrial Functional MR   
Atrial functional MR occurs as the result of isolated mitral annular dilatation and 
inadequate leaflet adaptation despite typically normal LV size and function. Atrial 
functional MR typically occurs in the context of AF and/or HF with preserved 




1.1.3 Imaging Mitral Regurgitation 
The comprehensive evaluation of any valve disease requires the accurate 
assessment of the valve morphology, severity of the specific valve lesion and 
assessment of the resultant effects on adjacent cardiac structures. For the 
assessment of MR, evaluation of valve anatomy, regurgitation severity, 
biventricular dimensions/function, left atrial size and any resultant pulmonary 
hypertension can help to guide optimal patient management (36). Transthoracic 
echocardiography (TTE) is the advised first line investigation for MR assessment 
(1, 37), with transoesophageal echocardiography (TOE) a common second line 
modality in borderline cases or where TTE image quality is poor. Cardiovascular 
magnetic resonance (CMR) has developed as a useful imaging modality to be 
used as an adjunct to echocardiography, especially in borderline cases or those 
with suboptimal echocardiographic windows (38).  
1.1.3.1 Transthoracic Echocardiography 
TTE is the recommended first line investigation in mitral regurgitation assessment, 
as a result of it being a widespread, cheap and portable modality (1, 39). The 
European Society of Cardiology (ESC) and American Heart Association (AHA) 
guidelines both advise that MR is assessed using an integrated approach. This 
involves a combined assessment using semi-quantitative, quantitative and 
qualitative measurements to determine MR severity and various views to assess 
morphology (1, 39, 40). These assessments are to define MR as mild, moderate or 
severe. Additionally, MR can be defined as mild (1+), moderate (2+), moderate-
severe (3+) and severe (4+). Table 1-2 demonstrates the severity definitions 
assessed by various parameters as per the American Society of Echocardiography 






Table 1-2 Integrated echocardiographic severity grading criteria as per the American Society of Echocardiography 
  
Mitral regurgitation severity 




No or mild leaflet 
abnormality 
Moderate leaflet abnormality 
or moderate tenting 
Severe valve lesions (primary: 
flail leaflet, ruptured papillary 
muscle, severe retraction, large 
perforation; secondary: severe 
tenting, poor leaflet coaptation) 
LV/LA size Usually normal Normal or mildly dilated Dilated 
 
Qualitative 
Colour flow jet 
area 
Small, central, narrow, 
often 
Variable 
Large central jet (>50% of LA) or 
eccentric wall-impinging jet of 
variable size 
Flow convergence 
Not visible, transient 
or small 
Intermediate in size and 
duration 
Large throughout systole 








(may be blunted in LV 
dysfunction or AF) 
Normal or systolic blunting 
Minimal to no systolic flow/ 
systolic flow reversal 
Mitral inflow A-wave dominant Variable 




2D PISA (cm2) 
<0.20 0.20-0.29 0.30-0.39 
≥0.40 
(may be lower in secondary MR 
with elliptical ROA) 
Rvol (ml) <30 30-44 45-59 ≥60 
RF (%) <30 30-39 40-49 ≥50 
Adapted from the ASE guidelines (40). Abbreviations: 2D-PISA, 2-dimensional proximal isovelocity surface area; AF, atrial 
fibrillation; CW, continuous-wave; EROA, effective regurgitant orifice area; LV, left ventricle; LA, left atria; MR, mitral 




1.1.3.1.1 Qualitative assessment 
 
Morphology assessment 
TTE is the mainstay of assessing morphology of the mitral valve to assess 
underlying aetiology via a 2D approach (41). 3D-TTE can assist in identifying the 
location of valvular lesions, but the current lower spatial and temporal resolution of 
3D-TTE is a limitation when assessing valvular structure (39). In the pre-operative 
setting, if valve morphology is unclear from TTE, then further assessment via TOE 
may be required (41).    
 
Colour flow Doppler 
Visual assessment of the colour flow Doppler jet can give pointers towards the 
severity of MR, but should rarely be used in isolation to define severity. The colour 
flow jet area can be used to exclude MR, but is poor at defining severity as it can 
vary significantly dependant on afterload conditions such as blood pressure (BP) 
and the regurgitant jet eccentricity (42). Via a visual qualitative assessment, central 
jets are prone to overestimation, due to blood pool entrainment in the LA, and 
eccentric jets to underestimation due to the Coanda effect, whereby eccentric jets 
impinge upon the LA wall and follow parallel to the line of the wall, thereby 
decreasing the visual impression of the jet severity (43). Therefore any jet other 
than a small central MR jet, should be further assessed semi-quantitatively via the 
flow convergence/ proximal isovelocity surface area (PISA) and vena contracta 
methods (38). 
      
Continuous wave Doppler intensity 
The density and contour of the MR continuous wave (CW) Doppler trace can be 
useful in determining MR severity with a holosystolic dense and triangular shaped 
CW Doppler trace consistent with severe MR and a faint or partial Doppler trace 
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more common with mild MR (40). However, the technique has several limitations. 
As with all Doppler measurements it is highly reliant upon the Doppler alignment 
with the jet. This can create inaccuracies, for example, a CW Doppler trace poorly 
aligned to an eccentric jet could appear incorrectly less severe. The descriptors for 
moderate MR rely upon the absence of either mild or severe descriptors rather 
than having specific criteria (38). Given the described limitations of qualitative 
methods of assessing MR by echocardiography quantitative and semi-quantitative 
methods have developed.  
 
1.1.3.1.2 Semi-quantitative assessment 
 
Vena contracta 
The vena contracta (VC) is the narrowest portion of regurgitant flow that occurs 
directly downstream of the regurgitant orifice. The VC width is therefore used as a 
measure of the effective regurgitant orifice and has become an important TTE 
assessment for MR as it correlates well with quantitative Doppler techniques in 
both central and eccentric jets (44). Preferably, in MR, the VC should be measured 
in the parasternal long axis view. A VC width of <0.3cm denotes mild MR and 
≥0.7cm severe MR. However, there is significant overlap of intermediate values, 
therefore the use of an additional assessment, such as PISA, is advised in such 
instances. Limitations with this method arise in the underestimation of MR severity 
when multiple jets are present and errors that can occur in jets arising from a non-
circular orifice (40). Additionally, as the measurement being made is small with 
only ≥0.7cm measurement required for severe MR, then slight errors can result in 
severity misclassification (38).  
 
Pulsed wave Doppler measures 
Pulsed wave (PW) Doppler can provide additional semi-quantitative assessment 
(Table 1-2). For example, on mitral inflow assessment by PW Doppler, an E-wave 
velocity of ≥1.2m/s is suggestive of severe MR, whilst a dominant A-wave makes 
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severe MR very unlikely. Additionally, the presence of reverse systolic flow in the 
pulmonary veins, using PW Doppler, is supportive of severe MR (40)    
 
1.1.3.1.3 Quantitative assessment 
Several Doppler techniques exist to perform quantitative assessment of MR by 
echocardiography and derive the mitral regurgitant volume (MR-Rvol), regurgitant 
fraction (MR-RF) and effective regurgitant orifice area (EROA), which are 
parameters indicative of MR severity (40). MR-Rvol is the blood volume that 
regurgitates with each heart beat (ml/beat) and a measure of absolute volume 
overload. MR-RF is the percentage of the LV stroke volume (LVSV) that 
regurgitates back through the mitral valve with each beat. EROA is the mean area 
of the systolic regurgitant orifice (38). The echocardiographic Doppler techniques 
used to calculate these parameters are: the quantitative volumetric method, the 
pulsed Doppler method and the flow convergence (PISA) method (38). 
 
Quantitative volumetric method 
The quantitative volumetric method relies on the fact that blood is incompressible 
and the conversion of mass principle. Essentially, blood leaving the left ventricle 
that does not leave through the aorta, in the context of no intracardiac shunts, must 
leave back through the mitral valve (MR-Rvol).  The aortic stroke volume (SV) and 
LVSV must be measured to quantitate MR by this method. The aortic SV is 
calculated as shown in Equation 1 from measurements of the LVOT diameter using 
2D echo and LVOT velocity time integral (VTI) using PW Doppler. LVSV is 
calculated from LVEDV and LV end-systolic volume (LVESV), measured from 2D 
echocardiographic measurements. As per Equation 2, MR-Rvol is calculated by 
minusing aortic SV from LVSV, MR-RF calculated as the percentage of LVSV 
regurgitating back through the mitral valve and EROA calculated from dividing the 
MR-Rvol by the VTI of the MR jet. The pitfall of this technique can occur if LV 
volume is underestimated, often due to foreshortening or poor acoustic windows 
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(40). This can result in underestimating the MR severity, but can be improved with 
the use of contrast or 3D-echocardiography (45, 46). 
 
Equation 1 – Calculating valve stroke volume with annular and PW Doppler 
measurements 
𝑉𝑎𝑙𝑣𝑒𝐶𝑆𝐴 = 0.785 𝑥 𝑉𝑎𝑙𝑣𝑒 𝑎𝑛𝑛𝑢𝑙𝑢𝑠 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
2 
𝑉𝑎𝑙𝑣𝑒 𝑆𝑉 = 𝑉𝑎𝑙𝑣𝑒𝐶𝑆𝐴 𝑥 𝑉𝑎𝑙𝑣𝑒𝑉𝑇𝐼  
 
 
Equation 2 – Echocardiographic MR quantification (volumetric method) 
𝐿𝑉𝑆𝑉 = 𝐿𝑉𝐸𝐷𝑉 − 𝐿𝑉𝐸𝑆𝑉  
𝑀𝑅𝑅𝑣𝑜𝑙 = 𝐿𝑉𝑆𝑉 −  𝐴𝑜𝑟𝑡𝑖𝑐𝑆𝑉  
𝑀𝑅𝑅𝐹 =  
𝑀𝑅𝑅𝑣𝑜𝑙 
𝐿𝑉𝑆𝑉
 𝑥 100%  





Pulsed Doppler method 
Similar to the quantitative volumetric method the pulsed Doppler method also 
utilises the conversion of mass principle assessing the blood flow leaving the left 
ventricle, however, it utilises mitral inflow rather than LVSV, assuming that the 
volume of blood that enters the LV (mitral inflow/ mitral stroke volume) that doesn’t 
leave via the aorta must, in the context of no intra-cardiac shunts, leak back 
through the mitral valve (MR-Rvol). The method uses PW Doppler measurements 
at the aortic and mitral annulus, as the annulus is deemed to have the least 
anatomical variability of the valve apparatus. Cross sectional areas (CSA) are 
calculated from measurements of the valve annular diameters and valve stroke 
volume measured from CSA and VTI measured by PW Doppler as shown in 
Equation 1. MR-Rvol, MR-RF and EROA can therefore be derived from the mitral 
and aortic stroke volumes and mitral regurgitation VTI as shown in  
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Equation 3 (40). A limitation of the technique can arise if inaccurate measurements 
of the valve annular diameters occur, as slight errors in measurement can lead to 
significant errors (38). 
 
Equation 3 – Echocardiographic MR quantification (Pulsed Doppler method) 




 𝑥 100% 





Flow convergence (PISA) method 
Also known as the PISA method, the method assesses flow convergence that 
occurs proximal to the regurgitant orifice to quantitate MR, as flow through the 
convergence zone is assumed to be equivalent to flow through the regurgitant 
orifice (38). Flow convergence commonly forms hemispheric shells of decreasing 
area and increasing velocity (47) that can be visualised with colour flow Doppler. 
By reducing the Nyquist limit to 15-40cm/s and imaging in the apical 4-chamber 
view (or parasternal view for AMVL prolapse) a PISA radius can be measured (38). 
The PISA radius is measured from the VC to the colour Doppler aliasing threshold 
(seen as a demarcated colour change from yellow to blue, when jet direction is 
away from the transducer); this is used to calculate the area of the flow 
convergence hemisphere, which when multiplied by the aliasing velocity can be 
used to calculate the regurgitant flow (40). Regurgitant flow can then be used in 
combination with CW Doppler measurements of the regurgitant MR jet to calculate 
the EROA and MR-Rvol (38). The calculations required to perform the flow 







Equation 4 – Echocardiographic MR Quantification (flow convergence 
method) 
𝑅𝑒𝑔𝑢𝑟𝑔𝑖𝑡𝑎𝑛𝑡 𝑓𝑙𝑜𝑤 = 2𝜋𝑟2 𝑥 𝑁𝑦𝑞𝑢𝑖𝑠𝑡 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦  




𝑀𝑅𝑅𝑣𝑜𝑙 =  𝐸𝑅𝑂𝐴 𝑥 𝑀𝑅𝑉𝑇𝐼 
 
The flow convergence/PISA method makes several geometric assumptions which 
can result in errors in MR quantification if not true and therefore has some 
limitations. The method assumes a hemispheric flow convergence into a circular 
orifice that occurs at a planar angle. However, this is not always the case, 
especially in secondary MR where the regurgitant orifice can be elongated by LV 
dilatation and therefore be crescent shaped, in which the method can result in 
underestimation of quantitated MR (40). Additionally, given the PISA measurement 
calculates an instant peak flow rate it may not equal the average orifice area 
throughout the entirety of the regurgitation. To best represent an average EROA 
the PISA measurement should be performed at the time of peak regurgitant 
velocity. However, as MR jets can be dynamic, the method can result in 
underestimation in bimodal regurgitant flow, such as can occur in secondary MR or 
overestimation with late-systolic regurgitant flow, which can occur in primary MR 
(40). 
 
1.1.3.2 Transoesophageal Echocardiography (TOE) 
TOE has many benefits for assessing MR and is useful when TTE has been 
technically difficult or inconclusive, for planning MV surgery or percutaneous 
procedures and for intra-operative use. In general TOE is more accurate at 
defining MV pathology (40) and therefore useful pre-operatively to determine the 
likelihood of a successful repair. This is an important assessment given the 
variable outcomes that the underlying aetiology has on the durability/success of 
MV repair (48) and can be a determinant factor in advising early surgical 
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intervention as per international guidelines (1, 39). TOE uses many of the same 
methods to quantify MR as TTE, but the superior image quality likely makes 
measurements more accurate (40). However, due to its invasive nature, it is not 
ideal for sequential assessment (41) and given sedation is often required or 
general anaesthetic during intra-operative TOE; this can lower blood pressure, 
therefore reducing afterload, which can reduce MR severity (49).    
 
1.1.3.3 Cardiovascular Magnetic Resonance 
CMR is able to measure MR severity and the resultant effect on biventricular 
volumetrics and function accurately. Using balanced steady state free precision 
(bSSFP) sequences, blood pool has natural contrast to myocardium without need 
for intravenous contrast (50) and CMR allows imaging in any plane, without 
restriction due to body habitus and does not use ionizing radiation. As such, CMR 
has become the reference standard assessment for biventricular volume 
assessment (51, 52). Additionally, CMR is useful to assess mitral valve 
morphology in cases where echocardiography has been suboptimal (41). In 
addition to standard 2 and 4-chamber cine imaging, sequences can be planned to 
transect the mitral valve at the coaptation line of individual scallops to accurately 
identify the site of pathology (53). However, the lower spatial and temporal 
resolution of CMR, compared with echocardiography, can result in suboptimal 
assessment of subvalvular apparatus (e.g. ruptured chordae/flail leaflet) or 
vegetations (54).  
CMR can be used to perform qualitative (visual), semi-quantitative and quantitative 
assessment of MR severity. Qualitative assessment involves visualising the MR 
regurgitant jet in the left atrium on cine imaging, which is often visible due to the 
high velocity jet causing signal loss/spin dephasing (55). However, caution must be 
used with visual assessment as jet appearance can be significantly impacted by 
CMR parameters such as sequences used and echo time (56), therefore 
quantitative methods are preferred. Carefully planned cine imaging allows 
planimetry of the anatomical regurgitant orifice area, but it can be difficult to 
accurately align imaging planes and can resultantly be time consuming (38, 57). 
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CMR benefits from accurate quantification of MR, which can be done via indirect or 
direct methods, which shall be presented including their pros/cons.  
 
1.1.3.3.1 Direct MR quantification by CMR     
Direct MR quantification by CMR, involves CMR imaging of the MR jet using Phase 
contrast magnetic resonance (PCMR) sequences planned in line to the MR jet to 
quantitate regurgitant volume. Maximal velocity encoding must be set high to avoid 
aliasing. The use of only one measurement (rather than a combination of two with 
indirect MR quantification methods) is an advantage of the method. However as 
the PCMR imaging must be planned in line to the MR jet, eccentric jets or multiple 
jets can result in inaccuracies by this method and dynamic motion of the mitral 
annulus during ventricular systole can make the PCMR sequences technically 
difficult to plan and apply (58).     
 
1.1.3.3.2 Indirect MR quantification by CMR 
Indirect MR quantification involves the combination of two separate measurements 
to quantitate MR. The main methods of indirect MR quantification by CMR are:  
1. Using LV and aortic stroke volumes (LVSV-AoSV method) 
2. Ventricular stroke volume comparison (LVSV-RVSV method) 
3. Using mitral inflow and aortic forward flow (Mitral annular method) 
 
LV and aortic stroke volume method (LVSV-AoSV method) 
The LVSV-AoSV method works via the conversion of mass principle and assumes 
that no intra-cardiac shunts are present involving the left ventricle. The method 
assumes that blood pumped by the left ventricle, that doesn’t leave through the 
aorta, must leak back through the mitral valve (MR-Rvol). LVSV are derived from 
short axis cine imaging as the calculation of LVEDV-LVESV. Aortic SV are 
acquired from aortic PCMR imaging. MR-Rvol is calculated as LVSV-aortic SV ( 




Equation 5 – CMR indirect MR quanfication (LVSV-AoSV method)  




Figure 1-3 CMR MR quantification by the LV-Aortic stroke volume method 
Short axis cine stack is contoured from base to apex at end-diastole (A) and end-
systole (B) to provide left ventricular end-diastolic and end-systolic volumes 
respectively. The ascending aorta is contoured in every phase on the aortic phase 
contrast magnetic resonance flow imaging (C) to provide the aortic flow loop (D) 
and total aortic forward flow volume. MR regurgitant volume and fraction are 






The LVSV-AoSV indirect CMR method of MR quantification is often preferred due 
to numerous advantages. The method does not rely on geometric assumptions, 
unlike echocardiographic methods (38, 59, 60), and is not adversely affected by 
the number or eccentricity of the MR jet or the presence of aortic, pulmonary or 
tricuspid regurgitation unlike some CMR quantification methods (58). The method 
has demonstrated superior diagnostic accuracy over the CMR mitral annular 
method in detecting significant MR in mitral valve prolapse (61). Additionally the 
method has demonstrated superiority over TTE with superior reproducibility (59, 
60, 62, 63) and prognostic assessment of MR (63, 64). However, the method relies 
on accurate LV volume analysis, for which there are two accepted contouring 
methods which differ on whether LV trabeculation and papillary muscles are 
included as part of the blood pool or not. Including LV trabeculation and papillary 
muscles as part of the blood pool results in better reproducibility but results in 
higher LVSV and thus higher quantitated MR-Rvol, this must be taken into account 
when interpreting results and performing subsequent CMR to ensure the same 
method is used (58).  
 
Ventricular stroke volume comparison method (LVSV-RVSV method) 
In the context of no intracardiac shunts or valve disease the stroke volumes from 
the left and right ventricle should be equivalent. Therefore using the conversion of 
mass principle and in the context of no intracardiac shunts or other valve disease 
then LVSV and right ventricular stroke volume (RVSV) can be used to calculate 
MR-Rvol by Equation 6 (58). 
 
Equation 6 – CMR indirect MR quantification by ventricular stroke volume 
method (LVSV-RVSV method) 
𝑀𝑅𝑅𝑣𝑜𝑙 = 𝐿𝑉𝑆𝑉 − 𝑅𝑉𝑆𝑉 
 
The advantage of the ventricular stroke volume method is it can be calculated from 
short axis cine imaging without the need for PCMR sequences and therefore the 
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acquisition is time efficient. However, significant disadvantages make it less utilised 
and robust than the LVSV-AoSV method. The method is inaccurate in the context 
of intra-cardiac shunts or other valve disease. The significant prevalence of 
tricuspid regurgitation in the MR population can therefore limit its application (65, 
66). Additionally, as described above in presentation of the LVSV-AoSV method, 
the same caveats regarding methods of LVSV calculation apply; indeed, the issue 
is escalated in additionally requiring accurate contouring of right ventricular (RV) 
volumes, which often demonstrate greater variability than LV volumes (58). 
 
Mitral inflow and aortic outflow method (Mitral annular method) 
Also known as the mitral annular flow method, PCMR sequences are used to 
calculate mitral inflow and aortic stroke volume to derive MR-Rvol, as shown in 
Equation 7. Mitral inflow is assessed with PCMR imaging planned at the midpoint 
of the mitral leaflets whilst open in diastole. The mitral inflow (diastolic component) 
is measured and the mitral regurgitation (systolic component) is ignored (58). 
Aortic stroke volume is derived from PCMR imaging as previously described.  
 
Equation 7 CMR indirect MR quantification (mitral annular method) 
𝑀𝑅𝑅𝑣𝑜𝑙 = 𝑀𝑖𝑡𝑟𝑎𝑙 𝑖𝑛𝑓𝑙𝑜𝑤 − 𝐴𝑜𝑟𝑡𝑖𝑐𝑆𝑉 
 
The mitral annular method suffers from a similar issue as the direct method of MR 
quantification by CMR, as regards difficulties that can arise in accurately planning 
and performing PCMR imaging on a mitral annulus that is often highly mobile 







Optimal CMR quantification method 
As described, the direct and indirect CMR methods to quantify MR have varying 
pros and cons. Studies comparing reproducibility between methods provide 
conflicting results. The LVSV-AoSV method has demonstrated superior intra/inter-
observer reproducibility to the LVSV-RVSV method in several studies (60, 67) and 
over the mitral annular method in a study by Le Goffic et al (61). Conversely, Polte 
et al studied reproducibility of all indirect methods finding that the mitral annular 
method had superior inter-observer reproducibility, followed by the LVSV-AoSV 
method with the LVSV-RVSV method the worst with Coefficient of Variance (CV) of 
10%, 14% and 18% respectively. Intra-observer variability was similar between the 
LVSV-AoSV and mitral annular methods, but worse with the LVSV-RVSV method 
with CV of 5%, 5% and 7% respectively. The results were driven by greater inter-
observer variability on contouring the ventricles than PCMR flow imaging (68). 
Therefore no technique has emerged as clearly the most reproducible (58). 
However, more studies demonstrate the LVSV-AoSV method as the most 
reproducible (60, 61, 67) and it has been used in multiple studies to show superior 
reproducibility (59, 60, 62, 63) and prognostication compared to TTE (63, 64) and 
as such is the recommended MR quantification technique by the Society of 
Cardiovascular Magnetic Resonance (SCMR) (69).  
 
1.1.3.3.3 CMR vs echocardiography in the assessment of MR 
Several studies have compared CMR and echocardiographic assessment of MR 
severity, with the majority demonstrating moderate agreement between the 
modalities (59, 62, 63, 70, 71). The majority of comparative studies demonstrate 
superior reproducibility of MR quantification by CMR assessment (59, 60, 62, 63).  
In numerous studies, TTE overestimates MR severity compared to CMR (59, 63, 
64, 71-73), of which several studies demonstrate superior prognostic assessment 
with CMR, suggesting it is more accurate (63, 64).  
Myerson et al performed baseline CMR in 109 asymptomatic patients with 
moderate or severe primary MR on TTE and observed for up to 8 years (mean, 
2.5±1.9 years) for symptom development or other indications for surgery. TTE 
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assessment was performed by integrated qualitative and quantitative assessment 
including assessment of EROA by the PISA method when feasible. CMR 
quantification of MR was by the LVSV-AoSV method. The study suggested a cut-
off of MR-Rvol of >55ml or MR-RF of >40% as predicting those that progressed to 
symptoms or other indications for surgery within 5 years. 91% of patients remained 
free from surgery with an MR-Rvol ≤ 55ml reducing to 21% in those with MR-Rvol 
> 55ml (sensitivity 72%, specificity 87%). At 5 years patients with a MR-RF of 
≤40%, 41-50% and >50% demonstrated surgical free survival in 89%, 59% and 
16% respectively. In comparison, TTE EROA was less discriminatory; an EROA 
<0.4 cm2 predicted surgery free survival in 86% decreasing to 64% with EROA ≥ 
0.40cm2 (64). 
Penicka et al performed baseline CMR in 258 asymptomatic patients with at least 
moderate primary MR and preserved left ventricular ejection fraction (LVEF) 
(>60%) on TTE. Patients underwent combined TTE and TOE assessment with a 
CMR performed within 24hours. MR was assessed by TTE and TOE using an 
integrative approach and MR-Rvol was determined by an average value from PISA 
derived and Doppler volumetric methods. MR was quantified by CMR using the 
LVSV-AoSV method with aortic PCMR acquisition 2-3cm above the aortic valve. 
Severity of MR was classified as moderate or severe using ASE definitions (Table 
1-2). Mean CMR derived MR-Rvol was 17ml smaller than echocardiography 
derived. 76% of grading into either moderate or severe MR was concordant 
between CMR and echocardiography. In the discordant cases, the majority 
occurred in patients with multiple or late systolic jets, which showed poor 
concordance with CMR derived MR-Rvol (К=0.2), whilst patients with holosystolic 
central jets showed very good concordance (К=0.9) which decreased to moderate 
concordance in those with eccentric jets (К=0.53). CMR derived MR-Rvol 
demonstrated the best area under the curve (AUC) in determining mortality (0.72) 
and in combination with need for mitral surgery (0.83). The study suggested a 
CMR quantitated MR-Rvol cut off of ≥50ml best able to predict adverse outcomes 




LV remodelling post-surgery for primary MR correlates more strongly with MR 
quantitated by CMR rather than TTE. Uretsky et al prospectively observed 103 
patients with primary MR on TTE and performed baseline CMR. 38 patients 
subsequently underwent mitral surgery of which 26 had repeat CMR after 5-7 
months. MR was assessed by integrative approach as per ASE guidelines with MR 
quantitated by the PISA method. MR was quantitated by CMR using the LVSV-
AoSV method. MR severity correlation between CMR and TTE was modest overall 
(r=0.6), but poor in the cohort sent for surgery (r=0.4). Post-surgical LV remodelling 
correlated strongly with MR severity assessed by CMR (r=0.85), however there 
was no correlation between LV remodelling and echo defined MR severity (r=0.32). 
Significantly, only 32% of patients referred for surgery with severe MR, based upon 
echocardiographic assessment, had severe MR on CMR assessment (59). This 
finding was replicated in a recently published study in which 63 patients underwent 
CMR pre and post mitral valve ‘correction’. LV reverse remodelling (change in 
LVEDV) correlated with baseline MR-Rvol (r=0.78) when assessed by CMR, 
however only 37% of patients had severe MR on CMR assessment, despite 
significant MR on TTE; indeed 13 patients (21%) had only mild MR on CMR. This 
led the authors to advise that CMR assessment of MR severity should be strongly 
considered in all patients prior to mitral valve correction/surgery (72).  
Therefore, current studies comparing CMR vs echocardiographic assessment of 
MR suggest CMR MR quantification is more accurate (59, 72), more reproducible 
(59, 60, 62, 63), has superior prognostic value (63, 64) and that TTE may 
overestimate MR severity (59, 72). However, a few caveats exist with direct 
comparisons between TTE and CMR. CMR MR quantification using PCMR can be 
prone to background flow offset errors, which can make flow measurements 
inaccurate (74). This can be reduced by scanning the region of interest at the iso-
centre of the MRI scanner, as this minimizes inhomogeneities in the magnetic field 
(75). Studies solely utilising the PISA method to quantitate MR by TTE may do TTE 
a disservice, as although it is the most utilised method (1), it has significant 
disadvantages in the context of eccentric jets, multiple jets or jets with a non-
circular flow (76, 77). However, as demonstrated by Penicka et al, even when 
using combined TTE/TOE assessment and averaging two separate 
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echocardiographic MR quantification methods, CMR demonstrated superior 
prognostic ability (63). Additionally, current CMR vs echocardiography comparative 
prognostic studies did not utilise 3D-TTE, which has shown superior accuracy of 
MR quantification to 2D-TTE (76). Therefore, studies assessing prognostic 
outcomes of 3D-TTE vs CMR defined MR severity are warranted, but current 
evidence places CMR MR quantification as the reference standard. 
  
1.1.3.3.4 CMR grading of MR severity 
The severity grading thresholds of MR by CMR assessment are less clearly 
defined than echocardiography, with differing recommendations from individual 
research studies and international guidelines. Gelfand et al advises the severity 
grading as demonstrated in  
 
Table 1-3, based upon a CMR study performed in 83 patients with MR, in which 
MR was quantified by the LVSV-AoSV method and thresholds developed to 
optimise correlation with severity on TTE (70). In 2017, the American Society of 
Echocardiography (ASE) and Society of Cardiovascular Magnetic Resonance 
(SCMR) collaboratively advised that due to the paucity of data, CMR should use 
the same severity thresholds of MR-Rvol/MR-RF as echocardiography as 
previously shown in Table 1-2 (40). However as described in chapter 1.1.3.3.3, 
TTE can overestimate MR compared with CMR and data from observational 
studies suggest lower CMR quantified MR thresholds in predicting adverse 
outcomes, with Myerson et al suggesting an MR-Rvol of 55ml and Penicka et al 
suggesting 50ml as a threshold of prognostic significance (63, 64). Therefore it is 
likely that CMR MR severity thresholds are lower than TTE. Larger studies 
spanning the range of MR severity guided by prognostic outcomes are required to 
better define CMR MR severity thresholds. However, a recently published 
consensus statement from international experts advises altered severity cut offs ( 
Table 1-4), based upon all available up to date evidence from comparative 





Table 1-3 CMR defined MR severities as per Gelfand et al 
MR Severity Regurgitant 
fraction 
1+ Mild  ≤ 15%  
2+ Moderate  16 – 25%  
3+ Moderate-severe  26 – 48%  
4+ Severe  >48%  








Mild Moderate Severe Very severe 









MR-Rvol >60ml N/A 
Adapted from (75). Abbreviations: MR, Mitral regurgitation, Rvol, regurgitant 




1.1.3.4 Exercise imaging in MR 
The timing of intervention in primary severe MR is guided by the presence of 
symptoms or adverse imaging biomarkers in asymptomatic patients (1, 39). 
However, symptoms are subjective and onset in chronic valve disease can be 
indolent, with patients often unaware of subtle changes in exercise tolerance (78). 
MR patients most often initially develop exertional symptoms prior to the disease 
deteriorating and developing resting symptoms. As MR patients naturally have a 
varied range of physical fitness with varied regular exertion levels, the timing of 
symptom development can differ between patients. Therefore, exercise imaging 
can be useful to objectively assess a patient’s symptom status, individual functional 
capacity and determine imaging biomarkers that may benefit from early surgical 
intervention (1, 39, 78). As such, exercise imaging is typically used in 2 situations 
in MR: symptomatic patients with non-severe MR on resting imaging to assess if 
exercise regrades severity and in asymptomatic severe MR patients to detect 
symptoms. (79). Unfortunately dobutamine, which is commonly used in stress 
echocardiography, has afterload-reducing properties which can reduce the degree 
of MR, therefore its use is advised against in the assessment of primary MR (79, 
80). Indeed, dobutamine stress and physical stress can result in differing 
haemodynamic responses in cardiac disease (81). Additionally, compared with 
exercise, pharmacological stress does not as accurately replicate the 
neurohormonal response, assess a patient’s symptoms or functional state and can 
have more adverse events (80, 82). As such exercise imaging is the preferred first 
line stress assessment for MR (79, 83, 84). The following subchapters will discuss 
exercise imaging of MR including the currently identified imaging biomarkers that 
can assist in decision making in MR patients.  
 
1.1.3.4.1 Exercise Echocardiography 
Exercise echocardiography can provide additional prognostic information to resting 
TTE, with the absence of LV contractile reserve (LVCR) (<4% increase in LVEF or 
<2% increase in global longitudinal strain during exercise echocardiography) (85, 
86), limited RV contractile recruitment (87), increase in MR severity (≥1 grade)(88) 
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or dynamic pulmonary hypertension (defined as an exercise rise in systolic 
pulmonary artery pressure (SPAP) to ≥60mmHg) (89, 90) during exercise 
echocardiography being predictors of poor prognosis.  
Patients with poor LVCR more commonly develop LV dysfunction on observational 
follow-up (86)  with worse post-operative LV function than those with preserved 
LVCR (85). Initial work by Leung et al demonstrated that latent LV dysfunction in 
MR patients could be indicated by a poor LVCR, demonstrated by an increase in 
LVEF of less than 4% on exercise echocardiography and this was associated with 
worse LVEF post-operatively (91). Subsequent work by Lee et al performed 
exercise echocardiography in 71 patients with isolated degenerative MR. During a 
mean follow up of 3±1years, 85% patients without LVCR progressed to mitral 
surgery compared with 42% with LVCR. The absence of LCVR was an 
independent predictor of poorer follow up LVEF and persistent post-operative LV 
dysfunction (85). More recent work by Magne et al suggested that LVCR was 
better assessed by changes in myocardial longitudinal function by assessing global 
longitudinal strain rather than changes in LVEF, demonstrating the absence of 
LVCR was independently associated with a 2-fold increase risk in cardiac events 
(86).      
As regards exercise RV function, Kusunose et al investigated 196 patients with 
isolated moderate-severe MR, demonstrating that exercise tricuspid annular plane 
systolic excursion <19mm (TAPSE) was associated with valve-surgery free survival 
independent of resting LV/RV strain and exercise SPAP, suggesting that exercise 
RV dysfunction provides important incremental prognostic value in managing 
asymptomatic MR (87).           
MR severity can change during exercise, as demonstrated in exercise 
echocardiography. Magne et al performed exercise echocardiography in 61 
asymptomatic patients with moderate/severe degenerative MR to quantify changes 
in MR using the PISA method. 32% of patients had a marked increase in EROA 
(≥10mm2) and MR-Rvol (>15ml). Patients with a rise in MR-Rvol >15ml had a 
worse symptom free survival than those with no significant rise or a decrease in 
MR-Rvol (88). However, in the ‘real-world’ setting, MR quantification during 
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exercise echocardiography can be difficult and not achievable in all patients. 
Coisne et al investigated 71 unselected patients with at least moderate MR 
(primary & secondary MR) and minimal or no symptoms. They found that 
quantitating EROA via the PISA method was feasible in 76% at rest in the supine 
position required for cycling; this decreased to 55% at peak exercise and was 
lower in patients with mitral valve prolapse at 43%. This was in contrast to the 
ability to assess LVCR and SPAP at peak exercise in 71% and 83% of patients 
respectively, therefore suggesting LVCR and SPAP assessment may be more 
reliable in the real-world setting (92). 
Exercise induced pulmonary hypertension (ExPHT), identified on exercise 
echocardiography as developing exercise SPAP ≥60mmHg is associated with 
poorer observational and post-operative outcomes. Suzuki et al performed stress 
echocardiography on 49 patients with at least moderate MR on resting TTE, 
demonstrating worse 2-year symptom free survival in those with ExPHT (90). 
Additionally, Magne et al demonstrated worse post-operative outcomes in patients 
with ExPHT in a study involving 102 patients with primary MR and no/mild 
symptoms. All patients had baseline exercise echocardiography and underwent 
mitral valve surgery; those with ExPHT had significantly more cardiac events 
(postoperative cardiovascular-related death or cardiovascular-related 
hospitalisation, stroke or AF) than those without ExPHT at 39% vs 12% 
respectively.  
As a result of such studies, international guidelines advise that exercise 
echocardiography is useful to risk stratify MR patients and also for patients where 
there is a discrepancy between MR severity and symptoms at rest (1, 37).   
 
1.1.3.4.1 Exercise-CMR 
Exercise cardiovascular magnetic resonance (Ex-CMR) has developed over the 
past three decades to combine the superior image quality of CMR with the first line 
advised method of stress by physical exercise. Ex-CMR as a modality is discussed 
in depth in Chapter 1.2. Given CMRs highly reproducible MR quantification and 
reference standard biventricular assessment, the possibility to assess bi-ventricular 
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function and quantitate MR during Ex-CMR is appealing. Only one Ex-CMR study 
has been performed in patients with MR by Chew et al, who demonstrated the 
feasibility of assessing biventricular volume assessment in 5 severe degenerative 
MR patients. However, MR quantification during exercise was not performed (93). 
Therefore further research is needed to develop a CMR protocol feasible to assess 
biventricular function and quantitate MR during Ex-CMR to take full advantage of 
the capabilities of CMR in this patient cohort. 
 
1.1.3.5 Comparing imaging modalities in MR assessment 
Multiple imaging modalities can be utilised to assess MR patients, each with 
intrinsic benefits and weakness, these are summarised in Table 1-5. 
TTE is the advised first line investigation in MR assessment (1, 39). This is a result 
of significant benefits including widespread availability and cheap cost, portability 
and the ability to instantly visualise MR at the time of imaging. Both TTE/TOE 
share significant weaknesses including requiring the use of geometric assumptions 
in the assessment of MR, inaccuracies in the presence of eccentric or multiple jets 
and Doppler alignment issues that can reduce the accuracy of MR assessment 
(38). As a result an integrated assessment using qualitative, semi-quantitative and 
quantitative measures are advised as one single measurement is not sufficiently 
robust in the assessment of MR (40). TOE overcomes the limitation of acoustic 
windows that can reduce the accuracy of TTE assessments, but does not always 
guarantee good image quality. However, TOE generally offers the most accurate 
assessment of valve morphology of all imaging modalities and pathology 
localisation can be improved with the simultaneous use of real-time 3D-
echocardiography (16). The invasive nature of TOE results in it not being ideal for 
serial assessment (41) therefore often reserved for borderline cases or 
pre/intraoperative use. CMR has the benefit of allowing imaging of the valve in any 
plane, but the decreased temporal resolution compared to echo can limit its use in 
morphological assessment (54). The main strength of CMR is the accurate 
quantification of MR, which appears to offer superior reproducibility (59, 60, 62, 63) 
and prognostic information to TTE (63, 64). This paired with it being the reference 
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standard for biventricular assessment (51, 52) results in it being a useful imaging 
modality for assessing MR. However, CMR is not widely available, is comparatively 
expensive, contraindicated in those with non-compliant implants, poorly tolerate by 
claustrophobic patients, does not allow an accurate instant assessment of MR 
severity at the time of imaging due to significant caveats with visual assessment 
and as discussed does not currently have universally accepted modality specific 
severity definitions (38). Dobutamine stress echocardiography, although in 
widespread use in CAD assessment, is advised against in MR assessment due its 
positive inotropic effect reducing MR severity (79). As such exercise 
echocardiography is preferred as a stress modality in MR. Assessment of changes 
in biventricular function, MR and PASP during exercise TTE provides additional 
prognostic information (85-90), but the modality suffers from the same weaknesses 
described above in resting TTE (38). In addition the majority of exercise-TTE relies 
on post stress imaging and therefore resulting in deceases in peak HR during 
imaging. In contrast Ex-CMR allows assessment of biventricular function during 
continuous exercise (93). However, further research is needed to allow 
quantification of MR during Ex-CMR and Ex-CMR as a modality is mostly a 
research tool, with minimal research performed in valve disease and therefore 




      Table 1-5 Strengths/weakness of imaging modalities in MR assessment 
Imaging modality Strengths Weaknesses 
Transthoracic 
Echocardiography 
Widespread availability Acoustic windows 
Low cost Geometric assumptions 
Non-invasive Suboptimal Reproducibility 
Instant visualisation of MR Requires integrated assessment 
  Doppler alignment issues 




Instant visualisation of MR Invasive 




Reference standard assessment 
of valve anatomy/morphology 
Requires integrated assessment 
Doppler alignment issues 





Image in any plane  Expensive & not widely available 
Excellent image quality Claustrophobia 




Assessment of LV viability/scar Lower temporal resolution than 
echo 
Reference standard Biventricular 
volumes/function 
Limited evidence basis for defined 
severity cut offs 
Exercise 
Echocardiography* 
Additional prognostic information 
from assessment of LV/RV 
function, MR and PASP changes 
with exercise 
Not all patients can tolerate 
exercise 
 
Often reliant on post stress 
imaging 
Allows assessment of 
haemodynamic & functional 
response to exercise 
  





Technically easier to use than 
exercise echocardiography 
Inotropic effects of Dobutamine 
can reduce afterload and thus MR 
and is therefore advised against 
in MR assessment 






Potential to utilise benefits of 
CMR during exercise 
Research tool - not in clinical use 
in valve patients 
Imaging feasible during 
continuous exercise 
  
Minimal research in MR patients 
Not all patients can tolerate 
exercise 
 
* In addition to the strengths/weakness of transthoracic echocardiography listed above. ** In 
addition to the strengths/weaknesses of CMR listed above. 
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1.1.4 Management of Primary MR 
 
Primary MR is often a progressive disease. MR causes left ventricular and atrial 
enlargement, which in turn causes increase stress and damage to the mitral 
apparatus, such as annular dilatation which leads to increased EROA, coining the 
phrase ‘MR begets MR’ (39). As a result, MR-Rvol can progress from 5-7ml/year in 
primary MR (94). Severe primary MR patients have an excess mortality rate of 
6.3% per year (11). There are no known medical treatments that alter the natural 
progression of severe primary MR, symptomatic patients may gain relief of 
symptoms by diuretics and afterload reduction but ultimately the only current 
treatment is surgical or percutaneous intervention (11).  
The 2017 ESC guidelines (1) and the 2017 American Heart Association/American 
College of Cardiology (AHA/ACC) guidelines (39) provide similar guidance, as 
regards advising surgical intervention, with a few notable differences. Both 
guidelines advise mitral valve repair (MVr) as a Class I indication, when feasible 
above mitral valve replacement (MVR), if a successful and durable repair can be 
accomplished. Both advise surgical intervention as a Class I indication in 
symptomatic severe primary MR with LVEF>30%. However, for symptomatic 
primary MR patients with LVEF<30%, the AHA/ACC advise surgery as class IIb 
indication and the ESC advise medical therapy in the first instance. As per ESC 
guidance, if symptoms are refractory to medical treatment and the patient has low 
comorbidity then surgery is advised with repair if high likelihood of successful 
repair (class IIa) or replacement if not (class IIb). In the event surgery is deemed 
too high risk then extended medical therapy/percutaneous end-end repair is 
advised (class IIb) (1).  
In asymptomatic patients, the guidelines differ slightly. Both guidelines advise 
surgical intervention as Class I indication where there is evidence of LV systolic 
dysfunction (LVEF<60%) or LV dilatation, defined as LV end-systolic dimension 
(LVESD) ≥45mm (ESC 2017 guidelines) or ≥40mm (AHA/ACC guidelines). The 
AHA/ACC do not extend this guidance to those with LVEF<30%. In asymptomatic 
patients with preserved LV size/function the ESC 2017 guidelines advise surgery 
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should be offered if there is new AF, PASP >50mmHg or there is a high chance of 
a durable repair with low surgical risk and the patient has LVESD>40mm and 1 of 
the following: flail leaflet or LA volume ≥60ml/m2 in sinus rhythm (class IIa) (1). The 
AHA/ACC guidelines broadly provide the same guidance in asymptomatic patients 
with preserved LV size/function but are more liberal also advising surgery is 
reasonable if there is a progressive decline in LVEF or increase in LVESD (class 
IIa) (39). 
 
1.1.4.1 MV repair 
Mitral annuloplasty for primary MR was initially developed in the 1960s, however 
original techniques corrected insufficiency by narrowing the annulus. This resulted 
in 3 issues: 1, the correction resulted in altered anatomy of the valve leading to a 
degree of stenosis; 2, the localized plications used, focused tensile strength in a 
few critical points on the annulus, leading to a risk of sutures tearing out and 3, the 
original annuloplasty was still at risk of recurrent annular dilatation and therefore 
recurrent MR. Carpentier et al developed a surgical annuloplasty technique with 
the use of an annuloplasty frame/ring to overcome the described issues (95). Since 
this important development, MVr has progressed to become the recommended 
surgical technique to treat primary mitral regurgitation, when durable repair is likely 
(1, 39). Numerous surgical techniques have been developed, centring on the aims 
to restore/preserve correct leaflet mobility, to ensure appropriate leaflet coaptation 
and remodel and stabilise the annulus (96). Currently, successful repair is deemed 
likely, if performed by an experienced surgeon, in the vast majority of primary MR 
cases. However, the likelihood of a successful and durable repair is dependent on 
the underlying aetiology and the experience of the surgeon. Successful repairs are 
most likely in isolated posterior leaflet prolapse, with experienced centres boasting 
a near 100% repair rate with low early mortality (<1%) and reoperation rates (97). 
Experienced centres state successful repair is probable, with the use of varying 
surgical techniques, in >98% with PMVL prolapse, in >95% with AMVL prolapse, 
annular dilatation or commissural leaflet prolapse and 70-80% in those with leaflet 
restriction/small leaflets or annular calcification (96). However, early mortality, 
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recurrent MR and re-operation rates are often greater in those with AMVL or bi-
leaflet prolapse with studies reporting varying early mortality rates.  Some boast 
low early mortality (<1%) (98, 99), others, such as Castillo et al demonstrated 4.8% 
early mortality in AMVL prolapse patients, however, the study results may be 
biased by low numbers (n=48) in this group (97). Seeburger et al also 
demonstrated greater early mortality risk in AMVL/Bi-leaflet prolapse patients. The 
study was performed in a high-volume expert centre, using minimally invasive 
techniques, the 30-day mortality was 1.5%, 2.6% and 2.2% for PMVL, AMVL and 
bi-leaflet prolapse respectively (100). Recurrence of MR and reoperation rates are 
similarly higher in those who undergo MVr for AMVL/bi-leaflet prolapse (99, 101). 
The most significant impact on the success of mitral valve repair is surgeon 
experience, with a clear link between surgeon experience and outcome (102, 103). 
Therefore, reference centres of excellence for mitral valve repair have been 
developed. These centres must perform >50 MVr operations per year with >25 per 
specialist surgeon per year. Repair success rates must be >95% and operative 
mortality <1% (11). In addition to reference centres being created to improve 
outcomes, the use of minimally invasive surgery and robotic surgery has also 
developed to improve outcomes. Minimally invasive surgery has longer 
cardiopulmonary bypass, crossclamp and overall procedure times than 
conventional mitral surgery via sternotomy, however despite this it can offer 
equivalent success of repair, stroke rates and early mortality rates. Importantly, 
minimally invasive surgery results in reduced intensive care, hospital admission 
and recovery time as well as boasting preferred cosmetic results (104, 105).  
 
1.1.4.2 MV replacement 
As per current guidelines the contemporary mitral valve replacement is reserved 
for those unlikely to achieve a successful durable repair (1, 39), causing a 
significant reduction in MVR being performed in the developed world. MVR is 
utilised more often in patients with previous cardiac surgery, advanced age, LV 
dysfunction (LVEF<45%), mitral calcification, retraction or tethering of the PMVL or 
38 
  
in AMVL prolapse (with ≥2 segments affected)/Barlow’s disease and used by 
surgeons with less experience (96).   
Mitral valve replacement can be performed using either mechanical or tissue 
prosthesis. Mechanical prosthesis are robust with an extremely low possibility of 
structural failure, but necessitate life-long anticoagulation, with which come 
associated bleeding risks (106). Prosthetic valve thrombosis is more common in 
mechanical valves, most obviously in cases of suboptimal anticoagulation and 
mechanical valves are not immune to developing valve dysfunction from annular 
pannus formation, which may necessitate re-operation if significant (107). Despite 
this, mechanical valves are more robust than biological prosthetics with a lower 
need for re-operation (108). A bio-prosthetic valve is indicated if there is significant 
bleeding risk from anticoagulation, prior mechanical valve thrombosis despite 
adequate anticoagulation, in young women considering pregnancy or patients with 
life expectancy presumed to be less than presumed durability of tissue valve (1, 
109). Historic randomised controlled trials comparing mechanical and tissue 
prosthesis’ concur that mechanical valves result in an increased risk of bleeding 
and stroke, whilst tissue valves suffer from structural valve deterioration resulting in 
increased reoperations, with no overall significant difference in long-term mortality 
(110, 111). This finding remains true in modern studies (108). The age cut off at 
which to start offering tissue replacement valves is controversial, but decreasing 
with the advent of improved bio-prosthetics. At present, the ESC guidelines advise 
considering the use of mechanical mitral valves in patients <65years old, but 
advise to base the decision on an informed discussion with each individual 
regarding the risks/benefits (1).    
Historically MVR involved transection of the chordae tendinae which resulted in a 
decrease in post-operative LVEF. Modern surgical techniques with MVR utilise 
chordal preservation to preserve the subvalvular apparatus which results in better 
preservation of LVEF (112-114). Chordal preservation can be partial or complete, 
with full perseveration of the subvalvular apparatus providing superior cardiac 




1.1.4.3 MV repair vs replacement 
To date, no randomised controlled trials comparing the outcomes of MVr and MVR 
for the treatment of primary MR have been undertaken. Numerous studies have 
been performed to observe outcome differences between MVR and MVr, the 
majority of which were performed before the routine use of chordal preservation 
techniques with MVR or poorly document its use (116-121). Meta-analysis of 
studies inclusive of concomitant coronary artery bypass grafting (CABG) 
demonstrate superiority in MVr over MVR in terms of reduced operative and long 
term mortality (121). Indeed, studies comparing MVr vs MVR in purely isolated 
valve disease (no concomitant CABG) also prefer MVr demonstrating lower 
operative and long term mortality (120, 122, 123). Importantly, MVR is commonly 
used in patients with more complex mitral valve disease, advanced age, reduced 
LVEF and worse NYHA class, naturally resulting in a higher risk group pre-
operatively than those referred for MVr (123). Studies utilising propensity matching 
in an attempt to overcome these biases present conflicting results. Gilinov et al 
found no significant difference between long term survival and freedom from re-
operation between propensity matched MVr and MVR with chordal preservation 
groups to treat degenerative MR (123). Although, Lazam et al found lower 
operative mortality, better long term survival and fewer valve related complications 
post MVr than MVR when treating MR secondary to a flail leaflet, but the use of 
chordal preservation techniques with MVR was not clearly documented in this 
study, potentially biasing results (124). Interestingly, a randomised trial comparing 
MVr vs MVR with chordal preservation in severe ischaemic MR has been 
performed, demonstrating no significant difference in survival or left ventricular 
reverse remodelling at 2-years but with greater recurrent MR in the repair group 
resulting in more heart failure related adverse events and hospital admissions 
(125). Additionally, results from studies assessing cardiac reverse remodelling also 
demonstrate the importance performing chordal preservation with MVR. In 
echocardiographic studies comparing cardiac reverse remodelling between 
MVr/MVR, when chordal preservation is not used, MVr demonstrates superiority 
(117, 118), however, when chordal preservation is used with MVR, cardiac reverse 
remodelling is comparable between the surgical techniques (126, 127). These 
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findings are important as cardiac reverse remodelling is widely accepted as 
associated with more favourable prognosis in a wide variety of cardiac disease 
(128, 129). Therefore MVr/MVR comparative studies predating routine use of 
chordal preservation with MVR may bias the results in favour of MVr being 
superior.  
A frequent compared variable between MVR and MVr is the reoperation rate. 
Studies in primary MR report varying re-operation rates with some demonstrating 
higher reoperations after MVr (especially post AMVL repair) (130), others higher 
reoperations post MVR (124), but the majority demonstrate no significant 
difference between the two surgical options (120, 123). In elderly patients, 
numerous studies (with mixed primary and secondary MR aetiologies) show no 
reoperations being required post MVR, with a variable rate of reoperations post 
MVr (1.4-6.1%) (122, 131); despite this no statistical difference was found. Silaschi 
et al similarly demonstrated statistically comparable rates of re-operation in elderly 
mixed aetiology MR patients undergoing MVR (2.5%) and MVr (2.3%); all 
reoperations required on replacements were on bio-prosthetic valves (132).  
As demonstrated, the vast majority of MVr vs MVR comparative studies utilise 
‘freedom from re-operation’ as an endpoint, however this does not take into 
account all recurrent MR. Indeed, numerous patients who eventually develop 
significant MR may be deemed too high risk for a re-operation resulting in a lower 
re-operation end-point frequency and biased results.  Recurrent MR post MVr is 
not uncommon with variable frequencies reported. Grapsa et al describes recurrent 
mild-mod MR in 23.8% of patients within 6 months (133), Chan et al describe 
recurrent moderate MR (2+) in 5.7% of patients within 3.1±2.5years (134), Kim et 
al reported residual moderate-severe MR in 16.8% at 8.7±5.6years (135) and 
David et al reported recurrent moderate-severe MR of 12.5% at 20 years (136).  
In summary, the MVR vs MVr debate is ongoing. Current evidence supports MVr 
as the first line surgical treatment for primary MR, especially when performed in an 
expert ‘reference’ centre. However, as the MVR cohort is routinely higher risk, this 
can bias studies towards demonstrating MVr superiority. Additionally, given 
surgeon experience/operation volume has a significant impact on MVr outcomes 
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(137), there could theoretically be a similar effect on MVR outcomes. As per 
current guidance (1, 39), MVR is routinely performed in lower quantity than MVr, 
theoretically creating an un-explored bias. Without a randomised trial comparing 
the two procedures using modern techniques in primary MR, the question will not 
be addressed. However, given current evidence, such a trial could currently be 
deemed unethical and therefore rigorous hypothesis-generating observational 
studies are required first. 
 
1.1.4.4 Percutaneous MV interventions 
Mitral valve surgery, with repair when feasible, is currently recommended 1st line 
treatment for mitral regurgitation when indicated (1, 39). However a large 
percentage of severe MR patients, even though symptomatic, get declined surgical 
intervention as they are deemed too high risk. Surgery is often declined due to 
advanced age, severe LVSD or multiple co-morbidities, with one study finding 49% 
of severe MR patients declined surgery (138). Percutaneous interventions have 
emerged as a treatment option for this high risk cohort of patients. Multiple 
percutaneous options exist including edge-edge repair with the MitraClipTM or 
PASCAL system, transcatheter mitral valve implantation (TMVI), transcutaneous 
mitral annuloplasty or percutaneous Neochord placement (139). 
 
1.1.4.4.1 Percutaneous edge-to-edge repair  
Percutaneous edge-to-edge repair can be performed using the MitraClipTM or 
PASCAL systems. The MitraClipTM device procedure was designed to copy the 
central double orifice surgical repair technique initially developed by Alfieri et al in 
1991, which involved suturing the free edges of the leaflets at the site of 
regurgitation and was designed as a simple solution for complex lesions (140).The 
original MitraClipTM system is used via a trans-septal approach to attach a clip 
device, with a tri-axial catheter system, which grasps the mitral leaflet edges to 
create a double orifice (141). Newer designs of the MitraClipTM system have 
followed with the MitraClipTM NT and MitraClipTM XTR (Figure 1-4), the latter 
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designed with longer arms to facilitate grasping of the leaflets and assist in valves 
with large coaptation defects (139, 142). Safety of the MitraClipTM system in 
treating MR was initially demonstrated in the EVEREST (Endovascular Valve 
Edge-to-Edge Repair Study)  trial, in which 107 patients had low mortality and 
morbidity rates and acute MR reduction (64% discharged with ≤1+ MR severity) in 
the majority of cases (143). Subsequently, the EVEREST II trial randomised 
patients with severe MR as a result of mal-coaptation of the A2/P2 scallops, with 
LVEF>25%, who were deemed suitable for mitral valve repair or replacement to 
receive either MitraClipTM or conventional mitral valve surgery. The 5-year follow up 
data demonstrated greater residual MR (3+/4+ MR) and higher rates of subsequent 
surgery in the MitraClipTM group but a non-significantly lower rate of mortality at 5-
years than conventional surgery (144). Both EVEREST trials (I&II) consisted 
mainly of degenerative MR patients with 93% and 74% in EVEREST I and II 
respectively (143, 144). The MitraClipTM has since gained greater clinical use in HF 
patients with secondary MR and has been investigated further in this cohort in the 
form of two randomised-control trials. The Cardiovascular Outcomes Assessment 
of the MitraClipTM Percutaneous Therapy for Heart Failure Patients with Functional 
Mitral Regurgitation (COAPT) trial demonstrated reduced heart failure 
hospitalisation and mortality in patients with heart failure and moderate-severe or 
severe secondary MR treated with MitraClipTM and optimal medical therapy 
compared with those treated with optimal medical therapy alone (145). In contrast, 
the MITRA-FR study demonstrated no difference in primary endpoints (all cause 
death or HF hospitalisation) between the MitraClipTM and optimal medical therapy 
groups (146). The contrasting results are likely attributable to differing inclusion 
criteria. Both studies recruited patients with heart failure with reduced ejection 
fraction (ischaemic or non-ischaemic cardiomyopathy) and secondary MR. MITRA-
FR recruited patients with LVEF 15-40% and at least moderate secondary MR 
(EROA >20mm2, MR-Rvol >30ml). COAPT inclusion criteria was stricter with better 
LVEF (20-50%), worse MR severity (EROA> 30mm2 and RVol >45ml) and 
excluded patients with pulmonary hypertension, moderate/severe RV dysfunction 
or significant LV dilatation (LVESD >70mm). Recent observations comparing the 
studies highlight the importance of ensuring only selected patients (as per the 
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COAPT inclusion criteria) with secondary MR receive MitraClipTM treatment to 
ensure prognostic benefit (147).  
 
 
Figure 1-4 MitraClipTM NTR & XTR side by side (image reproduced with 
permission from Abbot) 
 
The Edwards PASCAL transcatheter mitral repair system is another percutaneous 
device available to perform edge-to-edge repair. The device was designed to 
overcome some of the limitations noted with the original MitraClipTM system and 
therefore was designed to simplify left atrial navigation, use a central spacer to 
improve reduction of MR, and allow for independent leaflet grasping. The initial 
multicentre study using the PASCAL system boasted high technical success rates 
and MR severity reduction (148) and a subsequent multicentre trial demonstrated 
reduced MR regardless of aetiology and improved quality of life, exercise capacity 
and functional status at 30 days (149) with residual MR ≤2+ in all patients and MR 




1.1.4.4.2 Transcatheter mitral valve implantation (TMVI) 
After the successful development and widespread clinical use of transcatheter 
aortic valve implantation (TAVI) in high risk aortic stenosis patients (151) and 
effective use of valve-in-valve TAVI for failed aortic bioprosthesis (152) the 
progression to TMVI was inevitable. In clinical practice TMVI is often reserved for 
annuloplasty ring failure (153), failed bioprosthesis (154, 155) or degenerative 
mitral valve disease with mitral annular calcification (156). Various emerging 
transcatheter mitral valve implantation devices exist that are either self-expanding 
(157-159) or balloon expandable (160, 161) and implanted by a trans-apical (157-
159, 161) or trans-septal approach (157, 160, 161). Outcomes from the 
transcatheter mitral valve replacement multicentre registry, including 521 patients 
(60.5% trans-apical access, 90% used SAPIEN valves) that underwent TMVI, 
demonstrate overall excellent technical success in 87% of cases but differing 
outcomes depending on the underlying rationale for TMVI. Those undergoing TMVI 
for bio-prosthetic valve failure demonstrated superior outcomes. Whilst TMVI used 
in failed mitral annuloplasty repairs were prone to significantly more recurrent MR 
and increased requirement for second valve implantation. Finally, TMVI used to 
treat MR as a result of mitral annular calcification more frequently suffered left 
ventricular outflow tract (LVOT) obstruction and higher 30-day and 1-year all-cause 
mortality (162).   
 
1.1.4.4.3 Transcatheter direct annuloplasty mitral valve repair 
Multiple transcatheter devices have been developed to mimic the standard surgical 
mitral valve repair technique that utilises annuloplasty (139), which is especially 
important in functional MR where annular dilatation can be a fundamental 
pathological cause (163). Transcatheter mitral annuloplasty can be performed 
directly or indirectly. 
 
Indirect transcatheter annuloplasty aims to reduce MR by altering the proximity of 
the coronary sinus to the posterior mitral valve annulus. The Carillon mitral contour 
system uses a distal anchor deployed deep in the coronary sinus to apply 
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backward traction, guided by echocardiography and fluoroscopy, to alter the mitral 
annulus shape and reduce MR. A proximal anchor is then deployed near the 
coronary sinus ostium.  Subsequent coronary angiography is performed to ensure 
no coronary artery compromise (due to the proximity of the circumflex artery to the 
coronary sinus) which necessitates recapture/removal of the device and can 
exclude patients from this approach (164). Two single arm trials (TITAN I & TITAN 
II) demonstrated that the device reduced MR severity, HF admission and produced 
favourable LV reverse remodelling (164, 165). A subsequent sham randomised 
control trial (REDUCE-FMR) in 120 patients with functional MR and reduced 
ejection fraction (87 treatment arm, 33 sham control arm) demonstrated reduced 
MR-Rvol and LV volumes in the treatment group compared with the sham control 
group (166).  
 
Direct transcatheter annuloplasty systems have been developed more recently and 
attach a ring or band directly to the mitral valve annulus under echocardiographic 
or fluoroscopic guidance. Although other devices exist (167, 168), to date, the 
Cardioband system has the most published data in clinical use. The Cardioband 
device is implanted via a transeptal approach with the ring positioned at the atrial 
side of the mitral valve annulus. Multiple anchors are used with the first and last 
deployed in the lateral and medial commissures respectively with intermittent 
anchors placed at short intervals in-between (169). In a recent multi-centre study in 
functional MR patients, 123 patients treated with the Cardioband device and 455 
patients treated by MitraClipTM were propensity matched into two groups of 93 
patients. Both device treatments resulted in reduced MR and heart failure 
symptoms but there were greater improvements in functional class and lower all-
cause rehospitalisation and all-cause mortality rates in those treated with the 
Cardioband device (170). 
 
1.1.4.4.4 Neochord procedure 
Transapical off-pump mitral valve repair with neochord implantation, also known as 
the Neochord procedure, uses the NeoChord artificial chordae delivery system 
(NeoChord, Inc., St. Louis Park, MN, USA) to place expanded 
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polytetrafluoroethylene sutures as replacement neochordae to treat degenerative 
mitral regurgitation. The procedure is performed under general anaesthetic on a 
beating heart using transoesophageal guidance and doesn’t require 
cardiopulmonary bypass (171, 172). A multicentre study in 213 patients 
demonstrated procedural success in 96.7% of cases. The underlying aetiology of 
primary mitral valve disease had a significant effect on the composite end-point at 
1 year which comprised of freedom from mortality, severe mitral regurgitation, 
stroke, rehospitalisation, re-intervention and a decrease of at least 1 New York 
Heart Association (NYHA) functional class. Patients with isolated central PMVL 
prolapse had superior outcomes with 94 ± 2.6% reaching the composite end-point, 
compared with 82.6 ± 3.8% and 63.6 ± 8.4% in patients with multi-segment PMVL 
disease and anterior/bi-leaflet mitral valve disease respectively.  Therefore careful 
patient selection is important for optimal outcomes (173).  
 
1.1.4.4.5 Combined percutaneous procedures 
Evidence from conventional surgical intervention suggests combined annuloplasty 
and leaflet repair provides superior outcomes to valve repair or annuloplasty alone 
(174-176), therefore similar outcomes may be found by combining percutaneous 
procedures. Indeed, combined MitraClipTM with transcatheter mitral annuloplasty 
have been reported (177, 178). Given the wide range of percutaneous techniques 
available the ability to be able to combine techniques/tailor the techniques used to 
individual pathology is inviting, but further research is clearly required using 





1.1.5 Mitral regurgitation: summary 
 
Mitral regurgitation is a common but complex disease, with multiple aetiologies and 
variables that effect prognosis and treatment outcomes. Accurate cardiac imaging 
is essential to assist optimal management. TTE provides a widely available and 
cheap first line investigation, but has limitations with regards body habitus and 
often utilises a semi-quantitative assessment of MR as quantitative assessment 
relies on geometric assumptions and careful Doppler alignment which can reduce 
accuracy. Therefore, in borderline cases additional imaging can be important to 
assist decision making. Exercise stress TTE can provide prognostic information not 
present at rest to assist decision making, but can be similarly limited by poor 
acoustic windows and suboptimal MR quantification. TOE overcomes the issue of 
acoustic windows and allows unparalleled assessment of valve morphology, but is 
invasive and still limited by geometric assumptions to quantitate MR. 
Consequently, CMR has developed as the reference standard in MR quantification 
with superior accuracy, reproducibility and prognostic ability compared to TTE. 
However, CMR assessment of valve morphology is inferior to good quality 
echocardiography owing to poorer spatial and temporal resolution. Therefore a 
multi-modality approach is essential to provide a comprehensive assessment and 
guide optimal management. Surgical intervention is the gold standard treatment in 
primary MR. MVr is recommended when feasible over MVR, on the basis of non-
randomised trials, however further research is warranted in light of recent studies. 
Excitingly, numerous percutaneous mitral valve procedures have developed to 
treat patients not suitable for surgical intervention and suggest a future where 





1.2 Exercise Cardiovascular Magnetic Resonance:  
development, current utility and future applications 
 
Stress cardiac imaging is the current first line investigation for coronary artery 
disease diagnosis and decision making and an adjunctive tool in a range of non-
ischaemic cardiovascular diseases. Ex-CMR has developed over the past 25 years 
to combine the superior image qualities of CMR with the preferred method of 
exercise stress. Presently, numerous exercise methods exist, from performing 
stress on an adjacent magnetic resonance imaging (MRI) compatible treadmill to 
in-scanner exercise, most commonly on a supine cycle ergometer. Cardiac 
conditions studied by Ex-CMR are broad, commonly investigating ischaemic heart 
disease and congenital heart disease but extending to pulmonary hypertension and 
diabetic heart disease. There follows an in-depth assessment of the various Ex-
CMR stress methods and the varied pulse sequence approaches, including those 
specially designed for Ex-CMR. Current and future developments in image 
acquisition are highlighted, and will likely lead to a much greater clinical use of Ex-
CMR across a range of cardiovascular conditions.  
 
1.2.1 Background 
Stress testing can be a pivotal tool for the diagnostic and prognostic assessment of 
cardiovascular disease. Historically for coronary artery disease (CAD), treadmill 
electrocardiography (ECG) was the reference standard (179, 180).  However, the 
use of stress cardiac imaging for exercise testing has significantly improved the 
diagnostic accuracy for CAD detection compared to exercise ECG alone (181-
186). Thus stress imaging is now the preferred investigation for CAD diagnosis in 
intermediate risk patients and a useful tool for prognostication and decision making 
(187, 188). CMR has several well established benefits over alternative imaging 
modalities, allowing a non-invasive comprehensive multi-parametric assessment, 
with few limitations from body habitus, no ionizing radiation (189), and is the 
reference standard for bi-ventricular volume and functional assessment (51-53). 
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Pharmacological stress CMR has become widely utilised clinically, demonstrating 
superiority over myocardial perfusion scintigraphy by single photon emission 
computed tomography (MPS-SPECT) in the diagnosis (190) and prognosis of CAD 
(191) and recently, a lower incidence of revascularization and non-inferiority in 
major adverse cardiac events compared to CAD management guided by coronary 
angiography with fractional flow reserve (192). However, pharmacological stress 
has more adverse events than exercise stress, as demonstrated in stress 
echocardiography (80, 82), contraindications and side effects patients may not 
tolerate (193) and does not replicate the neurohormonal and haemodynamic 
changes associated with physical exercise. As such, current guidelines advise 
physical exercise as the preferred method for stress imaging, when feasible (83, 
84). Exercise imaging studies primarily focus on CAD, however exercise testing is 
an important decision making tool in numerous cardiac diseases including valvular 
heart disease (37) and congenital heart disease (194).  
Despite the advantages of CMR as a modality and physical exercise advised first 
line, Ex-CMR is not widely used clinically. Limitations include difficulty with image 
acquisition and quality, the expense of commercially available MRI compatible 
exercise devices (195) and that exercise testing is technically more difficult than 
administering pharmacological stress (196). This section will focus on the recent 
development of Ex-CMR as a technique, its current utility and challenges, and its 
potential future applications and technical developments.    
 
1.2.2 Exercise CMR – methodology and development 
Ex-CMR is performed either by exercising outside the scanner bore on a MRI 
compatible adjacent treadmill (197) or by exercising in the MRI scanner, most 
commonly using a supine cycle ergometer. Exercise on a MRI compatible adjacent 
treadmill, utilising a Bruce protocol treadmill test, benefits from the safety of 12-
lead ECG monitoring, essential for identifying ECG changes which may prompt test 
termination, but with the limitation of requiring rapid transfer to the MRI isocenter 
for post stress imaging. In-scanner Ex-CMR overcomes this limitation, as exercise 
can be performed in the scanner bore, with imaging performed during exercise or a 
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brief cessation of exercise. However, CMR scanning during exercise creates 
several issues including increased physical and respiratory motion creating 
artefacts, ECG gating issues and safety cannot be monitored by 12-lead ECG 
(198). Indeed accurate ST segment monitoring is not feasible within the MRI 
scanner bore due to the magnetohydrodynamic effect distorting the surface ECG 
(199). ECG gating issues can occur at maximal heart rates and during exercise. At 
maximal heart rates this can be overcome with real time imaging after exercise 
cessation, as utilised in treadmill Ex-CMR (200), or with ungated real time imaging 
during maximal supine bicycle exercise (198). Exercise inherently causes 
movement, which can result in image acquisition away from the initial planned slice 
location. Movement can be reduced physically by using straps around the chest 
and anterior coil, and by counselling/training the patient. However, meticulous 
image planning is essential to ensure appropriate stress slice localisation. Short 
axis cine imaging, for ventricular volumetric analysis, should be planned with 
sufficient slices beyond the base and apex, to account for movement. Repeating 
left and right ventricular outflow tract views after/during exercise, with free 
breathing imaging, immediately prior to phase contrast imaging of the aorta or main 
pulmonary artery allows re-planning to account for movement that may have 
occurred whilst performing in-scanner exercise. Respiratory navigation can be 
performed to accommodate for respiratory motion and can be performed 
retrospectively with ungated real time CMR imaging by manually ‘gating’ 
respiration using a plethysmograph trace (198).       
 
Numerous exercise CMR studies have been performed using varying methods, 
including treadmill exercise, supine cycle ergometer or supine stepper-stress, 
upright cycle ergometry in an open magnet, isometric handgrip exercise (IHG) and 
prone exercise using either knee flexion or extension with resistance from cables 
or non-ferromagnetic weights. Similar to exercise echocardiography (80), the range 
of applications of Ex-CMR extends beyond CAD to a wide range of cardiac 
conditions (80). Each exercise method has inherent benefits and weakness (Table 
1-6). Treadmill exercise, to date, has demonstrated the most clinical utility, being 
the only validated method for ischaemia detection, however, in-scanner supine 
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cycle ergometer exercise has numerous publications in a broader range of cardiac 
conditions. Each exercise method will be reviewed including its benefits, 
limitations, published applications and the technological and imaging sequence 









































wall motion & 
perfusion) 
Maximal Patients better achieve maximal intensity 
exercise 
Post stress imaging allows recovery of HR before 
imaging Diagnostic 12 lead ECG performed during 
exercise Treadmill test provides separate prognostic data Logistically difficult to image at multiple exercise 
intensities Simultaneous Maximal oxygen uptake testing 
feasible  





















Light Allows imaging during exercise No 12-lead ECG monitoring/ST segment analysis 
Allows imaging to multiple exercise intensities Uses open magnet scanner: low field strength (low 
SNR), limited availability, CMR feasible but non-
standard.   
Only modality with upright in-scanner exercise 
Less claustrophobia in open magnet scanner 








Maximal Allows imaging during exercise No 12-lead ECG monitoring/ST segment analysis 
  Allows imaging to multiple exercise intensities Cycling can be restricted by magnet bore diameter 








Vigorous Allows imaging during exercise No 12-lead ECG monitoring/ST segment analysis 
Allows imaging to multiple exercise intensities Lower intensity exercise than cycle ergometer 





Allows imaging during exercise No 12-lead ECG monitoring/ST segment analysis 
 Unconventional form of exercise 
 Only modest exercise feasible 







Very-light Allows imaging during exercise No 12-lead ECG monitoring/ST segment analysis 
Stable stress HR Atypical form of exercise 
Minimal movement & no magnet bore restriction Limited increase in HR 
   







1.2.3 Treadmill exercise CMR 
Directly analogous to treadmill stress echocardiography, treadmill Ex-CMR is 
performed to achieve the required exercise intensity/THR. The patient is then 
rapidly transferred into the MRI scanner for post stress imaging. Treadmill Ex-CMR 
has progressed from exercising outside the scanner room (202), to the 
development of an MRI compatible treadmill to allow exercise to take place inside 
the scanner room (203) and eventually performed adjacent to the MRI scanner 
(197) (Figure 1-5). For ischaemia studies, this progression has reduced the 
‘cooling off period’ from peak stress to image acquisition, as even a 60-90 second 
delay in performing stress echocardiography image acquisition, has demonstrated 
recovery of ischaemic regional wall abnormalities and thus decreases the 
sensitivity of ischaemia detection (204, 205). Numerous studies in exercise 
echocardiography have demonstrated the differences between peak and post-
stress imaging, specifically demonstrating that peak stress imaging has superior 
sensitivity and accuracy at detecting ischaemia than post stress imaging (204, 206-
209). A direct ‘head-to-head’ comparison in stress echocardiography demonstrated 
that peak stress supine bicycle echocardiography was superior to post stress 
treadmill echocardiography in ischaemia detection (210). Consequently, stress 
echocardiography guidelines recommend post stress imaging be accomplished in 
under 60 seconds (196). However, as CMR can detect ischaemia by assessing 
myocardial perfusion in addition to assessing wall motion abnormalities, treadmill 
Ex-CMR may be less time sensitive post exercise cessation than treadmill 
echocardiography. Varying transfer times have been achieved in treadmill Ex-CMR 
studies (Table 1-7) (197, 200, 202, 203, 211-214). Since progression to an MRI 
compatible treadmill adjacent to the scanner, all studies demonstrate scan initiation 
in under 30 seconds (with the exception of La Fountain et al in which removal of 
the face mask assessing oxygen uptake prolonged transfer time (211)) and cine 






Figure 1-5 MRI compatible scanner adjacent treadmill 
MRI compatible scanner adjacent treadmill, developed and utilised in ischaemia 
studies by the Ohio State University Research group (197), reduces transfer times 
for post stress CMR imaging, whilst still allowing a diagnostic 12-lead ECG 
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angiography 27 62±11 
Outside 
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Jekic (2008) (203) 
Healthy 
volunteers 20 39±15 
Scanner 
room 





Raman (2010) (200) 
Patients 
referred for 
MPS-SPECT 43 54±12 
Scanner 
room 






Foster (2012) (197) 
Healthy 
volunteers 10 23-67 
Scanner 
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* Time to peak perfusion, ** 100% of patients completed diagnostic imaging in <60s, exact times not specified. *** CPET face 
mask removal increased transfer time. Abbreviations: BPM, beats per minute; CAD, Coronary artery disease; CPET, 
cardiopulmonary exercise test; HR, Heart rate; MRI, magnetic resonance; N/A, Not applicable; NS, not specified; N=, Number 







CAD 115 59±13 
Outside 
scanner 
room NS <60s** N/A 
88±12% 
THR NS NS 
Lafountain (2016) 
(211) Athletes 10 26±5 
Scanner 
adjacent 36±4*** NS N/A 
>95% 
THR 87% NS 
Raman (2016) (212) 
Patients 
referred for 
MPS-SPECT 94 57±11 
Scanner 
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1.2.3.1 Treadmill Ex-CMR Exercise Protocol 
The current treadmill Ex-CMR protocol entails performing initial resting survey 
imaging and LV cine imaging. The patient is removed from the scanner bore for a 
supine 12 lead ECG, then transfers to the scanner adjacent MRI compatible 
treadmill for an initial standing 12 lead ECG and subsequently performs a symptom 
limited Bruce protocol treadmill test. After achieving THR >0.85 x (220-age), the 
patient is rapidly transferred to the MR scanner for free-breathing multiplane cine 
imaging. 0.1mmol/kg gadolinium contrast is injected prior to stress perfusion 
imaging, after which the MRI scanner table is removed from the magnet bore to 
allow 6-8 minutes of recovery with 12-lead ECG and blood pressure monitoring. 
The imaging is completed with rest perfusion and late gadolinium enhanced 
sequences.  (212). This protocol is compared with adenosine/dobutamine 
pharmacological stress CMR imaging in Figure 1-6 (193, 212, 215).
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1.2.3.2  Treadmill Ex-CMR sequences 
CMR imaging sequences used after treadmill exercise have developed, to hasten 
acquisition and remove breath holding. Initially, retrospectively gated sequences 
were used with short breath holds to acquire short axis cine imaging for regional 
wall motion abnormality assessment (202). The use of real time bSSFP imaging 
with either TSENSE or GRAPPA acceleration, allowed progression to free 
breathing acquisition of short and long axis left ventricular (LV) cine images for 
regional wall motion assessment (200, 203, 211-213). Additionally, perfusion 
imaging has been performed in several studies, after cine image acquisition, using 
saturation recovery hybrid gradient echo, echo planar imaging (200, 212).      
Treadmill stress CMR offers several benefits over other Ex-CMR modalities (Table 
1-6).  Patients often tolerate treadmill exercise greater than cycling, as it is a more 
natural form of exercise (216) and some patients are unable to cycle (196).  
Patients more readily achieve >85% age predicted target heart rate on the 
treadmill compared to non-weight bearing exercise (210, 217). The treadmill test 
itself provides diagnostic and prognostic information independent of imaging (200, 
218-220) and a traditional maximal oxygen uptake assessment is feasible during 
treadmill exercise within the MR scanner room (211). Treadmill stress incorporates 
a 12-lead ECG exercise test, which is diagnostic even on an MR adjacent 
treadmill, compared with non-diagnostic ECG monitoring performed when 
exercising inside the MR scanner (221). This monitoring may be vital to assess for 
ST segment changes or arrhythmias which can be absolute indications to 
terminate an exercise test during ischaemia testing (222). Therefore treadmill Ex-
CMR is arguably the safest Ex-CMR methodology to assess CAD. There are 
limitations to treadmill Ex-CMR. Imaging at numerous exercise intensities is 
logistically difficult and post stress imaging restricts the time available before a 
decline in heart rate, thus limiting applications to those achievable within a few 
minutes. The transfer process also interrupts the advised post-exercise ECG 
observation period (222). However, whilst MR stress perfusion is feasible using the 
supine cycle ergometer in healthy volunteers (223), treadmill Ex-CMR is currently 





the only Ex-CMR modality to demonstrate utility in ischaemia detection in CAD 
patients, with clinical evidence from single and multi-centre studies (200, 202, 212, 
214).  
 
1.2.4 In-scanner Exercise CMR 
In-scanner Ex-CMR can be performed by supine cycle or stepper ergometer, 
upright cycling in an open magnet, exercise in the prone position or using isometric 
handgrip; the strengths and weaknesses of the varying methods are presented in 
Table 1-6. In-scanner exercise overcomes the main limitation of treadmill Ex-CMR 
of heart rate (HR) reductions between exercise cessation and image acquisition. 
Imaging during exercise does however have difficulties. Exercise invariably creates 
movement, increased respiratory motion and interference to the surface ECG, all of 
which increase with increasing workload. Movement can be reduced with the use 
of straps or harnesses, but not entirely, especially at higher levels of exercise. 
Breath held images can be performed during exercise but are non-physiological 
and difficult at higher exercise intensities (198) . Imaging during free breathing can 
cause significant through plane motion, making obtaining reliable flow 
measurements difficult, with the pulmonary trunk especially challenging due to its 
short length before bifurcation (224). ECG interference during exercise can create 
ghosting artefacts with gated images and as previously described, accurate 12 
lead ECG monitoring with ST segment analysis cannot be performed during in-
scanner exercise (198, 199, 221). Finally, reaching maximal heart rate is more 
difficult with supine exercise compared with upright exercise; this is well 
documented in stress echocardiography with comparisons between treadmill and 
supine cycle exercise (210, 217, 225, 226). One explanation is early termination 
due to leg fatigue (210, 222), thus maximal oxygen uptake (VO2max) is often 10-
20% lower in supine cycle exercise than treadmill exercise. Despite this, evidence 
from stress echocardiography demonstrates equivalency or superiority in detecting 
ischaemia over post stress treadmill exercise (210, 217, 225). Indeed, 
comparatively higher blood pressure attained during supine ergometry (210, 217, 
226, 227), results in a similar rate-pressure product to treadmill exercise, such that 





target heart rates during supine exercise are generally lower when compared to the 
same exercise intensity in the upright position. Despite the described difficulties of 
performing in-scanner exercise CMR, techniques have been adapted, with the use 
of the supine cycle ergometer, such that it is possible to perform in-scanner Ex-
CMR to maximal intensity heart rates with imaging during exercise to assess either 
bi-ventricular function or great vessel flow (198, 224), but often not both, due to 
time constraints of scanning at incremental levels during or immediately post 
exercise. 
 
1.2.4.1 Supine Ergometer Exercise CMR 
The first published use of a CMR compatible cycle ergometer was in 1995 using a 
0.5T whole body scanner to measure exercise changes in aortic flow (228). 
Studies utilising commercially produced cycle ergometers followed in 1998 with the 
use of the Lode BV MRI compatible ergometer (Figure 1-7) on a 1.5T MRI scanner 
(229).  Whilst the majority of Ex-CMR cycle ergometer studies use this system (81, 
198, 223, 224, 229-248), some institutions have created custom made MRI 
compatible cycle ergometers (195, 249, 250). Other approaches include the supine 
MRI compatible ‘stepper’ ergometer, that utilises an up/down motion, such as the 
Lode BV up/down ergometer (251-254), Ergospect cardio-stepper (251) and 
custom built supine steppers as demonstrated in Figure 1-8 (255).  Studies using 
stepper systems report the benefit of reduced upper body motion, thus reduced 
motion artefact, and less restriction of leg movement compared with cycle 
ergometers, however no studies directly comparing the ergometers have been 
performed. Importantly, the up/down motion recruits less muscle mass than the 
cyclical motion. Thus no study has demonstrated supine ‘stepper’ ergometer Ex-
CMR to maximal intensity, as has been demonstrated with supine cycle 
ergometers (198). 






Figure 1-7 Lode BV supine cycle ergometer during in-scanner supine 
exercise cardiac magnetic resonance 
The Lode BV supine cycle ergometer allows in-scanner exercise, up to maximal 
exercise intensity, during CMR scanning, as demonstrated by La Gerche et al 
(198).  The ergometer attaches firmly to the MRI scanner bed by screw 
attachments and is safe to use in MRI scanners up to 3T. The patients’ feet attach 
into the stirrups and strap securely in place. Resistance can be altered manually in 
1-watt intervals. This ergometer is the most utilised modality in Ex-CMR research 
studies.      
 
 






Figure 1-8 Custom supine stepper ergometer.  
An example of a supine stepper ergometer utilised in research at the University of 
Wisconsin (255). A. The ergometer outside the MRI-scanner. B- The ergometer in 
use. The ergometer allows for exercise via an up/down motion, a technique which 
is reported to cause less movement artefact than the cycle ergometer at the cost of 
less muscle mass recruitment and thus lower achievable maximal heart rates.    
  





1.2.4.2 Exercise Protocol 
Exercise protocols used with supine cycle ergometer Ex-CMR vary depending 
upon the aims of the study/investigation. An example protocol is presented in 
Figure 1-9. The number of stages of exercise is variable depending upon the aims. 
A typical protocol often entails a period of supine cycling with no resistance (0 
Watts) on the ergometer, to allow the patient to accustom to the cycling positon 
and the advised cadence. This is followed by a graduated increase in resistance, 
for example by 25 Watts every 2 minutes, until THR is achieved. However, in 
athletes a faster increase in resistance may be advised. The resistance is then 
maintained whilst at the specific exercise intensity heart rate. Indeed minute 
changes in resistance can be made, if required, to ensure tight control of heart rate 
during scanning. Once THR has been maintained for 60 seconds CMR imaging will 
commence. After completion of a specified exercise intensity stage, the process of 
‘ramping up’ resistance, acquiring a stable THR prior to imaging and maintaining 
that THR during imaging is repeated for each exercise stage required. 











Figure 1-9 Example of supine bicycle Ex-CMR protocol 
An example of a supine bicycle Ex-CMR protocol. In-scanner Ex-CMR protocols may vary depending on indication, number of 
exercise stages required and participant fitness. Participants with superior cardiovascular fitness may benefit from shorter 
intervals between, or more aggressive, increases in resistance to achieve THR before leg fatigue. Using the Lode BV supine 
cycle ergometer, small alterations in resistance are possible, which can assist a tight control of THR. Abbreviations: LV, left 
ventricular; THR, target heart rate; W, Watts.






1.2.4.3  In-scanner ventricular volumetric assessment 
Supine ergometer Ex-CMR ventricular volume assessment has progressed from 
imaging during exercise cessation with breath holding (81, 195, 238-240, 249), 
breath holding during exercise (250, 251), free breathing with exercise cessation 
(223, 233, 235), to free breathing during continuous exercise (198, 252). This 
progression has been due to the use of novel CMR sequences and the progression 
from the use of retrospective cardiac gating to real-time and un-gated real time 
techniques to overcome issues with ECG gating. 
Initial Ex-CMR studies utilised retrospective cardiac gating with turbo field echo 
planar imaging (EPI) (81, 238, 239) or b-SSFP sequences (195, 249, 250, 256, 
257) to assess biventricular volumes during Ex-CMR. These were not initially 
feasible with free breathing during continuous exercise. However, recently, Chew 
et al used a free-breathing, multi-shot, respiratory navigated cine imaging method 
to assess biventricular function during continuous supine Ex-CMR with 
retrospective cardiac gating. Healthy volunteers exercised to high exercise 
intensities (mean peak HR= 131bpm) demonstrating excellent intra- and inter-
observer reproducibility and highly reproducible Inter-scan LV and RV ejection 
fraction (93).   
Prior to the recent development using retrospective cardiac gating in Ex-CMR by 
Chew et al, published retrospective cardiac gating techniques had not performed 
image acquisition with free breathing during exercise, this was instead achieved 
using real time techniques. The seminal real time Ex-CMR study by Lurz et al used 
a CMR sequence novel at the time (real time radial k-t-SENSE) demonstrating 
higher temporal resolution than the vendor provided sequences in patients 
exercised to submaximal intensity (252). Subsequent real-time Ex-CMR studies 
have utilised alternative techniques to optimise image quality including the use of 
re-binning, which improved SNR and temporal resolution compared with standard 
sequences, but suffered from ECG gating artefacts in 2 patients resulting in them 
being withdrawn from the study (258). Whilst Le et al preferred resorting back to 





exercise cessation with real time sequences, to overcome ECG interference during 
Ex-CMR and thus optimise image quality (235). 
Reliable biventricular assessment during maximal exercise has been achieved by 
La Gerche et al with the development of an ‘un-gated real time sequence’ (Figure 
1-10). Cine images are acquired by an un-gated real-time technique, physiological 
data is acquired separately, with respiration measured by a plethysmograph 
attached to the abdomen and ECG recorded via a haemodynamic monitor. 
Specialized in-house software was then used to retrospectively synchronise the 
physiological data and cine images. The un-gated technique overcame the issue of 
excessive ECG artefact encountered during high intensity exercise with the gated 
sequence on direct comparative assessment. The cardiac output derived by this 
technique was validated against the direct Fick method with excellent agreement 
and showed excellent correlation with cardiac outputs on repeat Ex-CMR 
performed 1-hour later (198). Although major limitations of this approach are the 
prolonged post processing time and the requirement for bespoke in-house analysis 
software to synchronize the ECG and respiratory movement with the images, it is 
the only method to date to allow accurate biventricular quantification during 
maximal exercise and has since been utilised in a number of clinical studies (231, 
232, 234, 241, 244, 245, 248).  
 






Figure 1-10 Example of real-time ungated CMR imaging at rest and during 
maximal exercise.  
Ungated real-time biventricular volume assessment methodology as developed by 
La Gerche et al (198) and subsequently utilised in numerous clinical studies. 
Abbreviations: HLA, horizontal long axis, SAX, short axis. 
 





It should be noted that the physiological response to exercise can differ depending 
on exercise type (aerobic/anaerobic/dynamic) and position (upright/semi-
supine/supine) (222). Previous non-CMR exercise studies have published 
contradicting LVEDV responses to supine exercise, demonstrating an increase 
(259), a decrease (260) or no significant change (261-263) in LVEDV with 
exercise. However, a recent meta-analysis of LV function during supine Ex-CMR, 
involving a pooled analysis of 16 studies, demonstrated a significant rise in LVEF 
with exercise, driven by a fall in LVESV, whilst LVEDV remained unchanged (251). 
 
1.2.4.4 In scanner flow assessment 
Ex-CMR studies for flow assessment began by imaging during cessation of 
exercise and have progressed to free breathing acquisition during continuous 
exercise. Ex-CMR studies have predominantly assessed aortic and/or pulmonary 
artery flow, although flow assessment of the superior and inferior vena cava, left 
and right pulmonary arteries and all four pulmonary veins are feasible (264, 265). 
However, inferior vena cava flow assessment requires specialist sequences and 
respiratory compensation owing to significant diaphragmatic movement during 
exercise (265).  
Initially Ex-CMR flow studies utilised retrospective cardiac gating with EPI 
sequences, with the initial study demonstrating feasibility at low resolution and 
heart rates equivalent of low exercise intensity (228). Faster imaging techniques 
were then adopted with EPI sequences and retrospective gating, reducing breath 
hold times to facilitate imaging after cessation of higher exercise intensities in 
healthy volunteers (236) and subsequently patients with congenital heart disease 
(81, 266). 
Ex-CMR flow acquisition using retrospective cardiac gating with free breathing 
during exercise was first performed by Niezen et al in 1998 during low intensity 
exercise (229), and subsequently during moderate exercise intensity (237, 242) 
and post exercise cessation (264). Retrospective gating via pulse oximetry is 
commonly used to overcome ECG gating artefact at higher exercise intensities 
(229, 237). 





To facilitate optimal image quality during free breathing continuous exercise, Ex-
CMR studies assessing flow have utilised real time imaging. Various techniques 
have been developed, but require the use of either in-house plug-ins for open 
source software or in-house developed specialist software. Steeden et al used a 
spiral phase contrast real time sequence accelerated with sensitivity encoding 
(SENSE) to acquire aortic flow and a radial KT-SENSE sequence to assess LV 
volumes, during light/moderate exercise on the Lode BV (Up/Down) ergometer. 
Aortic flows acquired by the real time technique had good agreement at rest with a 
standard 2D retrospective free breathing flow acquisition technique and at rest and 
during exercise with the stroke volume from LV volumes (267). The same research 
group then utilised real-time unaliasing by Fourier-encoding the overlaps using the 
temporal dimension and sensitivity encoding spiral phase-contrast magnetic 
resonance sequence (UNFOLDed-SENSE) in subsequent studies. Initially the 
UNFOLDed-SENSE aortic flow sequence was used in a magnetic resonance 
augmented cardiopulmonary exercise test (MR-CPET)  to demonstrated  feasibility 
of MR-CPET in healthy adult volunteers (253) and subsequently in combination 
with real time k-t SENSE short axis cines to perform MR-CPET in paediatric 
healthy controls, repaired tetralogy of Fallot and pulmonary arterial hypertension 
(PAH) patients (254). A limitation of this continuous flow technique, highlighted by 
the authors, is the need to continuously measure flow to guarantee acquisition of 
data at peak exercise. This results in acquiring ≤25,000 frames of flow images and 
therefore creates a significant reconstruction and post processing problem. As 
such, the reconstruction requires an online graphics processing unit reconstruction 
system and in-house post processing tool to cope with the volume of data (254). 
Recently, ungated real time biventricular volume and aortic and pulmonary flows 
were performed during exercise to moderate exercise intensity in healthy 
volunteers and patients with pulmonary arterial hypertension, the flow volumes 
acquired were similar to stroke volumes acquired from biventricular volumes (268). 
Therefore, simultaneous Ex-CMR assessment of ventricular volumes and flow is 
feasible during continuous exercise and free breathing via either real-time or ‘un-
gated real-time’ techniques, but all such techniques currently require the use of 





specialist software/in-house software adaptation which may limit widespread 
attainability.     
 
1.2.5 Upright cycle ergometer 
Cheng et al demonstrated the feasibility of assessing pulmonary artery flow during 
continuous exercise to moderate intensity in adults and children in a 0.5T vertical 
open bore scanner (269). Although upright cycling may be more tolerated than 
supine exercise, it requires the use of an open low field MR scanner, with benefits 
of easing claustrophobia, but inherent issues of lower signal to noise ratio. CMR is 
feasible at lower field strengths (270), however, although the scanners are 
commercially available they are not in mainstream use, as such very few Ex-CMR 
studies have utilised this approach.  
 
1.2.6 Isometric handgrip Ex-CMR 
Isometric exercise involves the contraction of skeletal muscle without the 
elongation of the muscle, as such is also called static exercise (271). This is 
feasible during CMR by IHG exercise or isometric bicep exercise (272). IHG 
exercise comprises the constant squeezing of a lever on a hand dynamometer, 
generally to a percentage of the subjects maximum force. The technique only 
allows for modest increases in heart rate, typically 10-20bpm above resting rates, 
but causes minimal movement. As such, the technique has mainly been used for 
MR-spectroscopy (MRS) or coronary artery flow imaging where minimal movement 
artefact is pivotal and minimal HR increases are acceptable. Weiss et al performed 
the seminal work with IHG-Ex CMR, developing the phosphorus MRS (31P-MRS) 
stress test which remarkably can detect ischaemia in patients with CAD, despite 









1.2.7 Prone exercise CMR 
Prone Ex-CMR was first employed by Conway et al who performed exercise MRS 
studies using knee extension with a custom system of straps, cables, pulleys and 
weights (274). Numerous subsequent Ex-CMR studies have similarly used prone 
Ex-CMR performing alternative knee flexion with ankle weights (275-277). Low-
moderate intensity exercise is feasible by this approach, with the most significant 
response from the custom knee extension system by Conway et al, with a mean 
stress HR of 119bpm. This technique has other inherent limitations; exercising 
whilst prone is an unnatural form of exercise which uses weights or resistance 
bands attached to the legs, increasing the resistance can be labour intensive, 
requiring alterations during exercise/scanning or exercise cessation. Prone Ex-
CMR often requires an auditory cue from a metronome to determine work speed, 
however if this isn’t strictly adhered to, then the exact workload is unknown.  As 
such, only Conway et al employed incremental resistance by increasing the 
attached weights to the pulley system used. As such, prone Ex-CMR is not ideal to 
assess incremental levels of exercise intensity or where strict HR increases or 
levels are required.  
 
1.2.8 Exercise CMR assessment of cardiac disease  
Ex-CMR has been utilised to study a wide range of cardiovascular pathology from 
coronary artery disease to potential cardiomyopathic conditions and 
structural/congenital heart disease. Ex-CMR is a larger field of research than 
appreciated, with over 70 publications using it as the primary investigative tool 
across a broad range of cardiac diseases. CAD has been investigated by treadmill 
Ex-CMR assessing regional wall motion and/or myocardial perfusion with post-
stress imaging (197, 200, 202, 203, 211-213), or isometric handgrip exercise to 
assess coronary endothelial function by assessing coronary artery cross-sectional 
area change and coronary flow by velocity encoded CMR (278-281). Ex-CMR is 
developing as a useful tool in athletic heart disease with the ability to differentiate 
the athletic heart adaptation from cardiomyopathy, and to risk stratifying endurance 
athletes against RV arrhythmias (232, 234, 243). Of reassurance for the potential 





widespread future application of Ex-CMR, even patients with complex congenital 
heart disease are able to perform supine exercise in the confines of the MR bore 
during Ex-CMR. Doing so, a wide range of congenital heart diseases have been 
investigated including: Fontan circulation (245, 246, 265, 266, 282, 283), 
transposition of the great arteries (81, 239, 248), tetralogy of Fallot (254, 284, 285) 
and ventricular septal defects (230). The numerous Ex-CMR studies in congenital 
heart disease is unsurprising given the unique ability of CMR to accurately image 
the right heart and complex congenital anatomies by allowing image acquisition in 
any plane. Ex-CMR studies in chronic pulmonary hypertension patients 
demonstrate reduced RV contractile reserve compared with healthy volunteers 
(233) and even those with iatrogenic induced acute pulmonary hypertension (268). 
Additionally, during Ex-CMR post pulmonary endartectomy CTEPH patients display 
an abnormal pulmonary vascular reserve, not appreciable via resting imaging, 
which can be partially reversed by Sildenafil (244). Ex-CMR studies demonstrate 
adolescent diabetics having decreased cardiac reserve compared with non-
diabetic controls (249, 256, 257), which may be a result of impaired cardiac 
energetics being exacerbated by coronary microvascular dysfunction during 
exercise (277). Furthermore, multiple Ex-CMR studies have utilised 31P-MRS as a 
non-invasive means of assessing the myocardial phosphocreatine to adenosine 
triphosphate concentration ratio, a sensitive indicator of myocardial energy status, 
to investigate multiple different cardiac diseases (273, 276, 277, 286-288). 
 
1.2.8.1 Exercise CMR studies in valve disease 
Despite the multiple Ex-CMR studies referenced in section 1.2.8 and the benefits 
CMR can offer in valve disease assessment, very few Ex-CMR studies have been 
performed in valve disease to date, with the small number of studies presented 
below. 
Ex-CMR studies in aortic regurgitation (AR) have demonstrated that isolated AR in 
children and adults decreased during ‘steady state submaximal exercise’ CMR, 
which equated to prolonged light in-scanner exercise on a custom built device 
(289). Roberts et al assessed the short term effects metoprolol and losartan had on 





exercise haemodynamics in chronic AR patients after supine exercise in a cross-
over study, showing that with metoprolol there was a lower heart rate, greater AR 
regurgitant fraction, lower aortic distensibility and greater indexed EDV and ESV 
compared to Ex-CMR on losartan (290). Recently, a study by Chew et al, 
demonstrated the feasibility of assessing biventricular function during supine 
moderate intensity Ex-CMR in 5 primary MR patients, however simultaneous 
exercise PCMR aortic flow assessment was not performed, preventing 
quantification of MR during exercise, therefore further development and research is 
required to take full advantage of Ex-CMR in this patient cohort (93). An Ex-CMR 
study assessing the exercise biventricular response to percutaneous pulmonary 
valve implantation (PPVI) in patients with either PR or pulmonary stenosis of 
heterogeneous congenital aetiologies, demonstrated that PPVI resulted in 
restoration of RVEF exercise reserves in pulmonary stenosis patients but only a 
mild augmentation of exercise SV post PPVI in PR patients (291). 
 
1.2.9 Comparing Ex-CMR methods 
Within this section, all types of available/previously studied Ex-CMR methodologies 
have been presented, with each having benefits and weaknesses as displayed in 
Table 1-6. To date, treadmill Ex-CMR has demonstrated the most clinical utility, 
with the multicentre EXACT trial, demonstrating excellent diagnostic value in CAD 
and superiority over exercise MPS-SPECT (212). Additionally treadmill Ex-CMR is 
arguably the safest Ex-CMR technique to stress patients with suspected CAD, 
owing to exercise being performed with 12-lead ECG monitoring which is not 
feasible with in-scanner methods. Therefore currently, treadmill Ex-CMR is 
undoubtedly the first choice Ex-CMR method for diagnosing CAD and ischaemia 
assessment. Studies comparing treadmill Ex-CMR and pharmacological stress 
CMR, in the form of adenosine stress perfusion or dobutamine stress cine CMR 
have not been performed. Treadmill Ex-CMR also benefits from simultaneously 
performing a Bruce protocol treadmill test, which provides additional prognostic 
and diagnostic information. However as demonstrated in Figure 1-6, the average 
treadmill Ex-CMR test may take longer than pharmacological stress CMR and 





requires additional specialist equipment and technician training. In-scanner Ex-
CMR, as discussed, allows for CMR imaging during multiple stages of continuous 
exercise. As such, supine bicycle Ex-CMR is best placed for investigating 
biventricular response and/or flow changes in non-CAD. With further 
developments, the ability to perform biventricular volume, aortic and pulmonary 
flow assessment during exercise will allow for accurate direct quantification of 
aortic and pulmonary flow and indirect assessment of mitral and tricuspid 
regurgitation. Given resting CMR quantification of valvular regurgitant flow has 
demonstrated superior reproducibility and prognostic value over TTE (63, 64, 292) 
and an abnormal response during stress echocardiography can prompt 
intervention in asymptomatic valve disease (1), Ex-CMR could become an 
important clinical tool to assess valvular and congenital heart disease. However, 
commercially available MRI compatible supine cycle ergometers are expensive, 
therefore institutions wishing to perform Ex-CMR research, in which achieving 
maximal heart rates are not required, may opt to create a custom device or utilise 
cheaper alternatives such as prone exercise with ankle weights or resistance 
bands, indeed isometric hand grip may be preferable for performing exercise MRS 
as it produces minimal movement artefact and the modest HR increases achieved 
are sufficient to detect changes in numerous cardiac diseases.         
 
1.2.10 Future of Ex-CMR 
The potential clinical applications for Ex-CMR are considerable, however further 
technological developments and multicentre trials are needed to demonstrate the 
clinical utility of Ex-CMR. Ex-CMR will likely dichotomise into treadmill Ex-CMR as 
an investigation for CAD, and in-scanner Ex-CMR for non-CAD indications, owing 
to the safer monitoring treadmill Ex-CMR offers and the ability to assess 
biventricular volumes at numerous exercise stages with in-scanner Ex-CMR. The 
recently published multi-centre EXACT-COST trial may assist treadmill Ex-CMR 
gaining greater clinical use in CAD diagnosis and assessment (293). In-scanner 
Ex-CMR could benefit from new faster imaging techniques, to further reduce 
scanning and exercise time, to take full advantage of the multiparametric benefits 





CMR offers. Development of imaging techniques which allow volume and flow 
assessment during continuous exercise that can be analysed in a timely fashion on 
commercially available software is another important need to increase attainability. 
The potential techniques to perform this include Compressed SENSE (C-SENSE) 
imaging with cine and PCMR sequences or the use of intracardiac 4D-flow. 
 
1.2.10.1 Compressed SENSE 
C-SENSE is a novel vendor provided parallel imaging technique that utilises both 
compressed sensing and SENSE parallel imaging to perform faster imaging. C-
SENSE uses variable density subsampling combined with an iterative 
reconstruction algorithm thus combining the wavelet transformation of compressed 
sensing with the coil information of SENSE (294). By combing two fast imaging 
techniques it can be used to higher acceleration factors than SENSE alone (which 
is a clinical standard parallel imaging technique). As such C-SENSE acquires 
images faster than standard SENSE (295, 296). In addition, Compressed SENSE 
has been deemed more robust to respiratory motion than alternative parallel 
imaging techniques, as theoretically the iterative reconstruction process may 
reduce respiratory artefact (297) and studies demonstrate improved robustness to 
motion artefact than SENSE (298). Therefore at present, C-SENSE may 
theoretically be the optimal fast imaging technique for use with Ex-CMR, as it 
allows faster image acquisition (295), is robust to physical (298) and respiratory 
motion (297) and is now vendor provided, thus increasing widespread attainability. 
Research assessing the feasibility of using C-SENSE with Ex-CMR is therefore 
warranted.  
1.2.10.2 4D-Flow 
4D flow has recently emerged as a valuable research tool (299). Its use in Ex-CMR 
has recently been demonstrated as feasible during continuous supine stepper 
exercise in healthy volunteers by MacDonald et al. The study demonstrated 
excellent reproducibility of 4D flow in the ascending aorta and main pulmonary 
artery, but poor inter-observer reproducibility of quantified kinetic energy in the left 
and right ventricles (300). Clearly further research is needed with such emerging 





techniques to further enhance the capabilities of Ex-CMR, but with further 
technological advances Ex-CMR could potentially revolutionise stress CMR. 
 
1.2.11 Ex-CMR conclusion 
Exercise CMR offers the potential to combine the superior imaging quality of CMR 
with the preferred and physiological method of stress by exercise. Numerous 
exercise options exist, including MRI scanner adjacent treadmills or in-scanner 
exercise with a supine cycle ergometer or stepper, prone exercise or isometric 
hand grip exercises. Imaging during maximal intensity in-scanner exercise is 
feasible using a supine cycle ergometer with ungated real-time imaging. Further 
advances are required to improve acquisition techniques and decrease scan time, 
to allow for a comprehensive multi-parametric assessment during exercise, which if 
feasible could revolutionise stress CMR.    
  





1.3 Exercise prescription for cardiovascular imaging 
 
Exercise prescription is the prescription of a defined exercise type and intensity to 
achieve a desired goal. In cardiac imaging the goal is often to ensure appropriate 
stress has been achieved and that it is done in a graduated manner to ensure 
safety, assess functional response and allow imaging at multiple exercise levels if 
required. Exercise imaging is an important aspect of this body of work. This section 
explains the methods in which to prescribe exercise intensity, determine maximal 
heart rates and assess the subjective and objective measures of exercise intensity. 
This understanding is vital to ensure exercise is individually prescribed to each 
patient to ensure equivalent stress levels are achieved despite differing resting 
variables and fitness levels between patients. Additionally, the general explanation 
that follows serves as a rationale for the methodology of the exercise prescription 
used in Chapters 2&3.   
As described in Section 1.2, Ex-CMR has been utilised in multiple studies to 
various exercise intensities which differed depending on individual study aims. 
Exercise prescription is required with exercise cardiac imaging to define the level of 
stress required for the imaging indication. Exercise prescription requires 
determining the patients maximal exercise capacity to allow prescription of 
exercise levels as percentages of the maximal level.  Maximal oxygen uptake 
(VO2max) assessment during cardiopulmonary exercise testing (CPET) is the 
reference standard way to assess maximal exercise capacity/tolerance (301), 
therefore allowing intensities levels to be prescribed as a percentage of the 
confirmed individuals confirmed VO2max. However, assessing heart rate response is 
often done in lieu of VO2max as heart rate is easy to measure and increases in a 
linear fashion with VO2 throughout exercise (302). As a result, for exercise cardiac 
imaging, patients response to exercise is commonly measured by assessing heart 
rate, usually to an age predicted maximal heart rate (HRmax), calculated using a 
formula, which is most often the ‘HRmax=220-age’ formula. The accuracy of the 
predicted maximal heart rate and resultant prescribed exercise stages is important 
to ensure patients are imaged at the desired intensity. Therefore, important 





aspects pertaining to maximal heart rate prediction, exercise intensity prescription 
and subjective methods of assessing exercise intensity shall be discussed in the 
following sections. 
 
1.3.1 Age predictive maximal heart rate formulas 
As described the optimal method of assessing an individual’s maximal exercise 
capacity is to derive VO2max via CPET testing. However, for cardiovascular 
imaging, this would require an additional test, thus increasing the time and cost of 
exercise imaging. Therefore, age predictive maximal heart rate formulas are an 
accepted method to assist exercise prescription in lieu of performing CPET (201). 
Frequently utilised age predicted HRmax formulas are shown in Table 1-8. The 
commonest utilised equation clinically is ‘HRmax = 220 –Age’. Although the use of 
this formula in stress echocardiography is advised by the ASE (83) and its 
simplicity has resulted in widespread use, the validity of the formula to accurately 
predict HRmax is surprisingly lacking (303). The original formula, attributed to Fox et 
al (304), was created as a rough formulation (with no regression analysis 
performed) of HR decline with age, from 10 studies with varying criteria for having 
reached HRmax ,with the majority investigated aged under 55 years old (303-305). 
Criticisms of this formula are that it can overestimate HRmax in younger patients 
and underestimate it in older patients (305-307). Thus, subsequent formulas, 
created via meta-analysis or laboratory testing, generally suggest a lower intercept 
and smaller age co-efficient (Table 1-8).  
Numerous formulas have been created with varying demographics of the test 
group. Given predictive formulas should not be applied universally but ideally to the 
population in which they were tested (201), using a formula developed from a 
cohort with a wide age range, equal sex representation and broad range of 
physical fitness is important. One such formula was created by Tanaka et al: 
‘HRmax = 208 - (0.7 x age)’. The formula was initially developed from a meta-
analysis of 18712 patients and then validated via laboratory testing on a further 
514 patients (305). The meta-analysis involved 18712 patients from 351 studies, 
with the inclusion criteria of: English language studies, published in peer-reviewed 





journals, at least 5 subjects per group, adult participants, data on men and women 
reported separately and the maximal exertion being documented using objective 
criteria. As the studies had varying groups of patients, in regards physical fitness, 
Tanaka et al allocated patients into one of three arbitrary groups: Endurance 
trained (regular vigorous endurance exercise ≥3 times a week for ≥1 year), active 
(occasional/ irregular aerobic exercise ≤2 times a week) or sedentary (no 
exercise). Treadmill and cycle ergometer data were pooled together as there was 
no significant difference between the two groups. The meta-analysis showed no 
significant difference in results between men and women for endurance trained 
(206 - 0.7 x age), active (207 - 0.7 x age) or sedentary groups (211 - 0.8 x age). 
When the groups are combined the formula created is: HRmax = 208 - (0.7 x age). 
A laboratory study was performed on 514 patients (277 women and 237 men) with 
a broad age range (18-81years). Patients with a body mass index (BMI) >35 were 
excluded. Maximal exertion was identified by ensuring patients had: a respiratory 
exchange ratio of ≥1.15, a plateau in VO2 with increasing exercise, a respiratory 
rate (max) of ≥35 and a perceived rate of exertion of ≥18 on the Borg rating of 
perceived exertion (RPE) scale. The laboratory study formulated a regression 
equation of ‘HRmax =(209 - 0.7xage)’, which showed no significance difference 
between men or women and was not significantly different to the meta-analysis 
derived equation ‘HRmax = (208 - 0.7xage)’. Therefore, ‘HRmax = (208 - 0.7xage)’ 
was advised as a more generalizable equation than ‘HRmax = 220 –Age’, but due to 
exclusion criteria, may not be valid in those with a BMI>35.
 





Table 1-8 Common equations for estimating maximal heart rate and the development method and study cohort 
Equation Author Study method Patient number Population 
220 – age Fox et al (304) Approximate fit from HRmax 
achieved in 10 studies 
Not disclosed Mostly <55yrs (304) 
207 – (0.7 x age) Gellish et al (308) Longitudinal analysis of patients 
over a minimum of 6 annual 
GEX tests 
132 (had a total of 
908 GEX)* 
100 men, 32 women, 
 Age 27-78 
206 – (0.88 x age) Gulati et al (309) ETT via Bruce protocol until 
symptoms or ECG changes (no 
VO2max assessment) 
5437 Women Age 35-86 





Study population:  
237 men, 277 women,  
aged 18-81 
Table 1-8 legend: * 132 participants had multiple GEX over several years, allowing assessment of results from 908 GEX. 
Abbreviations: CPET, cardio-pulmonary exercise test; ETT, exercise tolerance test; GEX, Graduated exercise test; HRmax, 







1.3.2 Prescribing exercise intensities 
Once maximal exercise intensity has been discerned, prescription of the desired 
exercise intensity can be done as a percentage of the maximum. Estimating 
exercise intensity can be done via absolute or relative measures. Absolute 
measures include caloric expenditure, absolute oxygen uptake and metabolic 
equivalent tasks. However, absolute measures can misclassify exercise intensity 
as they do not take into account individual factors such as: age, body weight, sex 
and fitness level. Therefore relative methods are often preferred that include: 
percentage of HRmax (%HRmax), percentage of HRmax reserve method (%HRR), 
percentage of VO2max (%VO2max) and percentage of VO2 reserve (%VO2R) (201). 
Calculating the %HRR via the Karvonen method (310) involves calculating the 
difference between resting HR and maximal HR, dividing the value by the 
percentage of exercise intensity required and adding this value to the resting HR, 
as shown in Equation 8 (302, 310).  
 
Equation 8 – How to calculate heart rate reserve percentage via Karvonen 
method 
%𝐻𝑅𝑅 = ((HRmax − HR rest) x % desired intensity of exercise)  +  HR rest 
 
%HRR and %VO2R methods are often preferred for accurate exercise prescription 
over %HRmax and %VO2max methods as these latter methods can under and 
overestimate exercise intensity in comparison (201, 311, 312). As such, numerous 
studies demonstrate that assessing rises in HR via the %HRR method correlates 
better with VO2max than the %HRmax method (302, 313). This superior correlation 
has been attributed to the %HRR method taking into account resting heart rate and 
therefore the significant variations in resting heart rates than can occur between 
individuals. As such, %HRR is often preferred over %HRmax for exercise 
prescription (201). Indeed, as resting and exercise heart rates are lower in the 
supine than upright positions (227, 314), the use of the %HRR method is likely 
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preferable to a %HRmax method when prescribing exercise intensities for use 
during supine Ex-CMR as it should theoretically better account for this factor. The 
American College of Sports Medicine provide guidance on the classification of 
exercise intensity as presented in Table 1-9 (201). 
Table 1-9 American college of sports medicine classifications of exercise 





%HRmax %VO2max  Borg scale 
RPE 
(6-20 scale) 
Very light <30 <57 <37 <9 
Light 30-39 57-63 37-45 9-11 
Moderate 40-59 64-76 46-63 12-13 
Vigorous 60-89 77-95 64-90 14-17 
Near maximal 
to maximal 
≥ 90 ≥ 96 ≥ 91 ≥ 18 
Table 1-9 legend: Adapted from American College of Sports Medicine guidelines 
(201), Abbreviations: %HRmax, percentage of maximal heart rate; %HRR, 
percentage of maximal heart rate reserve; RPE, rating of perceived exertion; %VO2 
max, percentage of maximum oxygen uptake; %VO2R, percentage of maximal 
oxygen uptake reserve. 
 
1.3.3 Rate of perceived exertion 
Another method to assess exercise intensity is by assessing the rate of perceived 
exertion (RPE), which can be a useful adjunct to assessing heart rate or oxygen 
uptake to assess both subjective and objective response to exercise. Borg et al, 
developed and refined the Borg scale for rating of perceived exertion (315), which 
correlates moderate-strongly with objective measures of exercise intensity (316, 
317). An example of a Borg scale of ratings of perceive exertion is displayed in 
Table 1-10 and the classification of the points on this scale into exercise intensities 













Rating Rating of Perceived Exertion 



















19 Extremely Hard 




1.4 Thesis aims/hypothesis 
Mitral regurgitation is a common valve disease with multiple aetiologies and 
variables that effect prognosis and outcomes post-surgery/intervention. Primary 
mitral regurgitation can benefit from early intervention in carefully selected cases, 
to ensure preservation of LV function post-operatively. However, surgery is not 
without risk and therefore the accuracy of investigations advising intervention is 
paramount. TTE is the first line investigation in valvular heart disease (1, 39) and 
exercise-TTE provides additional prognostic information, not present at rest, to 
assist decision making (79, 80). However, as presented throughout this 
introductory chapter, CMR provides reference standard biventricular assessment 
(52, 53) and CMR quantified MR has superior reproducibility (59, 60, 62, 63) and 
prognostic ability compared to TTE (63, 64). Ex-CMR provides the ability to 
combine the superior image quality of CMR with the preferred method of stress. 
Therefore, further developments of Ex-CMR to allow biventricular function and MR 
quantification during exercise may provide a powerful tool to assist decision 
making in borderline cases of primary MR. To facilitate the widespread clinical use 
of Ex-CMR, protocols need developing using fast imaging techniques that can 
acquire high image quality using widely attainable sequences, software and 
equipment. C-SENSE has recently become vendor provided and offers fast image 
acquisition (295) and is robust to physical (298) and respiratory motion (297). As 
such C-SENSE may be well suited to use during Ex-CMR and warrants 
investigation. 
Once the decision to intervene on mitral regurgitation has been made, patients 
deserve an optimal correction based upon evidence based medicine using the 
most accurate techniques to assess outcomes. Currently MVr, when feasible, is 
advised over MVR (1, 39). Although multiple comparative studies between MVr & 
MVR have been performed, there are several limitations that bias the comparison 
and no randomised studies have been performed in primary MR. The limitations of 
prior studies primarily revolve around: studies performed before the routine use of 
chordal preservation with MVR, the use of TTE to define MR severity and assess 
remodelling and the intrinsic bias that often exists between surgical groups with 
MVR groups often older with more comorbities. Many comparative studies predate 
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modern chordal preservation techniques with MVR (116-121) which when used 
demonstrate comparable cardiac reverse remodelling between MVr & MVR (126, 
127). Given cardiac reverse remodelling is associated with a more favourable 
prognosis in a wide variety of cardiac diseases (128, 129), the lack of use in 
comparative studies is a significant limitation. Prior studies comparing outcomes 
between MVr/MVR have done so using TTE to define MR severity and therefore 
determine the need for surgery or assess cardiac remodelling using TTE. Given 
the inaccuracies and suboptimal reproducibility of MR assessment by TTE 
described in this introductory chapter, comparative studies may be biased by 
suboptimal patient selection. Finally, as described in section 1.1.4.2, patients 
referred for MVR are often older with more comorbidities (96), as such intrinsic bias 
often exist between prospective studies comparing MVr vs MVR. Given the greater 
risk of recurrent MR and potential for increased reoperations post MVr, updated 
studies comparing cardiac reverse remodelling and recurrent MR post MVr vs MVR 
with chordal preservation using the reference standard (CMR) are warranted. 
Ideally randomised trials comparing MVr vs MVR with chordal preservation using 
CMR, as the reference standard, to assess biventricular remodelling and quantify 
MR are warranted. However, due to the current evidence favouring MVr, rigorous 
hypothesis generating research is first required to ensure such studies are ethical 
and necessary. Additionally, the growing options of percutaneous treatments 
available to primary MR patients not suitable for surgery are increasing. Therefore 
continued research, accurately assessing outcomes is essential to assist optimal 
patient selection. Generally, smaller alterations in MR and cardiac reverse 
remodelling occurs post percutaneous intervention compared with surgical cohorts. 
As such, the increased accuracy offered by CMR is especially important when 
studying patients undergoing percutaneous intervention, to highlight smaller, but 
significant changes in MR and cardiac reverse remodelling and therefore assist in 
optimal future patient selection.    
In this thesis the following studies have been performed, using CMR as the 




Chapter 2) This study aimed to evaluate the feasibility and utility of biventricular 
function and flow assessment in healthy volunteers during continuous in-scanner 
exercise, using vendor supplied Compressed SENSE sequences and commercial 
analysis software. 
 
Chapter 3) This study aimed to evaluate the feasibility and reproducibility of 
assessing biventricular volumes and MR quantification in primary MR patients 
during continuous supine Ex-CMR, using vendor provided image sequences and 
commercially available analysis software, and to describe the biventricular and 
quantitated MR changes during supine Ex-CMR in asymptomatic primary MR 
patients.    
 
Chapter 4) This study aimed to assess the differences in cardiac reverse 
remodelling and MR reduction post MVr vs MVR with chordal preservation for 
significant primary MR, using sequential CMR and a longitudinal watchful-waiting 
control group (no surgical intervention) for comprehensive assessment.  
 
Chapter 5) This study aimed to assess cardiac reverse remodelling and quantitate 
changes in valvular flow after percutaneous valve intervention for primary MR 
using the reference standard (CMR). 
 
Each of the above chapters contain specific background, methods, results and 
discussion sections. Chapter 2 develops and validates the methodology 
subsequently utilised in chapter 3. Chapter 4 and 5 share similar methodology in 
separate cohorts of patients and are therefore presented separately. Chapter 6 
provides an overall discussion with comparisons between the Ex-CMR results from 
Chapters 2 & 3 and comparisons of the cardiac reverse remodelling results from 




Chapter 2  
 
Exercise cardiovascular magnetic resonance: feasibility of 
biventricular function and great vessel flow assessment during 
continuous exercise accelerated by Compressed SENSE 
 
2.1 Abstract  
Background 
Exercise cardiovascular magnetic resonance (Ex-CMR) typically requires complex 
post-processing or transient exercise cessation, decreasing clinical utility. We 
aimed to demonstrate the feasibility of assessing biventricular volumes and great 
vessel flow during continuous in-scanner Ex-CMR, using vendor provided 
Compressed SENSE (C-SENSE) sequences and commercial analysis software 
(Cvi42). 
Methods 
12 healthy volunteers (8-male, age: 35±9years) underwent continuous supine cycle 
ergometer (Lode-BV) Ex-CMR (1.5T Philips, Ingenia). Free-breathing, respiratory 
navigated C-SENSE short-axis cines and aortic/pulmonary phase contrast 
magnetic resonance (PCMR) sequences were validated against clinical sequences 
at rest and used during low and moderate intensity Ex-CMR. Optimal PCMR C-
SENSE acceleration, C-SENSE-3 (CS3) vs C-SENSE-6 (CS6), was further 
investigated by image quality scoring. Intra-and inter-operator reproducibility of 
biventricular and flow indices was performed. 
Results 
All CS3 PCMR image quality scores were superior (p<0.05) to CS6 sequences, 
except pulmonary PCMR at moderate exercise. Resting stroke volumes from 
clinical PCMR sequences showed stronger correlation with CS3 than CS6 
sequences. Resting biventricular volumes from CS3 and clinical sequences 
correlated very strongly (r>0.93). During Ex-CMR, biventricular end-diastolic 
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volumes (EDV) remained unchanged, except right-ventricular EDV decreasing at 
moderate exercise. Biventricular ejection-fractions increased at each stage. 
Exercise biventricular cine and PCMR stroke volumes correlated very strongly 
(r≥0.9), demonstrating internal validity. Intra-observer reproducibility was excellent, 
co-efficient of variance (CV) <10%. Inter-observer reproducibility was excellent, 
except for resting right-ventricular and exercise bi-ventricular end-systolic volumes 
which were good (CV 10-20%).  
Conclusion 
Biventricular function, aortic and pulmonary flow assessment during continuous Ex-
CMR using CS3 sequences is feasible, reproducible and analysable using 







Stress cardiac imaging is an important tool in assessing valvular (1) and congenital 
heart disease (194) and has significantly improved the diagnostic accuracy for 
CAD detection compared to exercise ECG (182, 183, 185). CMR has several well 
established benefits over alternative imaging modalities and as such is the current 
reference standard for bi-ventricular volume and functional assessment (52, 53). 
Pharmacological stress CMR is well established clinically and has demonstrated 
superiority over MPS-SPECT in the diagnosis (190, 318) and prognostication of 
CAD (191). However, physical exercise allows a more detailed assessment of 
symptoms, functional state and haemodynamic response to a graduated increase 
in workload and has fewer adverse events compared to pharmacological stress 
(80, 82). As such, current guidelines advise physical exercise as the preferred 
method for stress imaging when feasible (83, 84). Ex-CMR combines the superior 
image quality of CMR with the preferred method of stress by exercise. Despite 
development in research over the past 3 decades, Ex-CMR is not widely utilised 
clinically. Treadmill Ex-CMR has demonstrated clinical utility and superiority over 
MPS-SPECT, in the detection of ischaemia in CAD (212). However, heart rate 
reductions during transfer to the MRI-scanner limit its clinical utility beyond CAD 
assessment and make assessment at multiple exercise intensities logistically 
difficult. In-scanner Ex-CMR with a supine ergometer overcomes this issue, but 
CMR scanning during exercise results in increased physical movement, respiratory 
artefacts and ECG gating artefacts, all of which increase with increasing workload 
(198). Originally, Ex-CMR studies, using retrospective cardiac gating, performed 
imaging during exercise cessation and breath holding to overcome these issues 
(238), unfortunately both are non-physiological and reduce clinical utility. The 
development of un-gated real-time cine imaging, utilising post hoc cardiac and 
respiratory gating, has allowed biventricular volume assessment reliably to 
maximal exercise intensity (198). Recently, combining this technique with un-gated 
flow acquisition resulted in the first study assessing bi-ventricular volumes and 
aortic and pulmonary flow during continuous exercise (268). Unfortunately, the un-
gated real-time technique requires specialist software (for post hoc cardiac and 
respiratory gating) and prolonged post processing and analysis time, thus 
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decreasing clinical utility and widespread attainability (198). Also, real time Ex-
CMR studies assessing flow report the technique acquires a significant volume of 
flow data (<25000 images per patient), requiring the use of an online graphics 
processing unit reconstruction system (254). Therefore free-breathing methods that 
can acquire cine and flow image quality using retrospective cardiac gating during 
continuous exercise may increase the clinical utility of Ex-CMR, as specialist 
software and sequences will not be required. Thus increasing attainability and 
reducing post-processing/analysis time. Indeed recently, biventricular volume 
assessment during free breathing continuous exercise using retrospective cardiac 
gating was proven feasible, by using SENSE-2 short axis cine sequences with 
respiratory navigation to compensate for respiratory motion, the use of 
retrospective cardiac gating in this study allowed analysis on standard 
commercially available software (93). Given the ability to assess biventricular 
haemodynamic response and flow through the aortic and pulmonary valves during 
exercise could allow accurate assessment and quantification of valvular heart 
disease and congenital heart disease, a clinically attainable protocol assessing 
both volumes and flow is inviting. However, faster imaging is required to acquire 
PCMR sequences in addition to cine imaging during Ex-CMR before the onset of 
leg fatigue. As highlighted in section 1.2.10.1, C-SENSE is a novel vendor provided 
parallel imaging technique. By combining compressed sensing and SENSE parallel 
imaging, higher acceleration factors and thus faster imaging can be performed than 
by using SENSE alone (295, 296). C-SENSE is reportedly more robust to physical 
(298) and respiratory motion (297) than alternative parallel imaging techniques. 
Therefore C-SENSE sequences may be the optimal technique to facilitate 
biventricular function and flow assessment using retrospective cardiac gating. To 
date, C-SENSE has not previously been utilised in Ex-CMR. This study aimed to 
demonstrate the feasibility of assessing biventricular volume and flow during 
continuous exercise using vendor provided C-SENSE sequences and 






2.3.1 Study design 
Protocol development and feasibility testing was achieved by: 1) developing a free-
breathing C-SENSE protocol and validating this against our institute’s standard 
clinical imaging sequences at rest; 2) determining the optimal acceleration of C-
SENSE for PCMR sequences, for use in Ex-CMR, by assessing resting and 
exercise image quality and comparing the derived stroke volumes against standard 
clinical imaging sequences at rest; 3) utilising the C-SENSE protocol (validated 
against clinical sequences at rest) during continuous low and moderate exercise 
intensities to determine if the acquired biventricular volumes and flow have internal 
validity in terms of consistency of ventricular stroke volumes when derived 
separately from cavity volumes and great vessel flow measurements, and whether 
they are concordant with expected supine exercise physiology. 
A supine cycle ergometer (Lode BV) Ex-CMR was preferred to alternative stress 
modalities due to the ability to perform in-scanner imaging during exercise to 
reasonable exercise intensities as compared with alternative modalities discussed 
in Chapter 1.2. C-SENSE was chosen due to its faster image acquisition and 
increased robustness to respiratory and physical motion than other parallel imaging 
techniques as discussed in section 1.2.10.1 (295-298). Retrospective cardiac 
gating was utilised in this study because, as described in Chapter 1.2, it does not 
require specialist sequences or software and thus ensures our developed 
technique has increased widespread attainability and potentially reduced post-
processing/analysis time compared with real-time/ungated techniques.  
This study was approved by a local ethics committee in England (Yorkshire and the 
Humber – Leeds East 18/YH/0168). All participants provided written informed 
consent. All Ex-CMR studies were performed at the Leeds General Infirmary, UK 






2.3.2 Study population 
12 healthy volunteers (8 male, 4 female), aged 35±9 years (mean±standard 
deviation) (range 23-56 years) underwent CMR at rest and during continuous 
exercise using the Lode BV supine bicycle ergometer. Participants were of a 
healthy weight (BMI 23.9±2.3) and of varying levels of physical fitness, performing 
regular exercise between 0.5 and 15 hours a week (mean 5.0±3.5hours).  All 
healthy volunteers had no significant co-morbidities and no contraindications to 
exercise testing as per AHA guidelines (222). 
2.3.3 Patient preparation 
Specific patient preparations were undertaken to reduce common issues 
encountered in supine Ex-CMR, namely motion, respiratory and cardiac gating 
artefacts, to ensure optimal image quality. Prior to entering the scanner room 
patients were counselled on the importance keeping upper body movement to a 
minimum, this was facilitated by ensuring patients held onto the handles attached 
to the ergometer to help steady their upper body (Figure 2-1b). The patient’s feet 
were securely strapped to the pedals of the cycle ergometer, with additional straps 
applied around the feet, if required, to ensure a secure fit, thus smoother cycling 
and reduced excessive motion. Prior Ex-CMR studies report that cycling movement 
can be restricted by leg contact with the MR bore (93). Therefore, prior to scan 
initiation, patient position was optimised, with a trial in the MR bore whilst attached 
to the cycle ergometer, to ensure cycling could be comfortably performed without 
the knee contacting the MR bore and patients advised against moving from this 
position during Ex-CMR. To reduce ECG/cardiac gating artefact, prior to ECG 
placement, the patient’s chest was optimally prepared, including shaving where 
required and cleaning of the skin surface, the ECG was then secured to the 
patient’s chest with tape to reduce movement. The receiver coil was placed on the 
patient atop padding placed at the patient’s sides to reduce/remove contact 
between the coil and ECG leads during exercise which may produce ECG artefact. 
Pad positioning was individually optimised for each patient to ensure receiver coil 
placement did not cover the face or restrict cycling movement. Straps were placed 
around the patient and receiver coil to reduce motion artefact (Figure 2-1).  
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2.3.4 Exercise protocol 
Participants performed supine cycle ergometer (Lode BV, Netherlands) (Figure 
2-1) exercise during CMR using heart rate reserve and an age predictive maximal 
heart rate model (305), to prescribe individualised low (30-39% HRR) and 
moderate (40-59% HRR) exercise intensities. As described in Chapter 1.3, age-
predictive HR models are an acceptable substitute for CPET defined maximal HR, 
when necessary (201). The use of prior CPET to define maximal HR was 
purposefully avoided in this study to remove an additional step in any resultant 
developed Ex-CMR protocol. The age-predictive maximal HR formula validated by 
Tanaka et al (HRmax = 208 - 0.7 x age) was used due to its rigorous validation in a 
generalizable population, as described in Chapter 1.3.1 (305). The 
%HRR/Karvonen method was used to prescribe exercise intensities from the 
calculated HRmax as it better accounts for lower resting and exercising HR in the 
supine position (201).   
After completion of resting imaging, participants exercised with no resistance, 0 
Watts (W), for 1 minute at a cycling cadence of 60-70rpm (with verbal feedback 
given to maintain this) then at an increase of 25W every 2 minutes until ‘low 
intensity’ target heart rate (THR) was achieved; once THR was achieved, smaller 
alterations in resistance wattage were made to maintain THR. HR was stabilised 
for 30 seconds prior to initiating imaging. After completion of imaging at low 
exercise intensity, resistance was increased by 25W initially and every 2 minutes 
until the prescribed moderate intensity was reached and HR stabilised for 30 
seconds prior to initiating imaging. Exercise performed was continuous and all 
exercise imaging acquired during free-breathing. Participants perceived rate of 
exertion were assessed on the Borg scale (Table 1-10) after exercise cessation, to 




Figure 2-1 The Lode BV supine cycle ergometer  
Supine cycle ergometer before (a), during set up (b) and during use (c). 
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2.3.5 CMR imaging 
CMR imaging was performed on a dedicated cardiovascular 1.5 Tesla MRI system 
(Philips Ingenia system, Best, Netherlands). Initial survey and cine imaging was 
performed including: vertical long axis, horizontal long axis, LVOT and right 
ventricular outflow tract (RVOT) views. At rest, our institute’s standard clinical 
protocol to assess biventricular volumes, aortic and pulmonary flow was performed 
to validate the novel C-SENSE protocol.  The C-SENSE protocol was used at rest 
and during continuous exercise to low and moderate intensities. All image 
acquisitions, including cine imaging and PCMR imaging, were retrospectively 
cardiac gated. Through-plane velocity encoded (VENC) PCMR was acquired at the 
aortic sino-tubular junction for aortic PCMR and in the main pulmonary artery 
(MPA) 1cm superior to the valve for pulmonary PCMR. Resting VENC was set to 
150 cm/s and increased to 250cm/s during exercise; the VENC was increased 
further if aliasing occurred. All PCMR sequences were planned with region of 
interest in the iso-centre of the MRI scanner to reduce background phase-offset 
errors (74, 75). 
 
2.3.5.1 Standard clinical protocol 
At rest, our institute’s standard clinical protocol was performed, to allow validation 
of the novel C-SENSE protocol. Biventricular function was assessed using a 
breath-hold multi-phase, multi-slice short axis cine imaging stack. Great vessel flow 
was assessed from aortic and pulmonary through-plane phase contrast velocity 
mapping acquired during breath-hold (SENSE 2) and a separate free-breathing 
acquisition (no parallel imaging) to ensure a comprehensive comparison with the 
novel C-SENSE protocol.  
The clinical short axis cine imaging parameters were as follows: typical field of view 
(FOV) 360x300mm, repetition time (TR) 3.1msec, echo time (TE) 1.56msec, flip 
angle 60°, SENSE factor 2, multishot turbo field echo (TFE) factor 12, TFE 
acquisition duration 37.4ms, phase percentage 67%, slice thickness 10mm, 0mm 
gap, 30 phases, in-plane spatial resolution acquired at 1.88×1.88mm and 
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reconstructed to 1.25x.125mm, matrix 192x158, planned acquisition involved 7x 8-
second breath-holds.  
The Clinical breath held (SENSE 2) PCMR sequence imaging parameters were: 
typical FOV 350x320mm, TR 4.9msec, TE 2.9msec, flip angle 15°, number of 
signal averages 1, TFE factor 4, slice thickness 8mm, 30 phases, phase 
percentage 67%, acquired in-plane spatial resolution 2.5×2.5mm reconstructed to 
1.22x1.22mm, matrix 140x128, Cartesian sampling, planned acquisition time 13 
seconds.  
The Clinical free-breathing sequence (with no parallel imaging) imaging 
parameters were: typical FOV 400x280mm, TR 17msec, TE 2.4msec, flip angle 
40°, number of signal averages 1, slice thickness 6mm, 40 phases, in-plane spatial 
resolution 1.56×2.23mm, matrix 256x126, Cartesian sampling, typical acquisition 
duration: 101 seconds.  
 
2.3.5.2 C-SENSE protocol  
The evaluation protocol involved biventricular function assessment by free-
breathing, respiratory navigated, continuous cine imaging in short axis geometry 
accelerated by a C-SENSE factor of 3 (CS3). Great vessel flow was assessed by 
aortic and pulmonary through-plane phase-contrast imaging, with two separate 
free-breathing acquisitions using CS3 and C-SENSE 6 (CS6) acceleration. CS3 
and CS6 flow acquisitions were acquired to investigate if a higher acceleration 
would result in better image quality as a faster acquisition may be less prone to 
respiratory artefact.  
The C-SENSE short axis cine imaging parameters were as follows: typical FOV 
300x300mm, TR 2.4msec, TE 1.21msec, flip angle 60°, temporal resolution 
32msec. C-SENSE factor 3, multishot TFE factor 13, TFE acquisition duration 
31.5ms, phase percentage 67%, slice thickness 10mm, 0mm gap, in-plane spatial 
resolution acquired at 2.5×2.5mm and reconstructed to 1.34x1.34mm, matrix 
120x120, planned acquisition time 39 seconds. Respiratory navigation was used 
with the respiratory echo-based navigator positioned on the right hemi-diaphragm 
using a 5mm acceptance window with continuous gating level drift.         
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Imaging parameters of the CS3 and CS6 gradient echo PCMR sequences were: 
typical FOV 350x320mm, TR 4.9msec, TE 2.9msec, flip angle 15°, number of 
signal averages 1, TFE factor 4, slice thickness 8mm, 30 phases, phase 
percentage 67%, acquired in-plane spatial resolution 2.5×2.5mm reconstructed to 
1.22x1.22mm, matrix 140x128, Cartesian sampling, planned acquisition time (per 
slice) of 9 and 5 seconds for CS3 and CS6 PCMR sequences respectively. To 
accommodate for potential through-plane motion during exercise, the CS3 and 
CS6 PCMR sequences were performed using a novel ‘PCMR-imaging stack’ 
acquiring 3x8mm overlapping PC-slices orthogonal to vessel flow (Figure 2-2). 
Aortic PCMR sequences used a -3mm gap (thus the centre of the slices are 
spaced 5mm apart) and the pulmonary flows had -5mm gap (thus the centre of the 
slices are spaced 3mm apart).The increased overlap of the pulmonary PCMR 
sequences was to accommodate for the short length of the main pulmonary artery 
prior to bifurcation, which has led to difficulty performing pulmonary PCMR in 






Figure 2-2 Novel phase contrast magnetic resonance (PCMR) stack 
technique 
Example of planning of an aortic (A&B) and pulmonary (C&D) PCMR-stack. Aortic 
PCMR-stack geometry, 8mm slices with -3mm slice gap. Pulmonary PCMR-stack 
geometry, 8mm slices with -5mm slice gap. A) planning of aortic PCMR-stack in 
LVOT1 geometry. B)  planning of aortic PCMR-stack in LVOT2 geometry. C) 
planning of pulmonary PCMR-stack in RVOT1 geometry. D) planning of pulmonary 
PCMR-stack in RVOT2 geometry. Abbreviations: LVOT, left ventricular outflow 
tract; PCMR, phase contrast magnetic resonance; RVOT, right ventricular outflow 
tract. 
 
2.3.5.3 CMR imaging during exercise 
During exercise, the above evaluation C-SENSE protocol was used with the 
addition of free-breathing 4-chamber and LVOT/RVOT cine imaging being 
performed to assess for movement during exercise and re-plan the short-axis cine 
imaging and phase contrast imaging geometry if required. 
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2.3.5.4 CMR analysis 
Images were analysed using commercially available software (cvi42, Circle 
Cardiovascular Imaging, Calgary, AB, Canada). LV and RV endocardial contours 
were manually traced with the papillary muscles and trabeculations considered part 
of the ventricular blood pool and volumes calculated by summation of disks (319). 
Aortic and pulmonary flows were assessed by manually contouring the vessel 
endovascular contour in every phase. The CS3/CS6 PCMR-stack was assessed 
for the slice closest resembling the resting standard clinical acquisition to ensure all 
PCMR images had flow assessed at the same anatomical level. Image quality 
assessment was performed on all assessed PCMR images independently by two 
assessors (TC & NJ), whom were blinded to each-others results. Image quality 
was graded on the following scale: 3- excellent, 2- good, 1- adequate & 0- non 
diagnostic; the mean image quality scores from both assessors are presented. 
    
2.3.6 Statistical analysis 
Data were analysed using SPSS version 26 (IBM Corp.) and Microsoft Excel 2010. 
All continuous data were assessed for normality using Shapiro-Wilk test. Resting 
biventricular parameters comparing the breath-held standard clinical with CS3 
respiratory navigated SA acquisitions were assessed by Pearsons correlation and 
the bias and limits of agreement by Bland-Altman plots. PCMR image quality 
scores were assessed by Wilcoxon signed ranks test and the stroke volume 
comparisons assessed by repeated measures analysis of variance (ANOVA) with 
Bonferroni post-test analysis. Repeated measures ANOVA with Bonferroni post-
test analysis was used to compare cardiac volumetric and flow data between rest 
and different stages of exercise. Intra-observer analysis was performed by TC and 
inter-observer analysis by NJ; reproducibility was assessed by the Coefficient of 
Variation (CV) test, the standard deviation of differences between observations 
divided by the mean and by intra-class correlation (ICC) with a two way random 
model for absolute agreement. P<0.05 was considered statistically significant. Intra 





13 healthy volunteers completed the study protocol, 1 volunteer was excluded due 
to ECG gating issues at moderate exercise intensity, leaving 12 healthy volunteers 
for analysis (8 male, age 35±9 years, BMI 23.9±2.3 kg/m2).  
 
2.4.1 Validation of Compressed SENSE protocol at rest 
The novel C-SENSE protocol was validated against clinical standard sequences at 
rest, before being used during Ex-CMR.  
 
2.4.1.1 Biventricular assessment 
At rest, there were no significant differences between the biventricular volumes 
assessed by the standard clinical or novel CS3 short axis sequences, with all 
parameters demonstrating and very strong correlation (r >0.93, p<0.01) (Table 2-
1), minimal bias and acceptable limits of agreement of left ventricular (Figure 2-4) 
and right ventricular (Figure 2-5) indices. Figure 2-3 demonstrates the typical 
image quality comparison between the resting breath-hold standard clinical and 




Figure 2-3 Comparison of resting short axis cine image quality acquired by 
clinical breath held SENSE 2 sequences and Compressed SENSE 3 
respiratory navigated sequences  
Clinical breath held SENSE 2 sequences at end-diastole (a) and end-systole (b) 
and Compressed SENSE 3 respiratory navigated sequences at and end-diastole 










Table 2-1 Validation of Compressed SENSE 3 free-breathing short axis cine 
sequences at rest vs breath-held clinical standard 
Abbreviations: CS3, Compressed SENSE 3; EDV, end-diastolic volume; EF, 
ejection fraction; ESV, end-systolic volume; HR, heart rate; i, Indexed to body 







Measurement Image Sequence Bland Altman Correlation coefficient 
Clinical CS3 RC Upper  Lower Bias R p-value 
LVEDV (ml) 165±39 164±39 7.05 6.34 -7.76 -0.71 0.996 <0.01 
LVEDVi (ml/m2) 88.8±16 88.5±16 3.69 3.33 -4.05 -0.36 0.994 <0.01 
LVESV (ml) 73±23 71±23 10.38 9.46 -11.29 -0.92 0.976 <0.01 
LVESVi (ml/m2) 38.9±10 38.4±11 5.42 4.95 -5.88 -0.46 0.971 <0.01 
LVSV (ml) 92±19 93±19 6.38 6.58 -6.18 0.2 0.986 <0.01 
LVSVi (ml/m2) 50±7 50±7 3.35 3.46 -3.24 0.11 0.974 <0.01 
LVEF (%) 57±6 57±6 4.74 5.2 -4.28 0.46 0.932 <0.01 
RVEDV (ml) 166±36 166±34 8.59 9.21 -7.96 0.62 0.995 <0.01 
RVEDVi (ml/m2) 89.4±16 89.8±15 4.74 5.15 -4.34 0.41 0.991 <0.01 
RVESV (ml) 75±24 75±21 7.27 6.78 -7.76 -0.49 0.992 <0.01 
RVESVi (ml/m2) 40.6±11 40.4±10 3.84 3.6 -4.07 -0.23 0.99 <0.01 
RVSV (ml) 90±18 91±17 6.46 7.56 -5.35 1.1 0.985 <0.01 
RVSVi (ml/m2) 48.8±8 49.4±7 3.51 4.15 -2.88 0.63 0.977 <0.01 




Figure 2-4 Bland Altman plots comparing left ventricular indices derived from 
Compressed SENSE 3 vs clinical short axis cine sequences  
Dashed red line represents mean bias (mean difference in cardiac parameter 
between the CS3 and clinical sequences). Dashed black lines represent the 95% 
limits of agreement. Abbreviations: CS3, Compressed SENSE 3; EDV, end-
diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i, Indexed to 





Figure 2-5 Bland Altman plots comparing right ventricular indices derived 
from Compressed SENSE 3 vs clinical short axis cine sequences  
Dashed red line represents mean bias (mean difference in cardiac parameter 
between the CS3 and clinical sequences). Dashed black lines represent the 95% 
limits of agreement. Abbreviations: CS3, Compressed SENSE 3; EDV, end-
diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i, Indexed to 





2.4.1.2 Comparison of resting PCMR sequences 
Mean resting aortic and pulmonary stroke volumes acquired from all 4 PCMR 
sequences were comparable, with CS3 and CS6 free-breathing flow showing 
minimal bias with both breath-hold and free-breathing standard clinical flow 
sequences (Table 2-2). Bias and limits of agreement of attained indexed stroke 
volumes from different PCMR sequences were assessed by Bland Altman plots for 
aortic (Figure 2-6) and pulmonary flow (Figure 2-7). When compared with the 
current clinical standard breath held imaging, CS3 sequences showed minimal bias 
(aortic flow -0.12m/m2-, pulmonary flow -0.69ml/m2) and acceptable limits of 
agreement for aortic (upper limit 3.98ml/m2, lower limit -4.23ml/m2) and pulmonary 
flow (upper limit 5.9ml/m2, lower limit -7.29ml/m2). Whilst in comparison with clinical 
breath held sequences, CS6 sequences showed  minimally greater bias (aortic 
flow -2.15m/m2-, pulmonary flow -0.73ml/m2) and wider limits of agreement for 
aortic (upper limit 5.61 ml/m2, lower limit -9.91ml/m2) and pulmonary flow (upper 
limit 6.37ml/m2, lower limit -7.82ml/m2). CS6 aortic flow measurements were more 
prone to underestimate aortic flow, with a bias of -2.15ml/m2/cardiac cycle against 
the breath-hold clinical standard in comparison to a minimal bias of -0.12 
ml/m2/cardiac cycle using a CS3 flow sequence. Additionally, pulmonary stroke 
volumes from CS6 sequences only demonstrated moderate correlation with clinical 
free-breathing sequences (r=0.655). Therefore, compared with CS6 sequences, 
CS3 sequences show less bias, stricter limits of agreement and stronger 
correlation with clinical breath held sequences and pulmonary free breathing 
sequences. As such, results demonstrate CS3 sequences to closer represent the 
clinical standard than CS6 sequences, with minimal significant difference in aortic 










Table 2-2 Summary of comparisons of resting indexed stroke volumes derived from clinical and C-SENSE accelerated 





  Flow comparison Vs Clinical BH Flow comparison Vs Clinical FB 


















Upper Lower r-value Upper Lower r-value 
Aorta 
BH 48.3±7.1 
     
9.49 9.6 -9.38 0.11 0.762 
FB 48.4±5.7 9.49 9.6 -9.38 -0.11 0.762 
     
CS3 48.2±6.7 4.1 3.98 -4.23 -0.12 0.96 6.83 6.6 -7.06 -0.23 0.865 
CS6 46.2±6.4 7.76 5.61 -9.91 -2.15 0.849 6.38 4.12 -8.64 -2.26 0.873 
Pulmonary 
BH 48.9±5.9 
     
8.01 7.48 -8.54 0.53 0.8 
FB 48.3±6.4 8.01 7.48 -8.54 -0.53 0.8 
     
CS3 48.2±7.6 6.6 5.91 -7.29 -0.69 0.915 11 6.39 -6.71 -0.16 0.909 
CS6 48.1±6.6 7.1 6.37 -7.82 -0.73 0.85 6.55 10.8 -11.2 -0.2 0.655 
Abbreviations: BH, breath hold; CS3/CS6, compressed SENSE 3/6; FB, free-breathing; SV, stroke volume 




Figure 2-6 Bland Altman plots comparing resting indexed aortic stroke 
volumes Dashed red line represents mean bias (mean difference in cardiac 
parameter between the CS3 and clinical sequences). Dashed black lines represent 
the 95% limits of agreement. Aortic stroke volumes (SV) (ml/m2/cardiac cycle) 
derived from breath held (BH), free breathing (FB), Compressed SENSE 3 (CS3) 
and Compressed SENSE 6 (CS6) aortic phase contrast magnetic resonance 
sequences. 




Figure 2-7 Bland Altman plots comparing resting indexed pulmonary stroke 
volumes Dashed red line represents mean bias (mean difference in cardiac 
parameter between the CS3 and clinical sequences). Dashed black lines represent 
the 95% limits of agreement. Pulmonary stroke volumes (SV) (ml/m2/cardiac cycle) 
derived from breath held (BH), free breathing (FB), Compressed SENSE 3 (CS3) 
and Compressed SENSE 6 (CS6) pulmonary phase contrast magnetic resonance 
sequences. 
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2.4.2 Image quality scoring 
Examples of images defined into excellent (3), good (2), adequate (1) and non-
diagnostic (0) image quality categories are presented in Figure 2-8 and the 
different image quality scores between sequences at rest and during Ex-CMR 
presented in Table 2-3. As expected, resting clinical breath-hold image quality 
scores for aortic and pulmonary flows were significantly higher compared to free-
breathing sequences (p<0.01), except when compared with CS3 pulmonary flow 
(p=0.06). At rest, CS3 flow sequences had the highest image quality scores of all 
free-breathing sequences, including the free-breathing clinical sequence, and 
scores were significantly greater than CS6 sequences for aortic (p=0.02) and 
pulmonary (p<0.01) flow. Figure 2-9 demonstrates the image quality of the different 
resting flow images acquired in the same patient. During exercise the image quality 
scores of CS3 aortic and pulmonary flow sequences were consistently higher than 
CS6 flow sequences. Indeed at moderate exercise intensity, five aortic and two 
pulmonary flow CS6 sequences were considered non-diagnostic, whereas all CS3 
flow sequences were of adequate diagnostic quality. Due to the non-diagnostic 
image quality described in numerous CS6 flow acquisitions at moderate exercise 
intensity, the CS6 flow sequences were deemed unsuitable for Ex-CMR flow 
assessment and future studies. 
 
 
Figure 2-8 Example of image quality scoring of excellent, good, adequate and 








Table 2-3 Image quality score comparison between flow sequences at rest and exercise 
 
Flow sequence 
Resting Low exercise Moderate exercise 
Aortic Pulmonary Aortic Pulmonary Aortic Pulmonary 
Clinical BH 2.83±0.24*+# 2.88±0.30*# 
 
Clinical FB 2.21±0.38 2.08±0.45# 
CS3 FB 2.33±0.3# 2.38±0.58# 1.5±0.41# 1.46±0.62# 1.21±0.25# 1.08±0.19 
CS6 FB 1.75±0.32 1.63±0.30 1.33±0.37 1.13±0.22 0.88±0.46 0.88±0.41 
Image quality score: 3- excellent, 2- good, 1- adequate & 0- non diagnostic. * p<0.05 superior to clinical free-breathing 
sequence at same exercise stage, + p<0.05 superior to CS3 sequence at same exercise stage, # p<0.05 superior to CS6 





Figure 2-9 Comparison of image quality of resting phase contrast image 
sequences 
Figure comparing both clinical standard sequences (Clinical breath held SENSE 2 
& clinical free-breathing no parallel imaging) with Compressed SENSE 3 and 
Compressed SENSE 6 sequences. 
 
2.4.3 Supine bicycle exercise 
The participants’ haemodynamic responses to supine bicycle exercise are 
displayed in Table 2-4. Participants’ exercised for a total duration of 1947±542s (32 
minutes 27 seconds ± 9 minutes 2 seconds) and maintained within the target HR 
during each exercise stage increasing from 58±6bpm at rest, to 102±5bpm and 
119±5bpm at low and moderate exercise respectively. Systolic BP rose with 
increasing exercise intensity (119±10mmHg at rest to 143±15mmHg at low and 
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160±24mmHg at moderate exercise), whilst diastolic BP remained unchanged 
(71±8 mmHg at rest to 76±13mmHg at low and 75±13 mmHg at moderate 
exercise). BP was un-recordable at moderate exercise intensity in two subjects. 
Participants subjective RPE on the Borg scale (320) were 9.6±1.8 for low and 
13.7±2.4 for moderate exercise intensities, falling into the target ranges, as per 
American College of Sports Medicine guidelines (201), for the prescribed exercise 
intensities. Therefore, both the objective haemodynamic and the subjective Borg 
RPE scores were within the advised ranges for the prescribed exercise intensities.    
 
2.4.4 Cardiac indices response to exercise 
2.4.4.1 Biventricular volumes 
Table 2-4 demonstrates the cardiac volumetric and flow changes during exercise 
and Figure 2-10 shows the typical image quality obtained during exercise for both 
cine and aortic and pulmonary PCMR images.  
During Ex-CMR, LVEDVi did not significantly alter (88.5±16ml/m2 at rest, 
88.2±15ml/m2 at low an 85.9±14ml/m2 at moderate exercise, p=0.256 for rest to 
moderate exercise), indexed LV stroke volume (LVSVi) increased significantly 
(50±7ml/m2 at rest, 57.2±8ml/m2 at low and 59.5±7ml/m2 at moderate exercise; 
p<0.001 for rest to moderate exercise) driven by a significant fall in indexed LV 
end-systolic volume (LVESVi) (38.4±11ml/m2 at rest vs 31±10ml/m2 at low and 
26.4±10ml/m2 at moderate; p<0.001 for rest to moderate exercise) thus causing a 
rise in LVEF with exercise (57±6% at rest, 66±7% at low and 70±8% at moderate 
exercise; p<0.001 for rest to moderate exercise). Therefore, similar to a recent 
meta-analysis (251), results demonstrate no significant change in LVEDVi, but that 
LVEF is increased during Ex-CMR due to significant decreases in LVESVi. 
During Ex-CMR, indexed right ventricular end-diastolic volume (RVEDVi) 
decreased significantly (89.8±15ml/m2 at rest, 87.2±15ml/m2 at low and 
85.2±14ml/m2 at moderate exercise, p=0.023 rest to moderate exercise), indexed 
right ventricular end-systolic volume (RVESVi) decreased (40.4±10ml/m2 at rest vs 
31.1±10ml/m2 at low and 25.8±8ml/m2 at moderate exercise; p<0.001 for rest to 
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moderate exercise) driving a rise in indexed right ventricular stroke volume 
(RVSVi) (49.4±7ml/m2 at rest, 56.1±7ml/m2 at low and 59.4±7ml/m2 at moderate 
exercise; p<0.001 for rest to moderate exercise) and RVEF (56±6% vs 65±7% at 
low and 70±6% at moderate exercise; p<0.001 for rest to moderate exercise) with 
increasing exercise. Therefore during Ex-CMR, RVEF increased due to a more 





Figure 2-10 Typical image quality of cine and phase contrast imaging at rest 







Table 2-4 Haemodynamic response to supine bicycle exercise using the C-
SENSE 3 protocol 












HRR% of HRmax N/A 30-39% 40-59%  
HR (bpm) 58±6  102±5  119±5  <0.001 <0.001 <0.001 <0.001 
Systolic BP(mm/Hg)* 119±10  143±15  160±24  <0.001 0.001 0.038 <0.001 
Diastolic BP(mm/Hg)* 71±8  76±13 75±13  0.605 1 1 1 
Borg RPE 6±0  9.6±1.8 13.7±2.4 <0.001 <0.001 <0.001 <0.001 
Cycle workload (W) 0 52±26 84±24 <0.001 <0.001 <0.001 <0.001 
LVEDV (ml) 164±39 163±36 159±34 0.052 1 0.187 0.192 
LVEDVi (ml/m
2
) 88.5±16 88.2±15 85.9±14 0.066 1 0.173 0.256 
LVESV (ml) 71±23 58±21 49±20 <0.001 0.001 0.001 <0.001 
LVESVi (ml/m
2
) 38.4±11 31±10 26.4±10 <0.001 0.001 0.001 <0.001 
LVSV (ml) 93±19 106±19 110±19 <0.001 0.002 0.193 <0.001 
LVSVi (ml/m
2
) 50±7 57.2±8 59.5±7 < 0.001 0.002 0.177 <0.001 
LVEF (%) 57±6 66±7 70±8 <0.001 <0.001 0.002 <0.001 
Aortic SV (ml) 89±17 102±18 105±18 <0.001 0.001 0.708 <0.001 
Aortic SVi (ml/m
2
) 48.2±7 55.1±8 56.6±8 <0.002 0.001 0.682 <0.001 
RVEDV (ml) 166±34 161±33 158±31 0.003 0.104 0.18 0.025 
RVEDVi (ml/m
2
) 89.8±15 87.2±15 85.2±14 0.002 0.096 0.16 0.023 
RVESV (ml) 75±21 58±20 48±17 <0.001 <0.001 0.001 <0.001 
RVESVi (ml/m
2
) 40.4±10 31.1±10 25.8±8 <0.001 <0.001 0.001 <0.001 
RVSV (ml) 91±17 104±18 110±17 <0.001 <0.001 0.008 <0.001 
RVSVi (ml/m
2
) 49.4±7 56.1±7 59.4±7 <0.001 <0.001 0.008 <0.001 
RVEF (%) 56±6 65±7 70±6 <0.001 <0.001 <0.001 <0.001 
Pulmonary SV (ml) 89±18 100±17 102±16 <0.001 0.007 1 0.012 
Pulmonary SVi (ml/m
2
) 48.2±8 54.3±7 55.2±7 <0.001 0.005 1 0.009 
Abbreviations: BP, blood pressure; BPM, beats per minute; EDV, end-diastolic 
volume; EF, ejection fraction; ESV, end-systolic volume; HR, heart rate; HRR, 
heart rate reserve;  i, Indexed to body surface area; LV, left ventricle; RPE, rate of 
perceived exertion; RV, right ventricle; SV, stroke volume; W, Wat
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2.4.4.2 Flow 
Aortic stroke volumes increased significantly during Ex-CMR from 
48.2±7ml/m2/cardiac cycle at rest to 55.1±8ml/m2/cardiac cycle at low and 
56.6±8ml/m2/cardiac cycle at moderate exercise intensities (p<0.001, rest to 
moderate exercise). Indexed aortic stroke volumes showed very strong correlation 
with LVSVi at rest (r= 0.93), low (r= 0.97) and moderate exercise (r= 0.98). During 
Ex-CMR pulmonary stroke volumes increased significantly from 
48.2±8ml/m2/cardiac cycle at rest to 54.3±7ml/m2/cardiac cycle at low and 
55.2±7ml/m2/cardiac cycle at moderate exercise intensities (p=0.009, rest to 
moderate exercise) and correlated strongly with RVSVi at rest (r= 0.88) and very 
strongly during low (r= 0.90) and moderate exercise (r= 0.97). However, close 
correlation of stroke volumes acquired from PCMR and cine sequences is not 
unexpected given both are assessing similar indices.  
2.4.5 Intra/Inter-observer reproducibility 
Intra- and inter-observer reproducibility is shown in Table 2-5. Intra-observer 
reproducibility of all cardiac sequences assessed at rest and during exercise by CV 
were excellent (CV<10%) and all sequences assessed by ICC were excellent 
(ICC>0.9) with exception of pulmonary flow at low (ICC = 0.892) and moderate 
exercise (ICC= 0.847) and LVSV at moderate exercise (ICC = 0.897).  
Inter-observer reproducibility assessed by CV of cardiac parameters were similarly 
excellent (CV<10%), with the exception of RVESV by CS3 cine imaging at rest (CV 
12.96%) and LVESV and RVESV during exercise, with a CV of 11.38% and 
11.39% at low and 16.61% and 17.93% at moderate exercise intensities 
respectively. Cardiac parameters demonstrated excellent ICC (>0.9) at rest with 
the exception of RVSV & RVEF on clinical sequences and RVESV, RVSV & RVEF 
on CS3 sequences demonstrating good ICC (>0.8). During low intensity exercise 
all cardiac parameters demonstrated excellent ICC (>0.9), which decreased to 
good ICC at moderate exercise (ICC>0.75) with the exception of LVEDV and aortic 
flow which maintained excellent ICC (>0.9). The increase in variability of end-
systolic volumes with increased exercise intensity is unsurprising given the 
significant fall in ESV with exercise which allows for a smaller margin of error.  
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Table 2-5 Reproducibility of biventricular volumetric and flow indices 
Exercise level and 
sequence 
Cardiac Parameter Intra-observer Inter-observer 
CV ICC CV ICC 
Resting Clinical 
 
LVEDV 1.32 0.996 2.12 0.988 
LVESV 2.69 0.989 6.58 0.968 
LVSV 2.47 0.967 4.24 0.920 
LVEF 2.06 0.987 3.75 0.931 
RVEDV 2.29 0.985 2.65 0.979 
RVESV 5.34 0.968 8.60 0.918 
RVSV 3.94 0.953 6.89 0.808 
RVEF 3.55 0.957 6.35 0.877 
Aortic flow FB 1.14 0.990 3.07 0.930 
Aortic flow BH 0.83 0.997 2.05 0.980 
Pulmonary flow FB 1.18 0.993 2.15 0.973 






LVEDV 1.29 0.995 2.50 0.985 
LVESV 3.89 0.976 6.66 0.965 
LVSV 2.89 0.958 3.44 0.942 
LVEF 2.98 0.974 3.41 0.953 
RVEDV 1.92 0.986 4.15 0.937 
RVESV 5.40 0.957 12.96 0.814 
RVSV 3.67 0.945 6.24 0.824 
RVEF 3.23 0.968 7.26 0.817 
Aortic flow 0.83 1.000 1.19 0.993 







LVEDV 0.76 0.998 3.97 0.953 
LVESV 8.77 0.915 11.38 0.911 
LVSV 4.44 0.907 3.46 0.952 
LVEF 4.72 0.923 4.08 0.916 
RVEDV 1.95 0.984 3.72 0.955 
RVESV 8.78 0.907 11.39 0.909 
RVSV 2.97 0.947 3.07 0.940 
RVEF 4.37 0.934 4.09 0.908 
Aortic flow 1.99 0.986 5.88 0.917 







LVEDV 2.09 0.986 4.27 0.940 
LVESV 9.50 0.952 16.61 0.883 
LVSV 4.17 0.897 4.37 0.849 
LVEF 3.54 0.956 4.96 0.891 
RVEDV 3.48 0.964 5.77 0.878 
RVESV 9.23 0.926 17.93 0.754 
RVSV 3.77 0.923 4.99 0.830 
RVEF 2.95 0.955 5.12 0.837 
Aortic flow 2.22 0.975 4.01 0.918 
Pulmonary flow 6.22 0.847 6.11 0.879 
Abbreviations: CV, co-efficient of variance; Breath held; EDV, end-diastolic volume; 
EF, ejection fraction; ESV, end-systolic volume; FB, free breathing; HR, heart rate; 
i, Indexed to body surface area; ICC, intra-class correlation; LV, left ventricle; RV, 
right ventricle. 
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2.5 Discussion 
This study has shown that 1) free breathing CS3 sequences provide acceptable 
image quality and comparable assessment of biventricular size/function and flow to 
standard clinical sequences at rest 2) it is feasible to assess biventricular volumes 
and flow by CMR during continuous in-scanner supine bicycle exercise using free-
breathing C-SENSE, 3) Using CS3 compared to standard clinical imaging, image 
quality and reproducibility were good, but this was not the case with higher 
acceleration factors (CS6) and 4) Using CS3, we have shown superior 
reproducibility in comparison to the only previous study to perform biventricular 
volume and flow assessment during continuous Ex-CMR (which used un-gated 
real-time sequences) (268). 
To our knowledge, only one prior study, by Jaijee et al, has assessed biventricular 
volume and flow assessment with free-breathing during continuous exercise, and 
did so by utilising an un-gated real-time technique (268). The study was insightful, 
investigating right ventricular dysfunction in acute hypoxia and chronic pulmonary 
arterial hypertension. However the authors didn’t perform image quality 
assessment and demonstrated suboptimal reproducibility, on the basis of ICC for 
intra- and inter-observer variability for RVEF. Our RVEF ICC for intra- and inter-
observer analysis respectively was 0.968 and 0.817 at rest, and 0.955 and 0.837 at 
moderate exercise (vs 0.71 and 0.85 at rest and 0.625 and 0.744 at moderate 
exercise in the un-gated real-time study). One caveat with this direct comparison is 
we only studied healthy volunteers in this study, whereas Jaijee et al studied 
healthy volunteers and patients with pulmonary hypertension (268); patients may 
demonstrate increased respiratory motion, worse image quality and so a resultant 
decrease in reproducibility. Therefore our technique needs testing in patients with 
cardiac disease before direct comparisons can be confidently made. Both studies 
represent a significant progression in the potential clinical utility of Ex-CMR, 
however our study is the first study to demonstrate such feasibility using vendor 
provided sequences with analysis performed on standard commercially available 
software.  
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Comparatively lower heart rates are observed during supine exercise compared 
with upright exercise at the same intensity. Exercise in the supine position results 
in higher blood pressure than upright exercise (227), therefore a similar double 
product (systolic blood pressure x heart rate), which is an index of myocardial 
oxygen consumption (321), is achieved at lower heart rates than upright exercise 
(210, 217, 226). Therefore, we used HRR to determine subject specific THR, with 
the resting heart rate assessed when supine. Importantly, our study aimed only to 
assess subjects to moderate exercise intensity, and not to submaximal or maximal 
intensity. Maximal in-scanner continuous exercise can create significant motion 
artefacts, rendering images non-diagnostic, but more importantly may be unsafe in 
a patient population, given the inability to accurately assess ST segment changes 
which could prompt test termination. However, even at moderate intensity exercise, 
an Ex-CMR protocol assessing biventricular function and flow, may theoretically 
provide additional diagnostic and prognostic information in valvular and congenital 
heart disease, especially for valvular regurgitation assessment.  
 
2.5.1 Biventricular response to exercise 
The haemodynamic response to exercise demonstrated a minimal change in 
LVEDV and a rise in LVSV driven by a fall in LVESV during exercise, which is in 
keeping with a recent Ex-CMR meta-analysis of 16 Ex-CMR studies (251). Indeed, 
our study demonstrated a non-significant decrease in LVEDV with exercise as was 
demonstrated by the majority of Ex-CMR studies in the Ex-CMR meta-analysis. 
These findings replicate the theory that being truly supine (rather than recumbent 
in stress echocardiography) results in near maximal LVEDV at rest and thus no 
significant increase is seen with exercise. Additionally, in keeping with prior supine 
Ex-CMR studies (93, 250, 268, 322), the right ventricular response to supine Ex-
CMR in healthy volunteers in our study demonstrated decreases in RVEDVi, with a 
more significant decrease in RVESVi resulting in rises in RVSVi and RVEF.  
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2.6 Clinical Implications 
The clinical utility of Ex-CMR requires rapid image acquisition using accessible 
free-breathing sequences and analysis software. We demonstrated this is feasible 
using C-SENSE. C-SENSE is a vendor provided, CE-MARK’ed pulse sequence, 
permitting faster image acquisition (295, 296) and greater robustness to respiratory 
motion (297) than standard parallel imaging techniques. Our C-SENSE protocol’s 
ability to assess biventricular haemodynamics and great vessel flow, which could 
be used to quantify valvular forward flow/regurgitant flow, in response to 
incremental exercise could theoretically allow a comprehensive assessment in 
valvular and congenital heart disease. Further research in these patient cohorts is 
required.  In asymptomatic significant valve disease, ventricular 
dilatation/dysfunction or an abnormal exercise response can guide the decision to 
advise intervention (1, 37). Given CMR is the reference standard for biventricular 
assessment and CMR derived aortic and mitral regurgitation quantification displays 
superior prognostic value to transthoracic echocardiography (63, 64, 292), the 
additional assessment during exercise may theoretically provide further prognostic 
information. Additionally, in-scanner MR-CPET is feasible (253) and our protocol 
could be performed in combination, theoretically creating a single comprehensive 
investigation. C-SENSE acceleration may benefit other Ex-CMR applications. For 
example, free breathing first pass perfusion using compressed sensing at rest 
(323) and supine exercise stress perfusion CMR are both feasible (223), therefore 
C-SENSE accelerated Ex-CMR stress perfusion may also be feasible. Our 
technique requires further research to demonstrate feasibility in patient 
populations, assess if additional prognostic information is provided above a resting 
CMR scan and whether C-SENSE can be used for other Ex-CMR applications. 
 
2.6.1 Relevance of study findings in field of Ex-CMR 
Ex-CMR, although niche, is a larger field of imaging and research than is 
appreciated with over 70 publications in the field. As discussed in Chapter 1.2, 
numerous exercise modalities exist and numerous diseases have been 
investigated from coronary artery disease and congenital heart disease to diabetic 
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heart disease. The majority of Ex-CMR studies assessing non-ischaemic heart 
disease have done so using cine imaging or PCMR. Despite this and the significant 
developments in Ex-CMR over the past 3 decades only one prior study (268), 
discussed above, has successfully performed combined biventricular cine imaging 
and PCMR flow assessment of the aortic/pulmonary valves/vessels. This is largely 
in part due to the difficulty of performing imaging of sufficient quality and fast 
enough to acquire the data in the limited time available prior to the onset of leg 
fatigue in the exercising patient. This was feasible in our study due to faster image 
acquisition afforded by the use of C-SENSE sequences. Our developed protocol is 
a significant step forward in the field, as it allows assessment of biventricular 
function and great vessel flow, whilst using widely attainable sequences and 
without the need for specialist software.  The protocol could now be used to assess 
a wide range of structural heart disease. Most importantly, the ability to quantify 
aortic, mitral, pulmonary and tricuspid regurgitation, in the same protocol, during 
exercise significantly opens the door for valvular assessment by Ex-CMR. 
Hopefully the developed protocol will facilitate multiple future Ex-CMR studies in a 
broad range of structural and valvular diseases, with the eventual aim that Ex-CMR 
form part of routine clinical assessment in valve disease patients with borderline 
severe disease where accurate exercise imaging can assist decision making.      
 
2.6.2 Novelty of study findings 
This study has multiple novel aspects and findings, specifically being the first study 
to: use C-SENSE with Ex-CMR, assess the optimal C-SENSE acceleration factor 
for PCMR sequences for use in CMR/Ex-CMR and to validate an Ex-CMR protocol 
assessing biventricular volumes and flow using commercially available equipment, 
software and retrospective gating techniques.  
This is the first study to use C-SENSE with Ex-CMR and demonstrate its feasibility 
in the field. Although Jaijee et al previously demonstrated feasibility of performing 
free breathing acquisition of biventricular volumes/function and great vessel flow 
during continuous exercise (268), ours is the first to do so using retrospective 
cardiac gating techniques, with the benefits of increased widespread attainability 
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already discussed. Therefore ours is the first study to validate an Ex-CMR protocol 
assessing biventricular volumes and flow using easily acquirable commercially 
available software and equipment that can assess a broad range of structural 
cardiac disease. To the best of knowledge, this is the first study to investigate the 
optimal C-SENSE acceleration factor for PCMR sequences, in terms of image 
quality and flow correlation with reference standard, for use in CMR/Ex-CMR. Our 
findings have implications for future Ex-CMR studies but also provide novel insight 
for resting imaging. Indeed, the finding that CS6 free breathing aortic sequences 
underestimate aortic flow may be of importance to those using higher acceleration 
factors in resting clinical imaging.   
 
2.7 Study limitations 
The study sample size is small and in healthy volunteers with a healthy mean BMI 
(23.9±2.3 kg/m2) and a mean age (35±9 years) younger than patients typically 
referred for exercise cardiac imaging. Supine Ex-CMR is feasible in older patients 
(93, 241, 290, 324) and obese patients (249) but may be tolerated less well than by 
our study population, potentially resulting in more respiratory and motion artefacts. 
Thus our technique requires further evaluation in patients with cardiovascular 
disease. As with prior supine Ex-CMR studies using a cycle ergometer (93), knee-
to-bore clearance can restrict use in very tall patients. However, height was not an 
exclusion criteria in this study, with the tallest patient at 182cm. Additionally, all 
patients tolerated the Ex-CMR protocol well, completing the imaging without any 
significant restrictions to performing exercise in the scanner bore. Exercise 
duration in the study was longer than ideal for clinical use, but this was a feasibility 
and validation study, testing numerous sequences therefore prolonging exercise 
duration. Further adaption would be required to reduce exercise times for clinical 
use. This could be achieved by removing sequences depending on the aims and/or 
by removing the low intensity exercise stage and just imaging at rest and moderate 
exercise. Derived volumes and flow from biventricular cine images and phase 
contrast images respectively were not compared directly with the reference 
standard of the direct Fick method, however as we have demonstrated, the 
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biventricular cine and corresponding phase contrast flow stroke volumes correlated 
very strongly, demonstrating the internal validity of our technique. Additionally, our 
results follow prior supine Ex-CMR studies, as demonstrated in a recent meta-
analysis (251), demonstrating  rising stroke volumes with increasing exercise 
driven by a fall in LVESV but minimal change in LVEDV. Inter-scan reproducibility 
was not assessed with this study, but has been demonstrated in our institution 
previously in an Ex-CMR study assessing biventricular volumes using a similar 
retrospectively gated, respiratory navigated short axis cine sequence (93). As 
expected, and demonstrated in prior Ex-CMR studies (230, 250-252), image quality 
decreases with increasing exercise intensity, however our study still demonstrated 
good intra- and inter-observer reproducibility during moderate intensity exercise. 
ECG interference was encountered in one patient, early in the study, such that 
miss-triggering occurred at moderate exercise intensity. This made analysis 
technically unfeasible and so the subject was excluded from the study. Subsequent 
subjects had pulse oximetry attached as a backup cardiac gating technique should 
ECG interference occur, however this was not required.  
 
2.8 Conclusion 
Assessment of biventricular function, aortic and pulmonary flows during continuous 
exercise is feasible during exercise to moderate intensity using a free-breathing C-
SENSE accelerated protocol. The ability to use commercially available analysis 
software with this vendor provided technique increases the potential clinical utility 
of Ex-CMR. The developed protocol allows the direct quantification of flow across 
the aortic and pulmonary valves and indirect quantification of mitral and tricuspid 
regurgitation during exercise. Further evaluation is needed in patients with 
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Chapter 3  
 
Feasibility of biventricular volume assessment and MR 
quantification in primary MR patients during supine exercise 
cardiovascular magnetic resonance 
 
3.1 Abstract  
Background 
Biventricular volume and great vessel flow assessment during continuous supine 
free-breathing supine Ex-CMR has recently been demonstrated feasible using 
Compressed SENSE-3 (CS3) sequences. Exercise transthoracic 
echocardiography (TTE) provides additional prognostic information in primary 
mitral regurgitation (MR). Resting CMR offers reference standard biventricular 
assessment and MR quantification with superior reproducibility to TTE. Therefore, 
we aimed to determine the feasibility of biventricular assessment and MR 
quantification in primary MR patients using the recently validated Ex-CMR protocol.  
Methods 
10 patients with at least moderate primary MR on TTE (8 male, age 62, 55-67years 
IQR) underwent an Ex-CMR protocol involving free-breathing CS3 respiratory 
navigated short axis cine imaging and free-breathing CS3 aortic phase-contrast 
magnetic-resonance at rest and during individually prescribed low and moderate 
intensity in-scanner (1.5T Philips Ingenia) supine cycle ergometer exercise (Lode 
BV). Intra/inter-observer reproducibility of cardiac indices was assessed by 
coefficient of variance (CV). Images were analysed on commercially available 
software (Circle, CVi) 
Results 
All patients completed the Ex-CMR protocol with no complications. During 
exercise, there were no statistically significant changes in biventricular volumes or 
global left ventricular ejection fraction (LVEF). From rest to low and moderate 
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exercise: right ventricular ejection fraction increased (55±5.4% to 60±6.0% and 
63±6.6% respectively, p=0.001), mitral regurgitant fraction (MR-RF) decreased 
(40±14% to 36±11% and 30±15% respectively, p=0.006) and effective forward 
LVEF increased (38±9.3% to 43±9.3% and 46±11% respectively, p=0.004), which 
is a composite of aortic stroke volume and left ventricular end-diastolic volume. 
Intra-observer reproducibility was excellent (CV <10%), except right ventricular 
stroke volumes (RVSV) during low and right ventricular end-systolic volumes 
(RVESV) during both exercise stages, which were good (CV10-20%). Inter-
observer reproducibility was excellent (CV<10%), except RVESV and mitral 
regurgitant volumes at all stages, left ventricular end-systolic volumes during low 
and MR-RF during moderate exercise, which were good (CV 10-20%).       
Conclusion 
Biventricular assessment and MR quantification during continuous supine Ex-CMR 
is feasible and reproducible in asymptomatic primary MR patients. The use of 
vendor provided sequences and commercially available software increases the 
widespread attainability and potential clinical utility of the technique. Further 
research assessing the techniques prognostic ability in primary MR patients is now 
warranted.  
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3.2 Introduction 
The appropriate timing of surgical intervention in patients with significant primary 
mitral regurgitation is difficult and currently guided by symptom development and/or 
risk stratification by cardiac imaging (1, 39). However, onset of symptoms in 
chronic valve disease can be slow/indolent and patients may be unaware of subtle 
changes in exercise tolerance, even on direct questioning (78). Exercise imaging is 
therefore beneficial to accurately identify patients with a symptomatic response or 
imaging biomarkers that may benefit from early surgical intervention (1, 39, 78). 
Exercise-TTE is useful to risk stratify patients (1, 37), during which, the absence of 
LV contractile reserve (LVCR) (85, 86), limited RV contractile recruitment (87), an 
increase in MR severity (88) or exercise induced pulmonary hypertension (89, 90) 
are predictive of a poorer prognosis. Unfortunately, even in  the research setting, 
suboptimal acoustic windows can prevent stress echocardiography use in ~10% of 
patients (88). This deteriorates further in the ‘real world’ setting, where the 
feasibility of MR quantification (PISA method) during exercise-TTE was only 
feasible in 55% of patients, decreasing further to 43% in patients with mitral valve 
prolapse in a study by Coisne et al (92). The use of Ex-CMR could potentially 
overcome these issues as it is not limited by acoustic windows. Resting CMR 
provides reference standard biventricular assessment (51, 52) with MR 
quantification with superior reproducibility (59, 60, 62, 63) and prognostic ability 
compared to TTE (63, 64). In Chapter 2 the ability to perform biventricular volume 
and great vessel flow assessment during continuous supine Ex-CMR was 
demonstrated as feasible in healthy volunteers. This technique could provide the 
ability to assess biventricular response and changes in quantified MR during 
exercise in MR patients. Additionally the technique should allow calculation of 
effective forward LVEF which has never been previously assessed in MR patients 
during exercise before. Effective forward LVEF is a composite of LVEDV and aortic 
stroke volumes, which allows accurate determination of forward LV pump efficiency 
even in the presence of severe MR and has demonstrated accurate predictive 
value of determining post-operative LVEF in primary MR patients during a prior 
resting CMR study (325). Supine Ex-CMR in primary MR patients is feasible. 
Previous work by Chew et al, demonstrated feasibility of biventricular volume 
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assessment during supine Ex-CMR in 5 degenerative MR patients, however 
simultaneous exercise PCMR aortic flow assessment was not performed, 
preventing quantification of MR during exercise (93). Given that a dynamic 
increase in MR during exercise is associated with poorer outcomes (88), the ability 
to simultaneously accurately assess cardiac reserve and quantitate MR changes 
during Ex-CMR is appealing and could potentially overcome limitations described 
in exercise-TTE.  
 
3.3 Aims 
This study aimed to 1) demonstrate the feasibility of assessing biventricular 
volumes and MR quantification in asymptomatic primary MR patients during 
continuous supine Ex-CMR, using vendor provided image sequences and 
commercially available analysis software (Circle CVi) (as developed in chapter 2), 
2) assess the reproducibility of the acquired biventricular volumes and quantitated 
MR-Rvol and MR-RF by performing intra/inter-observer analysis and 3) describe 
the biventricular and quantitated MR changes during supine Ex-CMR in 
asymptomatic primary MR patients.    
 
3.4 Methods 
3.4.1 Study design and population 
Patients were prospectively recruited from the specialist valve clinic at the Leeds 
Teaching Hospitals NHS Trust. Inclusion criteria: At least moderate primary MR 
with LVEF>55% on TTE and asymptomatic (NYHA functional class I). Exclusion 
criteria: Secondary MR (atrial, ischaemic, functional), significant aortic valve 
disease on TTE (≥moderate severity), presence of AF, prior myocardial infarction, 
significant respiratory disease and any contraindications to exercise stress testing 
according to AHA guidelines (222). At least moderate MR severity on baseline TTE 
was defined by integrative approach using ASE guidelines (40), with severity 
parameters as described in Table 1-2.  
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This study was approved by a local ethics committee in England (Yorkshire and the 
Humber – Leeds East 18/YH/0168). All participants provided written informed 
consent. All Ex-CMR studies were performed at the Leeds General Infirmary, UK 
(See appendix).  
 
3.4.2 Exercise protocol 
The exercise protocol used is identical to that utilised in healthy volunteers in 
Chapter 2 and is described in depth in Chapter 2.3.4. In brief summary: patients 
underwent unloaded (0W) cycling for 1-minute on the Lode BV supine ergometer 
with subsequent increases of 25W every 2-minutes until low intensity THR 
achieved (30-39% HRR). Maintenance of THR for exercise stage was made by 
small alterations in resistance if required and THR stabilised for 30 seconds prior to 
CMR imaging. After completion of resting imaging, the ‘ramping’ process was 
repeated increasing resistance by 25W every 2-minutes until moderate intensity 
THR achieved (40-59% HRR) and heart rate stable for 30 seconds before CMR 
imaging.  
 
3.4.3 CMR imaging 
The CMR imaging performed in this study utilised the CS3 protocol developed and 
validated in healthy volunteers in Chapter 2. Pulmonary PCMR sequences 
validated in the healthy volunteers were omitted from this study, to reduce 
scan/cycle time and as they are not required to quantitate MR. CMR imaging was 
performed on a dedicated cardiovascular 1.5 Tesla MRI system (Philips Ingenia 
system, Best, Netherlands). Initial resting survey and cine imaging was performed 
including: vertical long axis, horizontal long axis, LVOT 1&2 views. Respiratory 
navigated CS3 short axis cine imaging and CS3 aortic PCMR stack, with planning 
centred around the sino-tubular junction (Figure 2-2), were performed at rest, low 
and moderate exercise intensity, during free breathing continuous exercise. Free-
breathing 4-chamber and LVOT images were re-acquired at each exercise stage to 
allow re-planning of the CS3 SA cines and aortic PCMR stack if required. CS3 
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CMR sequence parameters were identical to those developed in Chapter 2 and are 
described in-depth in Chapter 2.3.4.2. 
 
3.4.4 CMR analysis 
Images were analysed using commercially available software (cvi42, Circle 
Cardiovascular Imaging, Calgary, AB, Canada). LV and RV endocardial contours 
were manually traced with the papillary muscles and trabeculations considered part 
of the ventricular blood pool and volumes calculated by summation of disks (319). 
Aortic flows were assessed by manually contouring the vessel endovascular wall in 
every phase. The CS3 aortic PCMR stack was assessed for the slice closest 
resembling the resting acquisition to ensure all PCMR images had flow assessed 
at the same anatomical level. MR was quantitated by the indirect LVSV-AoSV 
method as described in Chapter 1.1.3.3.2. Effective forward LVEF was calculated 
by a ratio of forward aortic stroke volume and LVEDV (AoSV/LVEDV) as previously 
described by Gelfand et al (325). 
 
3.4.5 Statistical analysis 
Data were analysed using SPSS version 26 (IBM Corp.) and Microsoft Excel 2010. 
All continuous data were assessed for normality using Shapiro-Wilk test. The 
differences in continuous variables between rest, low and moderate exercise were 
compared by repeated measures ANOVA with Bonferroni correction for normally 
distributed variables and Friedman’s test with Bonferroni correction (if significant) 
for non-normally distributed variables (326). Intra-observer analysis was performed 
by TC and inter-observer analysis by NJ; the reproducibility was assessed by the 
Coefficient of Variation test, the standard deviation of differences between 
observations divided by the mean. Intra and inter-observer analysis was performed 
in a blinded method. p<0.05 was considered statistically significant.                   
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3.5 Results 
3.5.1 Patient demographics 
Ten patients with at least moderate MR on TTE were recruited (8 male, 2 female), 
with a median age of 62 years (55-67years IQR) and underwent CMR at rest and 
during continuous exercise using the Lode BV supine bicycle ergometer. Patient 
demographics are displayed in Table 3-1. Participants were of a healthy weight 
(BMI 24.8±3.3) and varying levels of physical fitness, with 50% performing no 
regular exercise and group median of 1hour/week (0-2.2hrs/week IQR).  All 
patients had no contraindications to exercise testing as per AHA guidelines (222). 
The underlying aetiology of MR was PMVL prolapse in 7 patients, bileaflet prolapse 
in 2 patients and a congenital cleft in the anterior mitral valve leaflet in 1 patient. 
The majority of patients (n=8) had severe MR on baseline TTE with 1 patient with 
moderate-severe MR and 1 with moderate MR. In terms of prior cardio-respiratory 
medical history: 2 patients were hypertensive, 1 had intermittent supraventricular 
tachycardia and 1 suffered multiple previous pulmonary emboli. Two patients were 
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Table 3-1 Baseline characteristics of patients in the CYCLE-MITRAL study 
Baseline characteristics 
Age (years) 62 (55-67) 
Male 8 
Height (cm) 173±6.7  
BMI (kg/m2) 24.8±3.3 
BSA (m2) 1.9±0.2 
Weekly exercise (hours) 1 (0-2.2) 
Cardiac medications: 
Beta-blockers 2 
ACE inhibitors 2 
MR aetiology: 
PMVL prolapse 7 
AMVL prolapse 0 
Bileaflet prolapse 2 
Congenital 1 




Abbreviations: ACE, angiotensin converting enzyme; AMVL, anterior mitral valve 
leaflet; BMI, body mass index; BSA, body surface area; MR, mitral regurgitation; 
PMVL, posterior mitral valve leaflet; TTE, transthoracic echocardiography. 
 
3.5.2 Baseline CMR  
Resting/baseline cardiac indices on CMR assessment are displayed in Table 3-2. 
Baseline LVEF was preserved at 64±4.9%. On CMR assessment, baseline/resting 
quantitated MR categorised MR severity as: 4 with severe MR, 5 with moderate-
severe MR and 1 with mild MR by Gelfand et al criteria (70), with a mean MR-Rvol 
of 56±25ml and MR-RF of 40±14%.      
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3.5.3 Supine bicycle exercise 
The patient’s haemodynamic responses to supine bicycle exercise are displayed in 
Table 3-2. Patients exercised for a mean total duration of 1206±303s (20 minutes 6 
seconds ± 5 minutes 3 seconds), with increasing resistance from 51±16W at low to 
82±10W at moderate exercise. Patients described increasing subjective RPE on 
the Borg scale (320) from 6±0 to 9.5±1.6 and 14.8±1.2 for rest, low and moderate 
exercise intensities respectively (p<0.001). From rest to low and moderate 
exercise, patients HR increased (61±10bpm vs 98±6bpm and 115±6bpm 
respectively, p<0.001), systolic BP increased (128±10mmHg to 145±16mmHg and 
163±27mmHg respectively, p=0.001), whilst diastolic BP remained unchanged 
(78±9 mmHg vs 81±15mmHg and 80±9 mmHg respectively, p=0.665).  
  
3.5.4 Cardiac indices response to exercise 
3.5.4.1 Left ventricular indices 
Changes in biventricular size/function during supine Ex-CMR are displayed in 
Table 3-2. From rest to low and moderate exercise, LVEDVi (112±23ml/m2, 
111±21ml/m2 and 107±22ml/m2 respectively, p=0.185), LVESVi (41±12ml/m2, 
36±9.8ml/m2 and 37±11ml/m2 respectively, p=0.055), LVSVi (71±14ml/m2, 
75±15ml/m2 and 70±15ml/m2 respectively, p=0.156) and LVEF (64±4.9%, 67±5.1% 
and 66±6.1% respectively, p=0.075) remained unchanged (Figure 3-1). As 
demonstrated in Figure 3-2, patients demonstrated a variable left ventricular 
response to exercise, with 4 patients showing the presence of LVCR (≥4% rise in 
LVEF), 4 patients absence of LVCR and 2 patients had an initial augmentation of 
LVEF≥4% at low intensity exercise, which then dropped below resting LVEF at 
moderate intensity, which has been termed ‘partial LVCR’.  
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Figure 3-1 Changes in left ventricular indices during supine Ex-CMR 
LVEDVi (upper-left), LVESVi (upper right), LVSVi (lower left) and LVEF (lower-
right) during supine Ex-CMR. Mean group values depicted by dashed black line. 
Statistical comparison across all exercise stages presented (top of graph), which if 
significant then intergroup comparisons (rest vs low, low vs moderate and rest vs 
moderate exercise intensities) are presented (bottom of graph). Abbreviations: 
EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; Ex-
CMR, Exercise Cardiovascular magnetic resonance; i, indexed to body surface 
area; LV, left ventricular; SV, stroke volume.  
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Figure 3-2 Line graph depicting the variable left ventricular cardiac reserve 
(LVCR) between primary MR patients during supine Ex-CMR.  
4 patients had the presence of LVCR with augmentation of LVEF≥4% (LVCR +, 
green), 2 a partial response with initial augmentation of LVEF ≥4% then 
deterioration in LVEF (partial LVCR, yellow) and 4 had an absence of LVCR 
(LVCR - , red). Abbreviations: Ex-CMR, Exercise Cardiovascular magnetic 
resonance; LVEF, Left ventricular ejection fraction; MR, mitral regurgitation. 
 
3.5.4.2 Right ventricular indices 
From rest, to low and moderate exercise, RVEDVi remained unchanged 
(86±16ml/m2 , 87±15ml/m2 and 87±12ml/m2 respectively, p=1), whilst RVESVi 
showed a non-statistically significant decreasing trend (38±8.0ml/m2, 34±5.0ml/m2 
and 32±6.5ml/m2 respectively, p=0.122) resulting in a significant increase in RVSVi 
(48±11ml/m2, 53±14ml/m2 and 55±11ml/m2 respectively, p=0.027) and RVEF 
(55±5.4% vs 60±6.0% at low and 63±6.6% respectively, p=0.001).  
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Figure 3-3 Changes in right ventricular indices during supine Ex-CMR. 
RVEDVi (upper-left), RVESVi (upper right), RVSVi (lower left) and RVEF (lower-
right) during supine Ex-CMR. Mean group values depicted by the dashed black 
line. Statistical comparison across all exercise stages presented (top of graph), 
which if significant then intergroup comparisons (rest vs low, low vs moderate and 
rest vs moderate exercise intensities) are presented (bottom of graph). 
Abbreviations: EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic 
volume; Ex-CMR, Exercise Cardiovascular magnetic resonance; i, indexed to body 
surface area; RV, right ventricular; SV, stroke volume. 
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3.5.4.3 Mitral regurgitant volume/fraction 
During Ex-CMR, from rest to low and moderate exercise, CMR quantitated MR 
showed a significant decrease in MR-Rvol (56±25ml to 52±23ml and 42±24ml 
respectively, p=0.032) and MR-RF (40±14% to 36±11% and 30±15% respectively, 
p=0.006). On Bonferroni post-test analysis, the differences in MR-RF were 
significant from rest to moderate exercise (p=0.035), but not significant for MR-Rvol 
differences between the exercise stages (Table 3-2) (Figure 3-4).  
 
3.5.4.4 Aortic flow and effective forward ejection fraction 
Despite no significant change in LV dimensions or LVEF during Ex-CMR, indexed 
aortic stroke volume increased from 41±8.3ml/m2/cardiac cycle at rest to 
47±8.3ml/m2/cardiac cycle at low and 47±6.5ml/m2/cardiac cycle at moderate 
exercise intensities (p=0.025). This was likely driven by the above described 
reductions in quantitated MR and allowed a significant increase in effective forward 
LVEF from 38±9.3% to 43±9.3% and 46±11% at rest, low and moderate exercise 
respectively (p=0.004) (Figure 3-4).  
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Figure 3-4 Changes in quantitated mitral regurgitation, aortic stroke volume 
and effective forward LVEF during supine Ex-CMR 
MR-Rvol (upper-left), MR-RF (upper right), aortic SVi (lower left) and effective 
forward LVEF (lower-right) during supine Ex-CMR. Mean group values depicted by 
dashed black line. Statistical comparison across all exercise stages presented (top 
of graph), which if significant then intergroup comparisons (rest vs low, low vs 
moderate and rest vs moderate exercise intensities) are presented (bottom of 
graph). Abbreviations: i, indexed to body surface area; LVEF, left ventricular 
ejection fraction; Ex-CMR, Exercise Cardiovascular magnetic resonance; MR-Rvol, 























HRR % Of HRmax N/A 30-39% 40-59% 
 
HR achieved (bpm) 61±10 98±6 115±6 <0.001 <0.001 <0.001 <0.001 
Systolic BP (mmHg) 128±10 145±16 163±27 0.001 0.014 0.228 0.008 
Diastolic BP (mmHg) 78±9 81±15 80±9 0.665  
Borg RPE 6±0 9.5±1.6 14.8±1.2 <0.001 <0.001 <0.001 <0.001 
Cycle resistance (W) 0 51±16 82±10 <0.001 0.025 0.025 <0.001 
LVEDV (ml) 210±41 209±37 199±36 0.116 
 
LVEDVi (ml/m2) 112±23 111±21 107±22 0.185 
LVESV (ml) 77±23 68±19 69±21 0.15 
LVESVi (ml/m2) 41±12 36±9.8 37±11 0.055 
LVSV (ml) 133±22 140±24 131±23 0.156 
LVSVi (ml/m2) 71±14 75±15 70±15 0.179 
LVEF (%) 64±4.9 67±5.1 66±6.1 0.075 
Aortic SV (ml) 77±12 88±13 89±13 0.005 0.006 1 0.052 
Aortic SVi (ml/m2) 41±8.3 47±8.3 47±6.5 0.025 0.076 1 0.042 
Effective Forward LVEF (%) 38±9.3 43±9.3 46±11 0.004 <0.001 0.6 0.001 
MR-Rvol (ml) 56±25 52±23 42±24 0.032 0.906 0.185 0.147 







RVEDV (ml) 162±21 162±19 163±21 0.971 
 
RVEDVi (ml/m2) 86±16 87±15 87±12 1 
RVESV (ml) 72±11 63±8.3 60±13 0.090 
RVESVi (ml/m2) 38±8.0 34±5.0 32±6.5 0.122 
RVSV (ml) 90±16 99±20 104±18 0.034 0.29 0.944 0.076 
RVSVi (ml/m2) 48±11 53±14 55±11 0.027 0.539 0.539 0.022 
RVEF (%) 55±5.4 60±6.0 63±6.6 0.001 0.042 0.791 0.001 
Abbreviations: BP, blood pressure; BPM, beats per minute; CO, cardiac output; CI, cardiac index; EDV, end-diastolic volume; 
EF, ejection fraction; ESV, end-systolic volume; Ex-CMR, Exercise Cardiovascular magnetic resonance; HR, heart rate; HRR, 
heart rate reserve;  i, Indexed to body surface area; LV, left ventricle; MR-RF, mitral regurgitant fraction; MR-Rvol, mitral 




3.5.5 Intra/Inter-observer reproducibility 
Reproducibility of cardiac parameters assessed by coefficient of variance of intra-
observer and inter-observer measurements are presented in Table 3-3. 
Intra-observer reproducibility of cardiac sequences assessed at rest and during 
exercise by CV were excellent (CV<10%) with exception of good intra-observer 
reproducibility of RVESV (CV 12.38%) and RVSV (CV 10.96%) at low and RVESV 
(CV 10.28%), MR-Rvol (CV 12.17%) and MR-RF (CV 10.62%) at moderate 
exercise intensities.   
Inter-observer reproducibility assessed by CV of cardiac parameters were similarly 
excellent (CV<10%), with the exception of good inter-observer variability in RVESV 
(CV 10.22%) and MR-Rvol (CV 10.63%) at rest, LVESV (CV 10.70%), RVESV (CV 
17.06%) and MR-Rvol (CV 10.38%) during low intensity exercise and RVESV (CV 
16.68%), MR-Rvol (CV 16.74%) and MR-RF (CV 15.23%) during moderate 





Table 3-3 Reproducibility of cardiac indices by supine Ex-CMR in MR patients 
Exercise stage  Cardiac Parameter Co-efficient of Variance 
Intra-observer Inter-observer 
Rest 
LVEDV 1.56 2.13 
LVESV 3.83 6.17 
LVSV 1.9 3.49 
LVEF 2.08 3.25 
RVEDV 4.59 3.03 
RVESV 7.3 10.22 
RVSV 7.17 6.8 
RVEF 4.8 7.08 
Aortic stroke volume 1.57 2.46 
Effective forward LVEF 1.64 3.24 
Mitral regurgitant volume 5.05 10.63 
Mitral regurgitant fraction 3.75 8.26 
Low 
LVEDV 2.09 4.65 
LVESV 4.85 10.7 
LVSV 2.52 3.33 
LVEF 1.69 3.34 
RVEDV 6.36 8.36 
RVESV 12.38 17.06 
RVSV 10.96 9.93 
RVEF 7.18 9.14 
Aortic stroke volume 2.27 3.57 
Effective forward LVEF 1.68 3.96 
Mitral regurgitant volume 5.98 10.38 
Mitral regurgitant fraction 4.44 7.92 
Moderate 
LVEDV  2.3 3.79 
LVESV 5.05 9.06 
LVSV 2.95 3.18 
LVEF 2.18 3.19 
RVEDV 5.01 4.72 
RVESV 10.28 16.68 
RVSV 6.06 8.32 
RVEF 5.57 8.31 
Aortic stroke volume 3.05 4.08 
Effective forward LVEF 2.24 5.6 
Mitral regurgitant volume 12.17 16.74 
Mitral regurgitant fraction 10.62 15.23 
Abbreviations: EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic 
volume; Ex-CMR, Exercise Cardiovascular magnetic resonance; LV, left ventricle; 





This is the first study to perform biventricular volume/function and quantitative MR 
assessment during continuous supine Ex-CMR in patients with primary MR. The 
study has 5 important findings: 1, biventricular volume/function and quantitated MR 
assessment during continuous moderate supine Ex-CMR is feasible with the use of 
C-SENSE sequences; 2, the study demonstrates good/excellent intra/inter-
observer reproducibility of biventricular indices and MR quantification; 3, the Ex-
CMR protocol uses attainable equipment, sequences and software, reducing 
barriers to clinical utility; 4, in asymptomatic patients with at least moderate primary 
MR on TTE, effective forward LVEF is augmented by a decrease in MR during 
exercise and 5, the study agrees with prior exercise-TTE studies in demonstrating 
variable LVCR (85, 86, 91) and dynamic changes in MR (88) during exercise 
between asymptomatic primary MR patients. 
 
3.6.1 Response to supine Ex-CMR 
In our group of primary MR patients there was no significant change in biventricular 
dimensions or global LVEF with increasing exercise, but significant increases in 
RVEF and reductions in MR-RF during exercise, which resulted in an increase in 
effective forward LVEF.  
 
3.6.1.1 Changes in LV volumes/function 
Prior exercise TTE studies demonstrate variable changes in LV 
volumes/dimensions with exercise. Numerous exercise TTE studies utilising 
upright exercise with post stress imaging demonstrate a decrease in 
LVEDV/dimensions during exercise (85, 91, 327, 328), whilst exercise TTE studies 
using semi-supine exercise demonstrate a more variable response with Magne et 
al showing decreases in LVEDV (88) and Suzuki et al increases in LVEDVi with 
exercise (90). In keeping with prior studies investigating MR patients during fully 
supine exercise (93, 329), our study demonstrated no significant change in LV 
dimensions during exercise. Chew et al performed supine Ex-CMR to moderate 
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exercise intensity in 5 primary MR patients, showing no change in indexed LV 
volumes (93) and Lavie et al performed radionuclide angiography during supine 
exercise in 11 severe MR patients, also showing no change in indexed LV volumes 
(329). These findings may be attributable to greater venous return/preload at rest 
and during exercise in the supine (with legs elevated in a supine 
ergometer/bicycle) than upright positions (330), which may theoretically maintain 
an unchanged LVEDV at higher levels of exercise compared to upright exercise, 
during which LVEDV appears to decrease in primary MR patients (85, 88, 91, 327, 
328) .  
LV contractility can vary between MR patients during exercise. Indeed, our study 
demonstrated non-statistically significant increases in LVEF during supine Ex-
CMR, whilst Chew et al found significant increases in LVEF (58±4% at rest to 
67±3% at moderate exercise, p=0.04), (93). As discussed in chapter 1.1.3.4.1, the 
change in LVEF during exercise can vary between patients with primary MR, with 
patients having an augmentation of LVEF <4% during exercise-TTE being defined 
as having an absence of LVCR. Exercise-TTE studies demonstrate LVCR as an 
independent predictor of outcomes between groups of primary MR patients, 
despite statistically comparable resting MR severity and indexed left ventricular 
dimensions/volumes and LVEF (85, 86). Due to the variable LVCR response 
between primary MR patients, Magne et al demonstrated no significant 
augmentation of LVEF in their overall cohort during semi-supine exercise TTE, as 
54 (47%) patients had LVCR, whilst 61 (53%) an absence of LVCR. The study 
recruited a similar cohort of patients to ours: asymptomatic patients with least 
moderate primary MR on TTE (as per ASE criteria) and preserved LVEF. 
Therefore the differential findings of LVEF between our cohort and that of Chew et 
al, is not un-surprising and likely explained by differing LVCR between groups. 
Indeed, 4 patients in our cohort failed to augment their LVEF ≥4% at any stage, 
whilst 2 had an initial augmentation followed by a reduction in LVEF during 





3.6.1.2 Changes in RV volumes/function 
Exercise changes in RV dimensions in primary MR patients have been minimally 
investigated, with the majority of prior exercise studies instead focused on changes 
in RV function (87, 331, 332). Only Chew et al has published the changes in RV 
volumes, also using supine Ex-CMR and demonstrated similar findings to ours. 
Both studies showed no change in RVEDVi during exercise. We showed a non-
significant trend of reducing RVESVi with significant increases in RVSVi and 
RVEF, whilst Chew et al showed a significant decrease in RVESVi and non-
significant increases in RVSVi and RVEF (93). Importantly, RV systolic function 
can differ between primary MR patients and has prognostic significance. Kusunose 
et al demonstrated using exercise-TTE that exercise TAPSE is an independent 
predictor of surgery free survival (87). Similar findings have also previously been 
demonstrated in an exercise radionuclide angiography study by Borer et al, where 
exercise RVEF was the best predictor of outcomes in asymptomatic severe MR 
patients with normal resting biventricular function, even over changes in exercise 
LVEF (332). The prognostic importance of exercise RVEF augmentation is not 
surprising, given changes in RVEF during exercise inversely correlate with 
changes in pulmonary pressures (87, 331, 332), rises in which during exercise are 
an independent predictor of adverse outcomes in patients with at least moderate 
primary MR with no/mild symptoms (NYHA≤II) (89, 90). Therefore, similar to LVCR 
being variable between primary MR patients, exercise changes in RVEF can also 
differ, with prognostic implications. As such, variable changes of exercise RVEF 
between studies with small numbers of patients is not unexpected.     
 
3.6.1.3 Changes in quantitated MR and effective forward LVEF 
MR can be dynamic during exercise. In secondary (functional/ischaemic) MR, 
numerous studies have investigated the dynamic changes in quantified MR during 
exercise TTE (36, 333-337), with patients demonstrating a dynamic increase in MR 
having poorer exercise capacity (337) and poorer outcomes (334, 335). In 
comparison, fewer studies have quantified the dynamic change in primary MR 
during exercise (86, 88, 92, 327). Our cohort demonstrated variable dynamic 
146 
 
changes in MR-Rvol during supine Ex-CMR (Figure 3-4). This is in keeping with 
prior exercise-TTE studies quantifying changes in primary MR (88, 327). Leung et 
al investigated 40 patients with at least moderate degenerative MR with exercise-
TTE, demonstrating an increase in MR-Rvol in 32% and decrease in MR-Rvol in 
68% of patients (327). Assessing our cohort by this metric, from rest to moderate 
exercise, 20% demonstrated an increase in MR-Rvol and 80% a decrease in MR-
Rvol. Magne et al investigated 68 patients with at least moderate degenerative MR 
with rest and exercise TTE. 10% of patients were excluded due to suboptimal 
images during exercise, preventing accurate MR quantification. Of the remaining 
61 patients, 32% demonstrated a dynamic increase in MR-Rvol (≥+15ml), 42% 
remained relatively unchanged, and 26% a dynamic decrease in MR-Rvol (≥-
15ml). The study found that patients with a dynamic increase in MR-Rvol ≥15ml 
had a worse symptom free survival (88). Assessing our cohort by the same metric, 
10% had a dynamic increase in MR-Rvol (≥+15ml), 40% remained relatively 
unchanged and 50% showed a dynamic decrease in MR-Rvol (≥-15ml). Therefore 
our study agrees with the prior exercise TTE studies, as regards the variable 
dynamic response that can occur between primary MR patients. Additionally, as 
discussed in section 1.1.3.3.3, MR severity is often overestimated by TTE 
compared with CMR during resting imaging (59, 63, 64, 71-73); the same may be 
true during exercise. Therefore theoretically, during Ex-CMR patients in whom MR 
doesn’t decrease may demonstrate a poorer prognosis, likely progressing along a 
spectrum, with those whose MR increases demonstrating the worse outcomes. 
Further research across a broad range of MR severities and symptom states is 
required to assess this hypothesis.    
In our cohort, reductions in MR during exercise allowed an increase in effective 
forward LVEF. Previously, effective forward LVEF has been demonstrated to be a 
predictor of LVEF post-surgical intervention (325), but changes during exercise 
have not been investigated. Given the measurement accounts for changes in LV 
dimensions, function and MR during exercise it could theoretically provide useful 
prognostic information. Additionally, as presented in Table 3-3 the measurement is 
highly reproducible during supine Ex-CMR and therefore warrants further 
assessment in prognostic studies.     
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Although Ex-CMR studies quantifying changes in MR have not been previously 
performed, our findings of reductions in valvular regurgitation with increasing 
exercise intensity mirror that of prior Ex-CMR studies in patients with pulmonary 
valve disease (285, 291). Lurz et al investigated pulmonary stenosis and 
pulmonary regurgitation patients with Ex-CMR pre and post PPVI, demonstrating a 
reduction in PR occurred in both groups during exercise. Pre-PPVI, both groups 
were unable to augment RVSV with exercise but maintained effective forward 
RVSV by reductions in PR with exercise. After PPVI, RVSV increased in both 
groups with exercise; however there was no significant improvement in the 
augmentation of effective forward RVSV during exercise in the PR group. This was 
attributed the significant reduction in PR pre-PPVI during exercise, due to this, the 
study concluded that exercise augmentations in RVSV post PPVI were mostly due 
to reductions in afterload rather than regurgitation (291). Therefore, Lurz et al 
demonstrated, similar to our study, that reductions in valvular regurgitation during 
exercise can facilitate an increase in effective forward flow. 
 
3.6.2 Reproducibility 
The study demonstrated that biventricular and quantitated MR assessment during 
supine Ex-CMR is highly reproducible with excellent reproducibility (CV<10%) of 
biventricular volumes and function during moderate exercise, with the exception of 
RVESV, which were good (CV 10-20%). However, as MR quantification by the 
LVSV-AoSV method is reliant on 3 measurements (LVEDV, LVESV and total aortic 
forward flow), a decrease in reproducibility occurred with increasing exercise. 
However, we still demonstrated good intra and inter-observer reproducibility at 
moderate exercise intensity (CV 10-20%). Interestingly, effective forward LVEF, 
which as discussed accounts for changes in LV volumes, function and MR showed 
excellent intra and inter-observer reproducibility at all stages (CV<6%). This is 
because it is not reliant on LVESV measurements, which are less reproducible. 





3.6.3 Clinical implications 
The rationale for use of exercise cardiac imaging in asymptomatic MR patients is to 
help determine which patients may benefit from early surgery. The aim is to find 
the optimal timing at which the MR is significant and deteriorating but has not yet 
resulted in such significant cardiac remodelling to cause increased peri-operative 
risk or adverse long term outcomes. As discussed in section 1.1.4, current 
guidelines advise intervention in asymptomatic patients once LV dilatation or 
dysfunction develop or after the onset of AF or if resting PASP is >50mmHg in the 
context of a valve with high probability of a durable repair (1, 39). However, once 
LV dilatation/systolic dysfunction develops, a patient’s prognosis is often already 
adversely affected (338). The use of exercise imaging to tease out which patients 
with normal resting LV size and function are likely to deteriorate could therefore of 
significant use. International guidelines recognise the potential benefit of exercise 
echocardiography, however there are no surgical indications in the guidelines that 
currently utilise exercise TTE due to these ‘not been sufficiently well defined to be 
included in current recommendations’ (1). This is likely a result of a deemed 
insufficiency of current evidence and potentially issues around suboptimal 
reproducibility and inability to acquire diagnostic images in a sufficient proportion of 
MR patients (92), as discussed in section 1.1.3.4.1. Therefore a more robust 
exercise methodology may be required. As discussed, resting CMR is the 
reference standard in biventricular assessment (51, 52) and CMR MR 
quantification provides superior reproducibility and prognostic ability in in primary 
MR compared to TTE (63, 64). As demonstrated in exercise-TTE, LVCR, RV 
function (TAPSE), and dynamic changes in MR are independent predictors of 
outcomes in patients with primary MR (85-88, 91). Therefore the ability to assess 
biventricular function and quantitate MR during supine Ex-CMR is clinically 
appealing. This study has demonstrated the feasibility of accurate biventricular 
volumes, function and quantitated MR assessment during supine Ex-CMR, using 
vendor provided sequences, a commercially available ergometer and standard 
analysis software. These features make it more attainable and potentially more 
clinically viable than alternative free-breathing supine Ex-CMR methods that utilise 
the un-gated real-time method, which require specialist sequences and software 
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and prolonged analysis time (198, 268). Using supine Ex-CMR, in comparison to 
exercise-TTE, there are no limitations from acoustic windows, Doppler alignment 
issues or geometric assumptions, when quantifying MR using the LVSV-AoSV 
method. Indeed, in the research setting Magne et al had to exclude 10% of patients 
(88), as accurate MR quantification with exercise-TTE was not feasible and in the 
real world setting, accurate MR quantification with exercise-TTE was only feasible 
in 43% of patients with mitral valve prolapse (92). Where-as all patients 
successfully completed our supine Ex-CMR protocol with all images acquirable and 
analysable with good/excellent intra/inter-observer reproducibility. This protocol 
now needs using in a larger cohort of primary MR patients who are followed up for 
adverse outcomes to allow assessment of its prognostic ability. If demonstrating 
good prognostic ability, given MR-CPET is feasible (253), the current protocol 
could theoretically be adapted to be performed in tandem, therefore potentially 
creating an even more comprehensive assessment for borderline cases of primary 
MR.  
 
Excitingly, the measurement of effective forward LVEF demonstrated excellent 
reproducibility at all exercise stages in our study. As discussed in section 3.2, the 
measurement has demonstrated prognostic utility in prior resting CMR studies 
(325). Given effective forward LVEF represents the ‘true’ forward flow and takes 
into account changes in both LVEF and MR, it may prove to be a useful single 
indices for use in resting and Ex-CMR. Clearly further CMR and Ex-CMR studies 
are needed to assess whether the measurement provides additional prognostic 
insight over other indices. If so, the use of a single reproducible measurement, 
which accounts for two significant cardiac determinants of outcomes in MR patients 
(MR severity and LVEF), could greatly increase the utility of both CMR and Ex-
CMR in the clinical assessment of MR patients. Especially given, as discussed in 
section 1.1.3.1, current resting TTE assessment of MR is reliant on an integrated 
assessment using multiple measurements (40) and is therefore dependent on 
subjective analysis/combination of the various measurements to define severity. 
Finally, although this study focussed on primary MR patients, it should theoretically 
allow accurate biventricular assessment and valve flow assessment in other 
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aetiologies of MR, aortic valve disease and, by reintroducing pulmonary PCMR 
sequences validated in Chapter 2, right heart valve or congenital heart diseases.  
3.6.4 Limitations 
The limitations in this study revolve around its small sample size and strict 
recruitment criteria, which could limit generalisability, but as will be discussed may 
not limit clinical application. Similar to the study in Chapter 2 and prior Ex-CMR 
studies, the MR scanner bore can restrict knee clearance making supine Ex-CMR 
difficult in tall patients. Importantly, height was not an exclusion criteria and our 
tallest volunteer in this study was 182cm. Our cohorts mean BMI was on the border 
between healthy and overweight (24.8±3.3 kg/m2), with 50% a healthy weight (BMI 
20-25) and 50% overweight (BMI 25-30), and therefore our protocol has not been 
validated in obese patients, who may find supine Ex-CMR more difficult, but supine 
Ex-CMR has previously been demonstrated feasible in obese patients in a prior 
study (249). All patients in our study were asymptomatic (NYHA I) and in sinus 
rhythm. Symptomatic patients may not tolerate supine Ex-CMR as well, which 
could result in increased physical and respiratory motion, artefacts from which 
could make image acquisition and analysis more difficult. The presence of AF may 
make retrospective ECG gating during supine-Ex-CMR more difficult, which could 
prolong image acquisition/exercise time and may impact on image acquisition and 
reproducibility. However, the rationale for developing this protocol for use in 
primary MR patients is to help guide management in borderline cases, where 
patients do not have clinical or echocardiographic indications for 
surgery/intervention at rest. Given the development of symptoms or new onset of 
AF, in the context of TTE defined severe MR, is an indication for surgical 
intervention (37, 39), then the lack of demonstrating feasibility in symptomatic 
patients, or those in AF may not significantly limit its clinical use.  
Cycle duration in the study was longer than ideal for clinical use (mean 20 minutes 
6 seconds), as patients were imaged at two exercise intensities, but well tolerated 
by all patients with none needing to terminate early. As demonstrated in Figure 3-2, 
this gives the benefit of demonstrating patients with an initial favourable exercise 
response prior to deterioration. Such findings would be missed by only imaging at 
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rest and one exercise stage. Future studies are required to assess if such features 
place patients in a different prognostic group. However, if such studies do not 
demonstrate any additional benefit to imaging at low intensity exercise, then 
removal of this stage would reduce overall cycling time, making the protocol more 
clinically viable.  
Patients in our study were exercised to moderate exercise intensity with a mean 
HR of 115bpm and not until exhaustion/peak stress.  However, our achieved HR at 
moderate fully supine exercise was only slightly lower than semi-supine exercise-
TTE studies by Magne et al, which were sufficient to demonstrate prognostic 
significance of LVCR at a mean exercise HR of 127bpm (86) and dynamic 
increases in MR at a mean exercise of HR 125±13bpm (88). Indeed, the LVCR 
study by Magne et al acquired the images to assess LVCR at heart rates between 
90-110bpm (86). Given CMR is a more accurate assessment of biventricular 
volumes/function and MR quantification, the data acquired during moderate supine 
Ex-CMR may theoretically be sufficient to provide beneficial prognostic information.  
As per SCMR guidelines (339), MR quantification in the study was performed by 
assessing aortic flow from PCMR sequences planned at the sino-tubular junction. 
This has the potential to overestimate MR severity compared with aortic flow 
assessed at the valve level (340). However CMR studies demonstrate MR 
quantification by this the technique is highly reproducible (62, 63, 71), provides 
superior prognostic assessment compared with TTE (63, 64) and as such is the 
recommended site and method of MR quantification by CMR (339). Indeed TTE 
MR quantification can overestimate MR severity compared with the LVSV-AoSV 
technique (59, 63, 64, 71-73). As a result, as our recruitment was reliant on 
baseline TTE, our cohorts baseline MR severity on CMR assessment was more 
variable than the planned initial recruitment, with one patient that had moderate 
MR on TTE, having mild MR on baseline CMR assessment. 
Finally, the sample size in this study is small, initial plans for this thesis was to 
include 20 patients in this study; unfortunately recruitment was restricted by onset 
of the COVID-19 pandemic. Fortunately sufficient patients were recruited before 
the onset of the pandemic to demonstrate feasibility and reproducibility in this 
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patient cohort. However, the small sample size prevents in-depth analysis to 
assess if resting CMR can predict exercise changes in biventricular 
volumes/function and quantitated MR. Importantly, recruitment in this study is 
ongoing to overcome this issue and assess the protocols prognostic ability.     
     
3.7 Conclusion 
Assessment of biventricular function and MR quantification during continuous 
supine Ex-CMR to moderate intensity is feasible and reproducible. The Ex-CMR 
protocol utilises vendor provided C-SENSE sequences, a commercially available 
ergometer and standard analysis software, increasing widespread attainability, 
potentially making it more clinically viable. Further research is now warranted to 
assess the prognostic ability of the Ex-CMR protocol in primary MR patients and 






Chapter 4  
 
Cardiac reverse remodelling for primary mitral regurgitation: 
mitral valve replacement vs. mitral valve repair     
 
4.1 Abstract  
Background  
When feasible, mitral valve repair (MVr) is recommended over mitral valve 
replacement (MVR), to treat primary mitral regurgitation (MR), based upon historic 
outcome studies and reverse remodelling studies using transthoracic 
echocardiography (TTE). Cardiovascular magnetic resonance (CMR) offers 
reference standard biventricular volume and function assessment with superior MR 
quantification reproducibility compared to TTE. In patients with primary MR we 
investigated cardiac reverse remodelling and quantitated changes in MR post-MVr 




83 patients with at least moderate-severe MR on TTE were prospectively recruited. 
CMR imaging and 6-minute walk tests (6MWT) were performed at baseline and 6 
months after mitral surgery or watchful waiting (control group). CMR protocol 
included: cines for left ventricular (LV) and right ventricular (RV) volumes, 
aortic/pulmonary through-plane phase contrast imaging. MR was quantitated 
indirectly by the LV-aortic stroke volume method.  
 
Results  
72 patients completed follow-up (Controls=20, MVr=30 and MVR=22). Baseline 
cardiac indices, co-morbidities and surgical risk scores were comparable between 
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surgical groups. Baseline biventricular volumes/function were also comparable 
between groups, except for greater right ventricular ejection fraction (RVEF) in 
controls than MVr and MVR groups (54±8% vs 46±6.6% and 46±9.4% 
respectively, p=0.002). Baseline MR regurgitant fraction (MR-RF) was lower in 
controls than MVr and MVR groups (39±13% vs 50±10% and 52±13% 
respectively, p=0.001). At 6 months, compared with controls, MVr and MVR groups 
demonstrated improved 6MWT distances (+0.1±55m vs +57±54m and +64±76m 
respectively, p=0.002) and decreased indexed left-ventricular end-diastolic 
volumes (-1.3±12ml/m2 vs -29±21 ml/m2 and -37±22 ml/m2 respectively, p<0.001), 
indexed left atrial volumes (+1.2±19ml/m2 vs -27±30 ml/m2 and -39±26 ml/m2 
respectively, p<0.001) and MR-RF (+0.4±7.0% vs -29±11 and  -40±14 respectively, 
p<0.001 ). Biventricular reverse remodelling was comparable between surgical 
groups, except poorer RVEF post-MVr compared with controls (47±6.1% vs 
53±8.0% respectively, p=0.01). MVR resulted in lower residual MR-RF than MVr 
(12±8.0% vs 21±11% respectively, p=0.022).  
 
Conclusion  
In primary MR, MVR with chordal preservation may offer comparable cardiac 
reverse remodelling benefits at 6-months compared to MVr. Larger, multicentre 
CMR studies are required, which if confirmed, might then have implications for 











Mitral regurgitation is the commonest valve disease in the US and second 
commonest indication for valve surgery in Europe (94, 341). Current guidelines 
recommend MVr over MVR whenever feasible (1, 39), as observational studies 
comparing techniques typically demonstrate worse early and long-term mortality 
post MVR (120, 121). However, numerous studies supporting this recommendation 
pre-date the routine use of chordal preservation techniques with MVR (116-120), 
which improves cardiac reverse remodelling post MVR (112-115, 342). Indeed, 
cardiac reverse remodelling between MVr/MVR is comparable when chordal 
preservation is used (126, 127) and inferior post MVR when not (117, 118). In a 
broad range of cardiac disease, cardiac reverse remodelling is associated with a 
more favourable prognosis (128, 129), therefore lack of chordal preservation in 
comparative studies may result in significant bias. Importantly, MVR is more 
frequently performed in patients with more complex mitral valve disease, advanced 
age, reduced LVEF and worse NYHA functional class, than patients referred for 
MVr (123). Unfortunately, a randomised trial comparing MVr/MVR in primary MR 
has not been performed and studies using propensity matching in an attempt to 
overcome intrinsic bias present conflicting results (123, 124). In ischaemic MR, a 
randomised trial demonstrated no significant difference in survival or left ventricular 
reverse remodelling at 2-years between MVr vs MVR with chordal preservation, but 
greater recurrent MR in the MVr group, resulting in more heart failure related 
adverse events and hospital admissions (125). In primary MR, recurrent MR post 
MVr is not uncommon, with mod-severe MR reported in 13-17% in longitudinal 
studies (135, 136) and associated with adverse LV remodelling and late mortality 
(343). MVr typically results in equivalent (120, 123, 124) or more reoperations than 
MVR (130), however, the reoperation end-point may not account for all recurrent 
significant MR if patients are not keen, or deemed too high risk for repeat surgery.  
Accurate assessment of mitral regurgitation is paramount to guide the need for 
surgical intervention and provide appropriate outcome comparisons between 
MVr/MVR. CMR is the reference standard for biventricular volume and functional 
assessment (52, 53) and compared to TTE, CMR MR quantification has been 
shown to have superior reproducibility (59, 60, 62, 63) and prognostication in 
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primary MR (63, 64). Importantly, MR severity assessment by CMR and TTE can 
be discordant, especially in cases of late-systolic, eccentric or multiple regurgitant 
jets (63). However, CMR defined MR severity correlates stronger with clinical 
outcomes than TTE (63, 64), suggesting it is more accurate. TTE can also 
overestimate MR severity in comparison to CMR (59, 63, 64, 71-73). Indeed, 
Uretsky et al demonstrated in two studies that only 32-37% of those who 
underwent surgical correction due to echocardiogram-defined severe MR, had 
severe MR by CMR criteria (59, 72). Ultimately randomised trials comparing MVr 
vs MVR and/or comparing outcomes post-echocardiogram vs CMR-guided surgical 
intervention could guide future clinical decision making. Prior to this, rigorous 
hypothesis-generating observational data will be required; this study aimed to 
assess differences in cardiac reverse remodelling and residual MR (assessed by 
CMR) following surgical MVr and MVR with chordal preservation for primary MR, 
compared to a matched control group (moderate-severe MR patients on a watchful 
waiting pathway). A control group has been included in this study to allow a 
comprehensive comparison between the surgical groups and controls.  
 
4.3 Methods 
4.3.1 Study design 
This single-centre prospective observational cohort study recruited patients 
between February 2016 and February 2020 with primary MR from the 
cardiology/cardiac surgery out-patient departments at Leeds Teaching Hospitals 
NHS Trust, Leeds, UK. Inclusion criteria: moderate-severe or severe primary MR 
on echocardiography, aged >18 years, suitable/accepted for surgical intervention, 
with capacity to provide written informed consent. Exclusion criteria: Secondary 
(functional/ischaemic/atrial) MR, contraindications to CMR, significant (≥ moderate 
severity) aortic valve disease, uncontrolled AF >120bpm, NYHA functional Class 
IV, terminal illness, haemodynamic instability, renal failure with an estimated 
glomerular filtration rate of <30ml/min/1.73m2, weight >130kg, pregnancy or breast 
feeding, or inability to lie flat for 60 minutes. A watchful waiting control group was 
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included to allow for a comprehensive comparison with surgical groups and to 
allow assessment of cardiac remodelling that occurs in these groups.   
At least moderate-severe MR was defined by a combined assessment of 
qualitative and quantitative echocardiographic measures as per ASE guidelines: 
vena contracta >0.7cm2, PISA radius >0.8cm, EROA >0.3cm2, MR-Rvol 
>45ml/beat, MR-RF >40% (40). Surgical intervention (timing and technique) was 
decided by a multidisciplinary heart team, as per international guidance (1, 37), 
that were independent from the study. Patients underwent standard pre-operative 
assessment for MV intervention including TOE and left+/- right heart 
catheterisation. Baseline clinical and demographic data were recorded for all 
patients. CMR imaging and 6-minute walk tests (6MWT) were performed at 
baseline and 6-months post-surgery (MVR or MVr) or post watchful waiting (control 
group). 6MWT was performed as per American Thoracic Society (ATS) guidelines 
(344). Written informed consent was provided by all patients. The study was 
approved by the local research ethics committee (Yorkshire & The Humber-South 
Yorkshire 15/YH/0503) and complied with the Declaration of Helsinki (see 
appendix).  
 
4.3.2 CMR imaging 
Baseline and 6-month follow-up CMR were performed (1.5T Philips Ingenia, Best, 
Netherlands). CMR protocol involved: 1. Survey images, 2. LV short axis multi-
slice, multi-phase cine imaging bSSFP sequence (TR 3msec, TE 1.6msec, flip 
angle 60°, SENSE factor 2, 10mm thickness, 0mm gap, in-plane spatial resolution 
1.2 x 1.2mm, 30 phases, matrix 192x131, voxel size 1.88x1.88mm, typical FOV 
340mm), 3. 4-chamber and 2-chamber cine imaging to calculate LA volume and 
right atrial (RA) area, 4. Dedicated transaxial RV multi-slice, multi-phase bSSFP 
cine imaging (TR 2.8msec, TE 1.41msec, flip angle 60°, SENSE factor 1.8, 8mm 
thickness, 0mm gap, in-plane spatial resolution 1.88 x 1.88mm, 20 phases, matrix 
192x143, voxel size 1.88x1.88mm, typical FOV 360mm).5. Two orthogonal LVOT 
and RVOT views to plan aortic and pulmonary PCMR imaging respectively, 6. 
Through-plane aortic and pulmonary PCMR, planned at the aortic sino-tubular 
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junction, orthogonal to the aorta, to assess aortic flow and approximately 1cm 
superior to the pulmonary valve, orthogonal to the main pulmonary artery to assess 
pulmonary flow. VENC was set to 150cm/s as standard and increased for repeat 
imaging if aliasing occurred. All PCMR sequences were planned with region of 
interest in the iso-centre of the MRI scanner to reduce background phase-offset 
errors (74, 75). Other PCMR parameters: typical FOV 350x280mm, TR 5.1msec, 
TE 3.2msec, flip angle 15°, temporal resolution 28msec, number of signal 
averages 1, SENSE factor 2, TFE factor 3, TFE acquisition duration 30.8ms, slice 
thickness 8mm, 30 phases, phase percentage 100%, in-plane spatial resolution 
2.5×2.5mm, matrix 140x112, Cartesian sampling, and typical acquisition times, 12-
15 seconds for breath-held sequences. In patients with AF, two acquisitions of 
aortic/pulmonary PCMR imaging with the same parameters were obtained and the 
results averaged to account for heart rate variation. 
 
4.3.3 CMR analysis 
Images were analysed using commercially available software (cvi42, Circle 
Cardiovascular Imaging, Calgary, AB, Canada). Biventricular endocardial contours 
were manually traced; the papillary muscles and trabeculations were considered 
part of the ventricular blood pool and volumes calculated by summation of disks 
(319). Maximal left atrial volume was calculated using the bi-plane area-length 
method from 2 and 4-chamber cine images during ventricular systole, 
corresponding to the last cine image before opening of the mitral valve (345). 
Maximal right atrial area was measured, inclusive of the right atrial appendage, 
from 4-chamber cine images during ventricular systole, corresponding to last cine 
image before opening of the tricuspid valve (345, 346). Aortic and pulmonary flows 
were assessed by manually contouring the vessel in every phase. As per prior 
studies (62-64) and SCMR recommendations (69), mitral and tricuspid 
regurgitation were quantified indirectly using the following formulas respectively: 
Mitral regurgitant volume (MR-Rvol) = left ventricular stroke volume – aortic stroke 
volume and tricuspid regurgitant volume (TR-Rvol) = right ventricular stroke volume 
– pulmonary stroke volume.  
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4.3.4 Surgical technique 
Surgical procedures were performed by one of four experienced cardiac surgeons 
in our centre, under general anaesthesia using a standard cardiopulmonary bypass 
technique via a 7-10 cm midline sternotomy incision and mild systemic 
hypothermia (30-34°C). Intra-operative TOE was utilised. Systemic heparinisation 
aorto-bicaval cannulation was performed. LA incision was made to expose and 
inspect the pathological mitral valve. All MVr were performed using Gore-Tex 
chordae sutures and supported by a Carpentier-Edwards Physio II annuloplasty 
ring (typical size 29-34mm). MVR were performed using the St Jude mechanical 
valve, Edwards Perimount Magna bioprosthetic valve or St Jude EpicTM Mitral 
stented tissue valve with LinxTM AC technology (typical size 27-33mm). At least 
partial chordal preservation was performed with MVR as routine practice. The type 
of prosthetic valve, preservation technique and suture placement technique were at 
the discretion of the surgeon. Protamine was administered prior to wound closure 
with stainless steel myowires over mediastinal drains. Mechanical MVR patients 
were treated with life-long anticoagulation (Vitamin K antagonist-warfarin) post 
procedure. In selected cases AF was ablated with radiofrequency and coinciding 
left atrial appendage ligation performed. 
 
4.3.5 Statistical analysis 
Data were analysed using SPSS version 26 (IBM Corp.). All continuous data were 
assessed for normality using Shapiro-Wilk test. Baseline, follow-up/residual and 
the changes from baseline to follow up variables were compared between the three 
groups (control/MVr/MVR). Continuous variables are expressed as mean±SD and 
categorical variables expressed as frequencies and percentages. Continuous data 
was assessed between all groups with ANOVA with Bonferroni post-hoc analysis 
for normally distributed variables and Kruskal-Wallis with Bonferroni post-hoc 
analysis for non-normally distributed variables. Categorical data was compared by 
Fisher’s Exact test, which was preferred to the Chi squared test as this test is less 
valid in small groups and/or those with low frequency of variables (n<5) (326, 347). 
If a significant difference was found between all groups, Fisher’s Exact tests were 
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performed between each group to assess inter-group differences. p<0.05 was 





Eighty-three patients were recruited and scanned at baseline. By group, 34 
patients underwent MVr (4 dropped out: 1 death, 3 declined follow up: 1 developed 
motor neuron disease and 2 declined due to COVID-19 pandemic); 24 underwent 
MVR (2 dropped out: 2 deaths); 25 controls were observed with watchful waiting (5 
dropped out: 3 deaths, 2 declined follow up: 1 due to claustrophobia and 1 
developed lung cancer). This resulted in 72 patients with paired CMR scans at 6 
months: 30 MVr, 22 MVR (14 metallic, 8 bio-prosthetic valves) and 20 controls 
(Figure 4-1).  
 
Figure 4-1 A figure to demonstrate the studies inclusion/exclusion criteria 
and patient flow 
*2 patients decline follow up imaging due to the COVID-19 pandemic. 
Abbreviations: AF, atrial fibrillation; CMR, cardiovascular magnetic resonance; 
eGFR, estimated glomerular filtration rate; MND, motor neuron disease; MR, mitral 
regurgitation; MVr; mitral valve repair; MVR, mitral valve replacement; NYHA, New 





4.4.1 Baseline patient characteristics 
Baseline characteristics of the groups are presented in Table 4-1. There was no 
difference in age or sex between the groups. The underlying leaflet(s) affected 
differed between surgical groups (p=0.014), with a greater proportion of PMVL 
disease in the MVr group and AMVL disease in the MVR group. The proportion of 
patients with flail leaflets was comparable between all groups (p=0.703). NYHA 
functional class was lower in the control, than the MVr and MVR groups at 1.3±0.6 
vs 1.9±0.7 and 2.2±0.7 respectively (p=0.001). There were no statistically 
significant differences in surgical risk scores (Log Euro/Log EuroII/ STS 
Mortality/morbidity) between groups. The MVr and MVR groups had a greater 
proportion of patients with AF than the control group (p=0.021) at 16 (53%) and 13 
(59%) vs 4 (20%) respectively. There were otherwise no statistically significant 























Male 11 (55%) 24 (80%) 16 (73%) 0.186       
Age (years) 64±18 67±11 66±10 0.935       
Duration to follow-up (days)* 233±8 188±27 194±25 0.001 0.001 0.008 1 
BMI (kg/m2) 24.1±3.3 26.2±3.8 25.3±5.0 0.275       
Systolic BP (mm/Hg) 125±25 125±15 125±13 1       
Diastolic BP (mm/Hg) 73±16 77±13 77±10 0.54       
Heart rate (bpm) 71±10 72±15 72±13 0.885       
6MWT distance (m) 393±118 365±103 358±79 0.485       
NYHA functional class: 
I 15 (75%) 8 (27%) 4 (18%) 
0.001 0.003 0.001 0.256 
II 4 (20%) 16 (53%) 9 (41%) 
III 1 (5%) 6 (20%) 9 (41%) 
IV 0 0 0 
Aetiology: 
Leaflet affected: 
PMVL 12 (60%) 26 (87%) 12 (54%) 
0.027 0.149 0.332 0.014 AMVL 1 (5%) 1 (3%) 5 (23%) 
Bi-leaflet 7 (35%) 3 (10%) 5 (23%) 







Surgical risk scores: 
Log Euro 5.6±4.7 4.7±3.5 3.7±2.4 0.736       
Log Euro II 1.5±1.4 1.4±1.0 1.6±1.2 0.523       
STS mortality 1.5±1.6 1.2±1.2 1.9±1.6 0.076       
STS mortality/morbidity 11.8±7.1 9.5±4.9 13.2±5.9 0.053       
Comorbidities: 
Smoking History 7 (35%) 14 (47%) 8 (36%) 0.713       
Diabetes mellitus 2 (10%) 1 (3%) 1 (5%) 0.679       
Hypertension 4 (20%) 11 (37%) 6 (27%) 0.486       
Atrial fibrillation 4 (20%) 16 (53%) 13 (59%) 0.021 0.022 0.014 0.781 
Prior myocardial infarction 1 (5%) 0 1 (5%) 0.507       
Prior PCI 2 (10%) 0 1 (5%) 0.183       
Prior Stroke 1 (5%) 0 0 0.278       
Prior TIA 1 (5%) 1 (3%) 1 (5%) 1       
COPD 2 (10%) 1 (3%) 2 (9%) 0.599       
Chronic Kidney Disease 1 (5%) 0 1 (5%) 0.507       
Haemoglobin (g/L) 137±11 143±10 140±14 0.15       
Creatinine (umol/L) 79±14 81±18 88±20 0.244       
* Duration of time until repeat CMR imaging after either surgical intervention or baseline CMR in control group. Abbreviations: 6MWT, 6-minute walk test; 
AMVL, anterior mitral valve leaflet; BMI, body mass index; BP, blood pressure; BPM, beats per minute; BSA, body surface area; COPD, chronic 





4.4.2 Baseline CMR cardiac parameters 
Baseline cardiac parameters as assessed by CMR are presented in Table 4-2. 
There were no statistically significant differences in baseline biventricular volumes 
between the groups, although lower RVEF in the MVR and MVr groups than 
controls at 46±6.6% and 46±9.4% vs 54±8.0% respectively (p=0.002). As per 
Table 4-2, there were no baseline differences in CMR quantified AR, PR or 
tricuspid regurgitation (TR) between the groups. The control group had lower 
baseline quantitated MR than the MVr and MVR groups with an MR-Rvol of 
49±25ml vs 66±26ml and 71±29ml (p=0.002) and MR-RF of 39±13% vs 50±10% 
and 52±13% respectively (p=0.001). There were no statistically significant 
differences on baseline CMR between both surgical groups. Therefore, there were 
no significant baseline differences between the two surgical groups, except 























LVEDVi (ml/m2) 118±25 124±31 131±27 0.332       
LVESVi (ml/m2) 50±14 56±20 61±19 0.153       
LVSVi (ml/m2) 69±14 68±16 70±13 0.85       
LVEF (%) 59±5 55±7.8 54±8.1 0.173       
LVMi (g/m2) 53±13 62±14 63±18 0.063       
LA volume indexed (ml/m2) 85±23 94±31 107±36 0.063       
AR Rvol (ml) 3.6±3.8 4.2±2.1 3.4±2.4 0.111       
AR RF (%) 4.8±3.9 6.8±3.7 5.8±4.1 0.106       
MR Rvol (ml) 49±25 66±26 71±29 0.002 0.012 0.004 1 
MR RF (%) 39±13 50±10 52±13 0.001 0.002 0.001 1 
RVEDVi (ml/m2) 93±24 94±20 98±17 0.429       
RVESVi (ml/m2) 43±12 51±14 54±16 0.034 0.113 0.041 1 
RVSVi (ml/m2) 52±16 43±10 44±9.3 0.033 0.041 0.102 1 
RVEF (%) 54±8 46±6.6 46±9.4 0.002 0.004 0.005 1 
PR Rvol (ml) 2.3±2.2 3.4±3.3 2.5±1.6 0.421       
PR RF (%) 2.9±2.2 5.2±5.5 3.9±3.0 0.191       
TR Rvol (ml) 12±16 16±15 15±13 0.385       
TR RF (%) 13±14 19±18 17±15 0.353       
RAAi (cm2/m2) 14±3 15±3.8 15±4.3 0.319       
Abbreviations: AR, aortic regurgitation; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i, indexed to 
body surface area; LA, left atrial; LV, left ventricular; LVM, left ventricular mass; MR, mitral regurgitation; PR, pulmonary 





4.4.3 Surgical variables 
The operation variables are compared between the two surgical groups in Table 
4-3. Thirty patients underwent MVr and twenty-two patients underwent MVR 
(Prosthesis: metallic =14, tissue=8). MVr and MVR groups were comparable in 
terms of concomitant coronary artery bypass grafting (2 vs 2 respectively, p=1.00), 
tricuspid valve repair (5 vs 2 respectively, p=0.685) and AF ablations (1 vs 2 
respectively, p=0.567). There were no statistically significant differences in the 
cardiopulmonary bypass time (CBT) and cross clamp time (CCT) between the MVr 
and MVR groups at 124±26min vs 132±47min (p=0.837) and 96±28min vs 
94±41min (p=0.333) respectively. After dividing the MVR group into those with 
direct MVR (n=16) and those with MVR after an attempted repair (MVRar) (n=6), 
the MVRar group had longer surgical procedure times than direct MVR and MVr 
groups, with CBT of 190±32min vs 111±31min and 124±26min (p=0.001) and CCT 
of 146±39min vs 74±19min and 96±28min (p=0.001) respectively. On sub-group 
analysis, direct MVR patients had equivalent bypass (p=0.216) but shorter cross 




















(8 tissue, 14 
metallic) P-Value(s) 
CABG 2 (7%) 2 (9%) 1 
  
AF ablation 1 (3%) 2 (9%) 0.567 
TV repair 5 (17%) 2 (9%) 0.685 
Bypass duration (min) 124±26* 132±47 0.837 




















Bypass duration (min) 124±26* 111±31 190±32 0.001 0.216 <0.001 0.012 
Crossclamp time (min) 96±28* 74±19 146±39 0.001 0.046 0.071 0.001 
Surgical variables between groups and differences between groups when mitral 
valve replacement was group divided into those that received direct replacement 
and those who had replacement after an attempted repair (MVRar). * Surgical 
duration unavailable for 1 patient in repair group. Abbreviations: AF, atrial 
fibrillation; CABG, coronary artery bypass grafting; MVr, mitral valve repair; MVR, 






4.4.4 Functional outcomes 
Changes between the groups from baseline to follow up are presented in Table 
4-4. Differences in NYHA functional class at baseline, follow up and change are 
shown in Figure 4-2. At follow up, compared with controls, the MVr and MVR 
groups demonstrated improved 6MWT distances (+0.1±55m vs +57±54m and 
+64±76m respectively, p=0.002) and NYHA functional class (p<0.001) with no 
statistically significant differences between both surgical groups in either outcome. 
After these changes, there were no statistically significant differences between all 
groups in residual 6MWT distances or NYHA functional class on follow up 
assessment (Table 4-5). 
  
Figure 4-2 Direct inter-group comparisons of baseline, delta change and 
residual NYHA functional class between control, repair and replacement 
groups 
Inter-group statistical comparisons displayed (Control vs repair, control vs replace, 







4.4.5 Cardiac reverse remodelling 
Changes to cardiac indices between baseline and follow up CMR are shown in 
Table 4-4 and the resultant residual cardiac indices are compared between groups 
in Table 4-5. Compared with controls, MVr and MVR resulted in comparable 
significant reductions in LVEDVi (-1.3±12ml/m2 vs -29±21ml/m2 and -37±22ml/m2 
respectively, p<0.001), LVEF (+0.4±3.9% vs -8.7±8.9% and -8.8±9.0% 
respectively, p<0.001) and indexed left atrial volumes (+1.2±19ml/m2 vs -
27±30ml/m2 and -39±26ml/m2 respectively, p<0.001) (Table 4-4), resulting in lower 
LVEDVi (94±28ml/m2 and 94±25ml/m2 vs 117±28ml/m2 respectively, p=0.005) and 
LVEF (47±9.2% and 46±8.1% vs 59±5.0% respectively, p<0.001) at 6-month 
follow-up CMR in the MVr and MVR groups compared with controls (Table 4-5). 
There were no statistically significant differences between surgical groups in the 
changes to, or, residual left ventricular volumes/function or left atrial volume. There 
were no statistically significant differences between groups in terms of change to 
right ventricular volumes/function and right atrial areas, resulting in comparable 
residual right heart indices, except for lower residual RVEF in the MVr group 
compared with the controls (47±6.1% vs 53±8.0% respectively, p=0.01). There was 
no statistically significant difference in residual RVEF between MVr and MVR 
groups (47±6.1% vs 50±5.7% respectively p=0.224).  
 
4.4.6 Changes in quantitated valve regurgitation 
Both surgical groups demonstrated a significant reduction in and lower residual 
MR-Rvol and MR-RF compared with the control group (p<0.001) (Table 4-4 & 
Table 4-5). MVR resulted in a superior reduction in MR-RF (-40±14% vs -29±11%, 
p=0.002), resulting in lower 6-month residual MR-RF compared with the MVr group 
(12±8.0% vs 21±11% respectively, p=0.022). There were no significant differences 








Table 4-4 Change in functional, haemodynamic and cardiac parameters from baseline to follow up assessment 















Systolic BP(mmHg) -0.2±21 +0.8±11 +0.1±12 0.952       
Diastolic BP(mmHg) +0.5±14 +2.8±10 +0.1±9.2 0.510       
Heart rate (bpm) -3.0±10 +3.1±21 -1.8±12 0.359       
6MWT distance (m) +0.1±55 +57±54 +64±76 0.002 0.007 0.005 1 
NYHA class 0.15±0.4 -0.8±0.7 -1.1±0.7 <0.001 <0.001 <0.001 0.281 
LVEDVi (ml/m2) -1.3±12 -29±21 -37±22 <0.001 <0.001 <0.001 0.584 
LVESVi (ml/m2) -1.7±7.4 -4.0±16 -8.3±18 0.360       
LVSVi (ml/m2) -0.1±8.4 -25±15 -28±13 <0.001 <0.001 <0.001 1 
LVEF (%) +0.4±3.9 -8.7±8.9 -8.8±9.0 <0.001 <0.001 0.001 1 
LVMi (g/m2) +0.3±4.3 -3.8±10 -3.7±11 0.256       
LA volume indexed (ml/m2) +1.2±19 -27±30 -39±26 <0.001 0.002 <0.001 0.545 
AR Rvol (ml) +0.3±1.4 -0.3±2.4 -0.2±2.1 0.117       
AR RF (%) +0.8±2.4 -0.8±3.4 -1.1±4.1 0.161       
MR Rvol (ml) -0.1±12 -47±21 -62±27 <0.001 <0.001 <0.001 0.064 
MR RF (%) +0.4±7.0 -29±11 -40±14 <0.001 <0.001 <0.001 0.002 
RVEDVi (ml/m2) -0.9±5.5 -5.0±16 -7.1±20 0.436       
RVESVi (ml/m2) +0.6±5.5 -3.5±14 -9.1±17 0.051       







RVEF (%) -0.8±4.0 +1.0±9.5 +4.9±7.9 0.067       
PR Rvol (ml) -0.4±1.5 +0.3±2.0 -0.1±1.7 0.224       
PR RF (%) -0.2±1.7 -0.2±3.4 -0.9±3.3 0.424       
TR Rvol (ml) +0.5±21 -5.1±17 -2.9±13 0.493       
TR RF (%) +2.1±21 -6.6±20 -4.5±14 0.614       
RAAi (cm2/m2) 0.0±2.5 0.0±2.9 -1.1±3.9 0.568       
Abbreviations: 6MWT, 6-minute walk test; AR, aortic regurgitation; BP, blood pressure; BPM, beats per minute; EDV, end-
diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i, indexed to body surface area; LA, left atrial; LV, left 
ventricular; LVM, left ventricular mass; MR, mitral regurgitation; NYHA, New York heart association functional class; PR, 
pulmonary regurgitation; RAA, right atrial area; RF, regurgitant fraction; Rvol, regurgitant volume; RV, right ventricular; SV, 

























Systolic BP (mmHg) 125±14 126±12 125±15 0.975       
Diastolic BP (mmHg) 73±10 80±11 77±11 0.134       
Heart rate (bpm) 68±11 75±15 71±8.3 0.141       
6MWT distance (m) 393±109 422±82 422±111 0.586       
NYHA (mean) 1.45±0.7 1.1±0.3 1.1±0.3 0.087       
LVEDVi (ml/m2) 117±28 94±28 94±25 0.005 0.011 0.016 1 
LVESVi (ml/m2) 48±15 52±23 52±20 0.863       
LVSVi (ml/m2) 69±15 42±9.3 42±8.6 <0.001 <0.001 <0.001 1 
LVEF (%) 59±5 47±9.2 46±8.1 <0.001 <0.001 <0.001 1 
LVMi (g/m2) 54±11 59±15 60±17 0.307       
LA volume indexed (ml/m2) 86±28 67±37 69±28 0.115       
AR Rvol (ml) 3.9±4.1 3.9±3.4 3.2±2.2 0.912       
AR RF (%) 5.6±5.1 6.0±4.3 4.6±3.2 0.588       
MR Rvol (ml) 49±23 19±13 9.5±7.0 <0.001 <0.001 <0.001 0.088 
MR RF (%) 39±13 21±11 12±8.0 <0.001 0.001 <0.001 0.022 
RVEDVi (ml/m2) 92±24 89±18 91±20 0.875       







RVSVi (ml/m2) 49±15 42±8.6 46±11 0.093       
RVEF (%) 53±8 47±6.1 50±5.7 0.011 0.01 0.698 0.224 
PR Rvol (ml) 1.8±1.6 3.7±3.5 2.3±2.2 0.022 0.086 1.000 0.145 
PR RF (%) 2.4±2.0 5.0±4.1 3.0±2.5 0.045 0.058 1.000 0.062 
TR Rvol (ml) 13±17 11±10 12±9.0 0.628       
TR RF (%) 15±20 13±11 13±8.8 0.809       
RAAi (cm2/m2) 14±3 15±3.6 14±3.6 0.511       
Abbreviations: 6MWT, 6-minute walk test; AR, aortic regurgitation; BP, blood pressure; BPM, beats per minute; EDV, end-
diastolic volume; EF, ejection fraction; ESV, end-systolic volume; i, indexed to body surface area; LA, left atrial; LV, left 
ventricular; LVM, left ventricular mass; MR, mitral regurgitation; NYHA, New York heart association functional class; PR, 
pulmonary regurgitation; RAA, right atrial area; RF, regurgitant fraction; Rvol, regurgitant volume; RV, right ventricular; SV, 





To our knowledge, this is the first study to compare cardiac reverse remodelling 
and quantify residual MR between MVr and MVR using the reference standard 
(CMR), with a longitudinal control group for comparison. Importantly, at baseline 
the study had naturally well matched surgical groups, with no statistically significant 
differences in cardiac parameters and co-morbidities. The study has three 
important findings: Firstly, MVr and MVR resulted in comparable LV reverse 
remodelling; secondly, RVEF was worse post-MVr vs controls than post-MVR and 
thirdly, MVR resulted in a greater reduction in MR and lower residual MR than MVr. 
As described CMR is the reference standard for biventricular assessment (52, 53) 
and arguably more accurate at assessing MR severity than TTE (59, 63, 64, 72). 
Indeed, disparity in accuracy may increase post operatively, as TTE assessment of 
MR severity is difficult due to acoustic shadow artefacts (348-350) occurring 
secondary to mitral annular rings (implanted during MVr or as a component of a 
bio-prosthetic valve) or more profoundly with metallic prosthesis (349, 350). 
Indeed, the ASE/ESC state no single parameter can reliably quantitate prosthetic 
MR via TTE, advising combined TTE and TOE assessment (348), potentially 
reducing the accuracy of TTE studies comparing residual MR between surgical 
groups (MVr vs MVR). Using CMR, prosthesis-related distortions of the magnetic 
field can create the potential for volume and flow miscalculation. However, this can 
be mitigated with consistent LV basal slice analysis and using indirect MR 
quantification (LVSV-AoSV method), as aortic PCMR, planned carefully to avoid 
artefact, increases the distance from the prosthesis and therefore accuracy of 
PCMR flow assessment (351). Therefore, to date, our study may provide the most 
accurate comparison of cardiac reverse remodelling and residual MR between 
MVr/MVR for primary MR.  
Patients undergoing MVR are typically older with more comorbidities than those 
referred for MVr. In primary MR, propensity matched studies performed to 
overcome these biases present conflicting results, with Gilinov et al demonstrating 
no significant difference between long term survival and freedom from re-operation 
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between MVr and MVR with chordal preservation (123), whilst Lazam et al found 
lower operative mortality, better long term survival and fewer valve related 
complications post MVr . However, Lazam et al specifically assessed patients with 
flail leaflets and the use of chordal preservation techniques with MVR was not 
clearly documented (124). In our study, baseline cardiac indices, surgical risk 
scores and co-morbidities were similar between surgical groups, potentially 
minimising this bias. There were differences in leaflets affected between groups, 
with the MVr group more typically having PMVL disease than the other groups. 
This is unsurprising given PMVL prolapse is more amenable to successful surgical 
repair (96) and international guidelines advise repair whenever feasible (1, 39), 
making this difficult to control for in an observational study. At baseline, compared 
to the watchful waiting control group, both surgical groups demonstrated worse 
NYHA functional class, quantitated MR, RVEF and had a greater proportion of 
patients in AF, demonstrating as expected that the surgical groups were at a more 
advanced stage on the MR severity spectrum. 
Our left ventricular reverse remodelling findings demonstrate equivalency between 
MVr and MVR. These findings are in keeping with prior echocardiographic studies 
(126, 127, 352) and the only prior CMR study (325), which compared remodelling 
at 3 months between MVr and MVR with chordal preservation (n=28). Similar to 
previous studies, we demonstrated a significant decrease in LVEF post-operatively 
(126, 127, 353), finding no significant difference between surgical groups. Given 
previous concerns over poorer LVEF post MVR (117, 118), our results from a 
rigorous study design using CMR to assess remodelling/LVEF, comparing both 
surgical groups at baseline and 6-months post-surgery and against an 
observational control group, will hopefully act as re-assurance against this concern. 
As discussed in section 4.2, prior studies demonstrating poorer outcomes post 
MVR typically have biased baseline variables with older MVR groups with more co-
morbidities (123) and/or predate the routine use of chordal preservation with MVR 
(116-120), with chordal preservation now known to be essential to help preserve 
post-operative LVEF (112-115, 342). Importantly, our study used chordal 
preservation with MVR and had naturally matched baseline variables between the 
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groups, reducing innate bias between surgical groups, and showed no difference in 
cardiac remodelling between MVr and MVR.  
In keeping with Uretksy et al, who similarly assessed cardiac reverse remodelling 
following corrective mitral valve surgery with CMR in two studies, we found no 
significant change in indexed right ventricular size (EDV/ESV) post-MVr and MVR 
(59, 72). Both studies by Urestky et al, the majority of which had MVr, 
demonstrated no significant change between pre- and post-operative RVEF 
(p=0.05). Unfortunately, the studies had small numbers of MVR patients and 
therefore remodelling comparisons between surgical techniques were not 
performed. Our study demonstrated lower RVEF post-MVr vs controls (p=0.01), but 
no statistically significant difference between the two surgical groups (p=0.224). 
However, our MVr group underwent a proportionally greater number of tricuspid 
valve repairs than the MVR group (5 vs 2 respectively), which may have blunted 
the RVEF augmentation in the MVr group. There were however no statistically 
significant differences in the quantified tricuspid regurgitant fraction between the 
groups pre-operatively or at follow-up to support this. Therefore, the lower RVEF in 
the MVr group vs controls may be as a result of a lower reduction in and greater 
residual MR-RF compared with the MVR group.   
MVR compared to MVr resulted in a greater reduction in MR-RF post-operatively 
and hence lower residual MR-RF. Whilst the absolute reduction in and residual 
MR-Rvol was lower for MVR vs MVr, this was not statistically significant. On 
explanation for this, MR-Rvol is a non-indexed measurement, and therefore more 
dependent on haemodynamic variables, chamber size and body surface area, 
whereas MR-RF takes into account the patients LV stroke volume, better 
accounting for these variables. As such, MR-RF has been considered a more 
accurate imaging biomarker of MR severity (354). Our findings of greater residual 
MR post-MVr are in keeping with prior echocardiographic studies (127, 133).  
Our study has the benefit of using a watchful-waiting control group. This has 
provided three specific benefits. 1, highlight the baseline differences between 
patients with mod-severe primary MR on TTE that are observed or referred for 
surgery, specifically demonstrating greater MR and poorer RVEF in those referred 
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for surgery. This is an important finding, as it suggests that quantifying MR and 
RVEF by CMR, rather than categorising severity as per TTE, may more accurately 
define severity. 2, the use of a control group allowed a more comprehensive 
comparison than between two surgical groups alone. Specifically, without the use 
of a control group, the poorer RVEF post-MVr would not have been highlighted. 3, 
the demonstration of minimal cardiac remodelling in the control group over the 6-
month period, suggests that (at least as regards cardiac remodelling) 
asymptomatic primary MR patients with similar characteristics/cardiac indices are 
unlikely to deteriorate quickly and therefore are reasonably monitored by watchful 
waiting with a 6-month interval between imaging. Further studies utilising CMR are 
required to investigate patients on watchful waiting observational management, to 
further define cut offs at which more intensive imaging is required and define when 
early intervention provides prognostic benefit.  
Only one prior CMR study by Gelfand et al has compared cardiac reverse 
remodelling between MVr/MVR (325). The study performed sequential CMR at 
baseline and 3 months in 20 primary MR patients that underwent mitral valve 
surgery (14 MVr, 6 MVR), 14 of which had a further CMR at 27-months. They 
demonstrated MR reduction and cardiac reverse remodelling post-surgery with no 
difference in outcomes between surgical groups. With the caveat of potential 
differences in CMR acquisition and analysis between the Gelfand study and ours: 
the baseline cardiac indices in Gelfand cohort had a lower mean age (53years), 
LVEDVi (113m/m2), LVESVi (45ml/m2), MR-RF (40%), MR-RVol (54ml) and 
higher LVEF (62%) and RVEF (51%) than either of our surgical groups. Indeed 
baseline cardiac indices in the Gelfand cohort bear closest resemblance to our 
control group. Therefore the Gelfand cohort were younger, had less severe MR 
and cardiac remodelling at baseline, potentially suggesting intervention was 
performed earlier in the disease process than in our cohort. Despite this, we 
present similar findings of LV remodelling with reductions in LVEDVi, LVESVi and 
LVEF in both surgical groups. Our study acquired follow-up imaging at 6-months 
demonstrating reduced LVEF than pre-operatively. Interestingly, at 27-months 
follow-up of the Gelfand cohort, the LVEF had normalised and LV volumes had 
further decreased. Therefore a reduced LVEF at 6-months compared to pre-
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operative values in both surgical groups in our study either suggests that cardiac 
reverse remodelling is incomplete with further improvement yet to occur, or that the 
increased LV volumes and lower LVEF pre-operatively in our cohort has resulted in 
poorer post-operative LVEF than compared with the Gelfand cohort. Additionally, 
residual MR was higher in both our surgical cohorts than the Gelfand cohort. This 
may also be a result of potentially earlier intervention in the Gelfand cohort, or 
potentially explainable by differential CMR protocols/analysis between our two 
studies. Further CMR studies, ideally larger and with longer follow-up are required 
to assess the optimal timing of surgery in the disease process for primary MR 
patients to improve outcomes and determine the approximate time at which 
reverse re-modelling post-surgical intervention is complete to assist in the design 
of future studies.  
 
4.5.1 Clinical implications   
Perhaps controversially, our findings of comparable cardiac reverse remodelling 
following MVr and MVR and lower residual MR-RF post-MVR, pose a challenge to 
the current recommendation of ‘repair whenever feasible’. If confirmed in larger 
series, they might suggest that current recommendations could be down-graded to 
permit direct MVR in more complex pathologies in order to reduce surgical 
procedural times. Given that CBT and CCT both correlate with post-operative 
mortality and morbidity (355, 356), relaxing the recommendations in selected cases 
may not adversely affect cardiac reverse remodelling and might positively impact 
on surgical outcomes. Given MVR is arguably more durable, with less recurrent 
MR (127, 133) then our results, if replicated in randomised trials could significantly 
impact clinical practice. However, the decision to offer a patient MVR or MVr has 
multiple facets. Bioprosthetic MVRs are prone to degeneration and are therefore 
best reserved for patients in whom it will last a lifetime (1, 109). A metallic 
prosthesis requires anticoagulation, coming with inherent bleeding risks and 
increased stroke risk if this becomes sub-therapeutic (106, 107). As such, it is 
understandable that a successful MVr is clinically appealing. However, our study 
demonstrates equivalent cardiac remodelling between the techniques and greater 
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MR post MVr. Therefore, in elderly patients in whom a tissue valve replacement 
will last a lifetime or younger patients with another indication for anticoagulation, 
our results suggest that an MVR may be the optimal treatment. Larger multi-centre 
studies will be required, using CMR to assess remodelling and quantify MR and 
with a longer follow-up period to assess clinical outcomes before such clinical 
recommendations could be made.  
Beyond the scope of the comparative findings between MVr and MVR, our study 
also adds to several prior CMR studies (59, 63, 64, 72) demonstrating the benefit 
CMR can offer in the assessment and decision making in mitral regurgitation 
patients. Our results are controversial, potentially challenging the current accepted 
premise that MVr is superior to MVR. Our findings may be in part due to the use of 
CMR highlighting significant changes that may be otherwise missed by TTE. Most 
notably greater residual MR post MVr compared with MVR. As the reference 
standard for biventricular assessment, with MR quantification with superior 
reproducibility to TTE, CMR is arguably the most accurate imaging modality 
currently available to assess MR severity and resultant cardiac remodelling. As 
such, subtle changes are more easily highlighted than with TTE. Therefore our 
findings, when assessed alongside prior CMR studies (59, 63, 64, 72), suggest 
CMR should provide a greater role in the clinical assessment of primary MR 
patients both pre and post-surgical intervention and to accurately guide research 
inclusion criteria and assess outcomes. Further research utilising CMR is therefore 
essential to continue to optimise management of patients with mitral regurgitation.   
 
4.5.2 Limitations 
This was a single centre prospective observational study therefore larger 
multicentre studies are required to validate the findings. We specifically recruited 
patients with primary MR and those undergoing elective surgery, therefore our 
results may not be generalizable to those with secondary MR or undergoing 
emergency surgery. As a non-randomised study intrinsic baseline differences 
between the groups could not be controlled. However, as demonstrated in Table 
4-1, there were no statistically significant differences between the surgical groups 
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in terms of age, sex or comorbidities. Despite differences in the underlying leaflet 
pathology between surgical groups there was no statistically significant difference 
in cardiac reverse remodelling. The group sizes are modest by comparison with 
prior longitudinal MVR and MVr outcome studies, however the use of CMR and its 
high reproducibility for volumes (51, 52) and flow quantitation (59, 60, 62, 63) 
means that much smaller sample sizes are required to detect a change compared 
to standard TTE.  Baseline cardiac indices were equivalent between surgical 
groups, but there was a non-significant tendency towards larger bi-ventricular 
volumes, left atrial volumes and quantitated MR in the MVR group. A larger study 
may have highlighted these differences as significant, potentially making the 
comparative residual cardiac indices between surgical groups more impressive. 
Except for 2 patients who had complete chordal preservation with MVR, MVR were 
performed with partial chordal preservation as routine practice in our study; 
however, complete chordal preservation is the optimal technique (115), which may 
have made remodelling differences between the groups more significant in favour 
of MVR. Finally, our study specifically assessed cardiac reverse remodelling and 
functional changes after 6-months, so the study is unable to confirm that residual 
differences between surgical groups would result in different long term clinical 
outcomes.  
 
4.6 Future directions 
Our findings demonstrate the need for further research comparing MVr vs MVR 
with chordal preservation, specifically using CMR to assess cardiac reverse 
remodelling. Multiple variables are involved in the long term outcomes of patients 
after mitral valve surgery including the effect of the surgery itself, coinciding cardiac 
conditions and other non-cardiac/un-related disease processes affecting 
morbidity/mortality. As such, studies assessing clinical outcomes often use 
significantly large sample sizes to balance out confounding variables (129). Indeed, 
many such studies can span decades, in which time period standards and success 
of treatment can change (124, 130), also potentially impacting results. The 
assessment of cardiac remodelling closely correlates with clinical outcomes (129), 
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doesn’t necessitate long follow up periods to assess (reducing the potential for 
confounding variables to impact follow up assessments) and can be assessed 
accurately and reproducibly by CMR. Therefore assessment of cardiac reverse 
remodelling can be a useful surrogate for assessing clinical outcomes (129). 
Indeed, theoretically it is arguable that non-cardiac processes/diseases more 
proportionally adversely impact a patient’s symptoms, morbidity and mortality than 
they do the cardiac remodelling process. Therefore, ideally future comparative 
studies comparing MVr/MVR should assess both cardiac reverse remodelling using 
CMR and perform long term follow up to assess long term clinical outcomes. This 
approach would allow for comparison of immediate follow up effects between 
surgical groups and assess long term results. Ideally future studies are required to 
build on the work presented in this Chapter. Initially multicentre studies comparing 
MVr vs MVR with chordal preservation in primary MR patients, using CMR to 
assess remodelling and prolonged follow up to assess clinical outcomes. If results 
of such studies prove promising, then a randomised trial comparing MVr vs MVR, 
using recruitment criteria defined from the prior multi-centre studies, would be 
warranted and may significantly alter clinical practice.    
 
4.7 Conclusion 
In primary MR, MVR with chordal preservation may offer comparable cardiac 
reverse remodelling benefits at 6-months compared to MVr. Larger, multicentre 
CMR studies are required, which if confirmed might then have implications for 




Chapter 5  
 
Assessment of cardiac reverse remodelling following 
percutaneous mitral valve intervention in primary mitral 




Mitral valve repair is advised, when feasible, to treat significant primary MR, 
however many patients are deemed too high-risk and declined surgery. 
Percutaneous mitral valve interventions have been developed to treat this high-risk 
cohort. Accurate assessment of cardiac reverse remodelling is essential to guide 
optimal patient selection. CMR is the reference standard for cardiac volumetric 
assessment and compared to TTE provides superior reproducibility in MR 
quantification pre and post MitraClipTM insertion. Prior CMR studies have analysed 
cardiac reverse remodelling post MitraClipTM in combined cohorts of primary and 
secondary MR patients. However, aetiology of MR can significantly impact 
outcomes. Therefore this study aimed to assess cardiac reverse remodelling and 
quantitate changes in MR after percutaneous intervention for primary MR using the 
reference standard (CMR).  
Methods 
11 patients with significant MR on TTE were prospectively recruited to undergo 
CMR imaging and 6-minute walk tests (6MWT) at baseline and 6 months post 
percutaneous mitral valve intervention. CMR protocol involved: left-ventricular (LV) 
short axis cines, transaxial right-ventricular (RV) cines, two and four chamber cines 
and aortic/pulmonary through-plane phase contrast imaging. MR was quantitated 





10 patients underwent MitraClipTM for PMVL prolapse with 1 suffering partial clip 
detachment and declining follow-up and 1 patient underwent TMVI for failing mitral 
bio-prosthesis. From baseline to 6-month follow-up assessment: significant 
improvements occurred in NYHA functional class (p=0.019), 6MWT distances 
(205±101m to 269±64m, p=0.016) and RVEF (43±8.3% to 50±9%, p=0.035), 
significant reductions occurred in LVEDVi (118±23ml/m2 to 92±28ml/m2, p=0.001), 
LVESVi (59±20ml/m2 to 47±21ml/m2, p=0.005) and quantitated MR-Rvol (55±23ml 
to 23±13ml, p=0.005). There were no significant changes in LVEF, right ventricular 
or bi-atrial dimensions or quantitated aortic/pulmonary/tricuspid regurgitation. 
Conclusion 
Successful percutaneous mitral valve intervention for primary MR results in 
reduced MR, positive left ventricular reverse remodelling, preservation of LVEF 
and augmentation of RVEF, but no significant changes to right ventricular or bi-
atrial dimensions at 6 months. Larger CMR studies are now required to further 
guide optimal patient selection and compare the varying percutaneous techniques 






When feasible, surgical mitral valve repair is advised as first line treatment for 
significant primary MR (1, 39). However, numerous symptomatic patients with 
severe primary MR are deemed high risk and declined surgical intervention (138). 
Percutaneous mitral valve interventions have developed to treat this cohort of high 
risk patients including the MitraClipTM procedure and TMVI. MitraClipTM has 
demonstrated excellent technical success resulting in acute MR reduction and low 
mortality and morbidity rates in treating high-risk MR patients (143), but has proven 
inferior to conventional mitral valve surgery in a randomised trial (144). In carefully 
selected patients with functional MR and reduced ejection fraction, MitraClipTM 
improves outcomes compared with optimal medical therapy alone (145, 147). TMVI 
is an effective treatment for high-risk patients with recurrent MR after prior mitral 
valve surgery, with proven clinical efficacy post failed bioprosthesis and failed MVr 
with annuloplasty ring (153-155).  
Assessing cardiac reverse remodelling after mitral valve surgery/intervention is 
important to guide future patient selection. Multiple previous studies have assessed 
cardiac reverse remodelling with TTE post MitraClipTM (144, 357-360). One such 
study by Brouwer et al investigated 79 patients (81% secondary MR) with 
echocardiography at baseline, 1 and 6-months post MitraClipTM. Reverse 
remodelling, no remodelling and adverse remodelling occurred in 51%, 42% and 
8% of patients respectively, with a higher mortality in adverse remodelling patients 
compared with reverse remodelling patients (359). The study demonstrated the 
importance of investigating characteristics of patients likely to have 
reverse/adverse remodelling to guide patient selection and success of treatment. 
Therefore the accuracy of the image modality assessing remodelling is also 
extremely important. CMR is the reference standard for biventricular assessment 
(52, 53) and compared to TTE demonstrates superior reproducibility in MR 
quantification (63, 64), even post MitraClipTM (361) and arguably offers a more 
accurate assessment of MR severity than TTE, with TTE more prone to 
overestimate MR severity compared with CMR (59, 72). CMR is therefore the 
optimal imaging modality to assess cardiac reverse remodelling and quantitate 
residual MR post percutaneous intervention. Indeed, prior CMR studies assessing 
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reverse remodelling post percutaneous mitral valve intervention have been 
conducted. Krumm et al demonstrated reductions in LVEDV, LVESV, LV mass and 
LA area by CMR in 27 patients (13 primary MR, 14 secondary MR) at baseline and 
3 months post MitraClipTM; RV remodelling and changes in quantified MR were not 
assessed (362). Radunski et al investigated biventricular remodelling with CMR in 
12 MR patients (5 primary MR, 7 secondary MR) at baseline and 6 months post 
MitraClipTM, demonstrating reductions in LVEDVi, LVESVi but no change in LVEF, 
LA volumes or RV parameters; unfortunately, changes in quantified MR were not 
assessed (363). Lurz et al demonstrated an acute reduction (within 7 days) of 
LVEDVi and MR-RF post MitraClipTM by CMR in 20 patients (5 primary MR, 15 
secondary MR) and similarly demonstrated no changes in RV parameters or 
tricuspid regurgitant fraction (TR-RF) (364). To date, no CMR study has assessed 
cardiac reverse remodelling post percutaneous intervention in primary MR alone, 
but performed pooled analysis inclusive of primary and secondary MR. Given 
underlying aetiology can significantly impact outcomes post percutaneous 
intervention (162, 357, 360, 365), a focussed study assessing remodelling in 
primary MR using CMR may be beneficial to guide future patient selection. 
Therefore, this study aimed to use the reference standard (CMR) to assess cardiac 
reverse remodelling and changes in quantified MR in primary MR patients post 
percutaneous mitral valve intervention.  
 
5.3 Methods 
5.3.1 Study design 
This single-centre prospective observational cohort study recruited patients 
between June 2016 and January 2020 with moderate-severe primary MR from the 
cardiology/cardiac surgery out-patient departments at Leeds Teaching Hospitals 
NHS Trust, Leeds, UK. The methodology for this study is the same as the study in 
Chapter 4 (described in Chapter 4.3), with identical echocardiographic criteria for 
defining moderate-severe MR and with the same investigations performed (CMR 
and 6MWT at baseline and 6-month follow-up). However, as the study involves a 
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different cohort of patients there are alterations to inclusion/exclusion criteria 
(described below).    
Inclusion criteria: moderate-severe or severe primary MR on echocardiography, 
aged > 18 years with capacity to consent to study participation and have been 
accepted for percutaneous mitral valve intervention.  
Exclusion criteria: Secondary (functional/ischaemic/atrial) MR, contraindications 
to CMR, significant (≥moderate severity) aortic valve disease, uncontrolled AF 
>120bpm, terminal illness, haemodynamic instability, weight >130kg, pregnancy or 
breast feeding, or inability to lie flat for 60 minutes.  
Percutaneous intervention was decided by a multidisciplinary heart team, 
independent from the study, as per international guidance (1, 37) and after patients 
had been declined for surgical intervention. Baseline clinical and demographic data 
were recorded for all patients. The study was approved by the local research ethics 
committee (Yorkshire & The Humber- South Yorkshire 15/YH/0503) and complied 
with the Declaration of Helsinki (See Appendix); all patients provided written 
informed consent.  
5.3.2 CMR imaging 
The CMR imaging protocol utilised in the study is as used in the Chapter 4 study 
and described in chapter 4.3.2. 
5.3.3 CMR analysis 
The methods of CMR analysis used in this study are as per the Chapter 4 study 
and described in chapter 4.3.3. 
5.3.4 Statistical analysis 
Data were analysed using SPSS version 26 (IBM Corp.). All continuous data were 
assessed for normality using Shapiro-Wilk test. The difference between variables 
at baseline and 6-month follow-up were compared. Continuous variables are 
expressed as mean±SD and categorical variables expressed as frequencies and 
percentages. Continuous data was assessed by the paired t-test and Wilcoxon 
signed ranks test for normally and non-normally distributed data respectfully. 
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Changes in categorical data were compared by Fisher’s Exact test, which was 
preferred to the Chi squared test due to low group numbers and small frequencies 




5.4.1 Baseline patient characteristics 
After assessment against the inclusion/exclusion criteria 11 patients were 
recruited.  10 patients underwent percutaneous MitraClipTM procedure and 1 
patient underwent TMVI. 1 patient who underwent percutaneous MitraClipTM 
suffered clip displacement resulting in device failure and declined further 
involvement in the study. This resulted in 10 patients (aged 82±5 years, 8-male) 
completing follow-up imaging after 6.7±1.4 months (9 MitraClipTM & 1 TMVI), who 
were included for analysis. At baseline, 3 patients had NYHA II, 6 patients NYHA III 
and 1 patient NYHA IV symptoms (Table 5-1). The majority (90%) of patients had 
MR as a result of PMVL prolapse and were treated with MitraClipTM. 1 patient had 
a failed bioprosthesis and was treated with TMVI. As expected in this cohort of 
patients, numerous patients had co-morbidities: diabetes (90%), hypertension 
(50%), AF (80%), prior MI (30%), prior stroke (10%), prior transient ischaemic 
attack (10%) and chronic kidney disease (50%). 
5.4.2 Functional and haemodynamic outcomes 
Changes in the functional and haemodynamic parameters are displayed in Table 
5-1. Post percutaneous mitral valve intervention, from baseline to follow up: 6MWT 
distances improved significantly (205±101m to 269±64m, p=0.016) and NYHA 
functional class improved significantly (p=0.019) (figure 5.1). There were no 
significant differences between baseline and follow up in: heart rate (73±7bpm to 
71±15bpm, p=0.568), systolic (126±15mmHg to 135±13mmHg, p=0.333) or 
diastolic (72±10mmHg to 78±8mmHg, p=0.268) blood pressure, haemoglobin 
(120±24g/L to 137±24g/L, p=0.062) or creatinine (113±37umol/L to 122±46umol/L, 
p=0.215).    
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Table 5-1 Changes in haemodynamic and functional parameters after 
percutaneous mitral valve intervention. 
Parameter Baseline 6-months P value 
Systolic BP (mm/Hg) 126±15 135±13 0.333 
Diastolic BP (mm/Hg) 72±10 78±8 0.268 
Heart rate (bpm) 73±7 71±15 0.568 
Haemoglobin (g/L) 120±24 137±24 0.062 
Creatinine (umol/L) 113±37 122±46 0.215 




I 0 4 
II 3 5 
III 6 1 
IV 1 0 
Abbreviations: BP, blood pressure; bpm, beats per minute; NYHA, New York Heart 
association functional class; m, metres. 
 
 
Figure 5-1 Changes in New York Heart Association (NYHA) functional class 





5.4.3 Follow up CMR data 
Baseline and follow up post percutaneous mitral valve intervention CMR derived 
cardiac indices are presented in Table 5-2. Percutaneous mitral valve intervention 
resulted in a significant decrease in LVEDVi (118±23ml/m2 to 92±28ml/m2, 
p=0.001) and LVESVi (59±20ml/m2 to 47±21ml/m2, p=0.005), but no change to 
LVEF (51±11% to 50±8%, p=0.661) (Figure 5-2). Indexed LV mass (LVMi) 
remained unchanged (73±19g/m2 to 68±21g/m2, p=0.181). Right ventricular 
parameters remained unchanged, except for a significant increase in RVEF 
(43±8.3% to 50±9%, p=0.035) (Figure 5-2). There were no significant changes in 
indexed LA volumes (105±41ml/m2 to 101±32ml/m2, p=0.677) or indexed right 
atrial area (17±4.2cm2/m2 to 17±3.3cm2/m2, p=0.777) (Figure 5-3). Quantitated MR 
decreased with a decrease in MR-Rvol (55±23ml to 23±13ml, p=0.005) and MR-RF 
(51±9% to 29±15%, p<0.001) (Figure 5-4); there were no significant changes in 





Table 5-2 Comparison of baseline and follow up cardiac parameters 
assessed by CMR imaging 
 
 
Baseline Follow up p-value 
LVEDVi (ml/m2) 118±23 92±28 0.001 
LVESVi (ml/m2) 59±20 47±21 0.005 
LVSVi (ml/m2) 59±14 45±11 0.005 
LVEF (%) 51±11 50±8 0.661 
LVMi (g/m2) 73±19 68±21 0.181 
LAV-i (ml/m2) 105±41 101±32 0.677 
AR Rvol (ml) 5.1±4.1 4.9±3.4 0.878 
AR RF (%) 10±8.9 9.6±7.2 0.959 
MR Rvol (ml) 55±23 23±13 0.005 
MR RF (%) 51±9 29±15 <0.001 
RVEDVi (ml/m2) 100±29 100±29 0.575 
RVESVi (ml/m2) 59±27 53±22 0.169 
RVSVi (ml/m2) 41±6.9 47±8 0.144 
RVEF (%) 43±8.3 50±9 0.035 
Pulm Rvol (ml) 3.1±3.0 2.1±2.1 0.139 
Pulm RF (%) 6.3±5.3 4.4±4.8 0.241 
TR Rvol (ml) 20±16 23±11 0.554 
TR RF (%) 25±21 29±19 0.241 
RAAi (cm2/m2) 17±4.2 17±3.3 0.777 
Abbreviations: AR, aortic regurgitation; EDV, end-diastolic volume; EF, ejection fraction; 
ESV, end-systolic volume; i, indexed to body surface area; LAV, left atrial volume; LV, left 
ventricular; LVM, left ventricular mass; MR, mitral regurgitation; PR, pulmonary 
regurgitation; RAA, right atrial area; RF, regurgitant fraction; Rvol, regurgitant volume; RV, 










Figure 5-2 Line graphs depicting biventricular remodelling post 
percutaneous mitral intervention  
Mean values depicted by dashed black line. Abbreviations: EDV, end-diastolic 
volume; EF, ejection fraction; ESV, end-systolic volume; i, indexed to body surface 





Figure 5-3 Line graphs depicting changes in indexed bi-atrial dimensions 
post percutaneous mitral intervention.  




Figure 5-4 Line graphs depicting changes in quantitated MR post 
percutaneous mitral valve intervention.  
Mean values depicted by dashed black line. Abbreviations: MR-Rvol, Mitral 




To our knowledge, despite the small sample size, this is the largest CMR study to 
assess changes to biventricular volumes, bi-atrial size and quantitate valvular flow 
using baseline and follow up CMR in a focussed cohort of primary MR patients. 
Importantly, recruitment to the study is ongoing to increase the sample size. Our 
findings are supportive of the use of percutaneous mitral valve intervention in the 
treatment of high risk primary MR patients both in terms of functional 
improvements and cardiac reverse remodelling.  
5.5.1 Functional outcomes   
NYHA functional class and 6MWT distances improved after percutaneous mitral 
valve intervention. This is in keeping with previous studies with well documented 
improvements in NYHA functional class (143, 357, 364, 366) and 6MWT distances 
(366, 367) post percutaneous mitral valve intervention for MR.  
 
5.5.2 Cardiac reverse remodelling  
5.5.2.1 Left ventricular remodelling 
Our study demonstrated positive left-ventricular reverse remodelling in primary MR 
patients treated with percutaneous mitral valve intervention. The findings of a 
reduction in LV dimensions are in keeping with previous studies that utilised 
percutaneous intervention to treat significant MR (362-364). With the MR reduction 
demonstrated in our patients, a consequent reduction in LV dimensions is 
expected, but is not always guaranteed and is dependent on baseline LV 
dimensions and function. Chronic volume overload occurs in chronic MR due to 
dissolution of collagen tissue resulting in reorganization and slippage of myocardial 
fibres which causes remodelling of the extracellular matrix (363). This 
compensatory response normalises wall stress resulting in an asymptomatic stage 
of MR. However, continued prolonged chronic volume overload can cause 
progressive LV dilatation, stretching myocytes beyond their normal contractile 
length and can cause interstitial fibrosis and reduced myofibre content. The 
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decompensation of the dilating LV due to overload from chronic MR can then result 
in patients developing dyspnoea and exercise intolerance. Should intervention not 
be performed in timely manner when symptoms develop or LV dysfunction occurs, 
irreversible LV dysfunction can occur (11). This may be a result of chronic volume 
overload induced myocardial fibrosis, suggested by Velu et al who demonstrated 
worse LV remodelling and outcomes in MR patients with myocardial fibrosis 
identified by CMR compared with those without (368). Our study supports timely 
intervention, as our cohort only had mild LV dysfunction (LVEF 51% in context of 
significant MR), but all demonstrated reverse LV remodelling, evidenced by a 
reduction in LVEDVi and LVESVi  in all patients as shown in Figure 5-2 and 
importantly no significant worsening of LVEF. 
 
5.5.2.2 Right ventricular remodelling 
We found no change in RV dimensions (RVEDVi/RVESVi) post percutaneous 
treatment for primary MR; this is in keeping with prior echocardiographic (369)  and 
CMR studies (363, 364). Despite this, a significant increase in RVEF occurred, 
which was due to a non-significant fall in RVESVi. Similar findings of no change in 
RV dimensions but improved RV systolic function post MitraClipTM have been 
demonstrated in a previous echocardiographic study. Gianni et al performed TTE 
at baseline and 6-months post MitraClipTM in 35 patients with significant functional 
MR. They found TAPSE increased from 16.8±3.9mm to 19.3±4.5mm and PASP 
decreased from 50.1±6.8mmHg to 38.1±6.8mmHg from baseline to 6-months 
respectively post MitraClipTM, but RV dimensions remained unchanged (370). The 
results suggest that reductions in MR after MitraClipTM may not be sufficient to 
reduce RV end-diastolic volumes, but sufficient enough to allow an improvement in 
RVEF, which may be mediated by reduced PASP. Additionally, the findings of no 
significant alteration in RV volumes are in keeping with surgical patients 





5.5.2.3 Bi-atrial remodelling 
This is the first CMR study to assess changes in right atrial size post percutaneous 
intervention. We demonstrated no significant change in bi-atrial size, in terms of 
indexed left atrial volumes and right atrial area, after percutaneous intervention. 
Prior studies demonstrate conflicting LA remodelling results post percutaneous 
intervention. Krumm et al and Brouwer et al both demonstrated a significant 
decrease in LA size, but used comparatively suboptimal methodology to ours, the 
former using CMR to assess LA area and the latter TTE to assess indexed left 
atrial volumes (360, 362). Given CMR is the reference standard for cardiac volume 
assessment (51), TTE biplane assessment underestimates atrial volumes and has 
worse intra/inter-observer variability compared with CMR biplane measurements 
(371) and LA volumes are a more robust marker of cardiovascular outcomes than 
LA area (372), then our use of CMR to perform area-length bi-plane atrial volume 
measurements is arguably the more robust methodology. Indeed our findings 
mirror that of Radunski et al (363), who similarly utilised CMR to perform bi-plane 
LA volume measurements. The advanced age and comorbidities of our study 
cohort may have impacted on the lack of LA reverse remodelling. Song et al 
demonstrated that increasing age, increasing pre-operative LA volume and the 
presence of AF and hypertension adversely affect LA reverse remodelling (373). 
Therefore our populations age (82±5 years), severe pre-intervention LA dilatation 
(105±41ml/m2) and presence of AF in 80% and history of hypertension in 50% of 
patients, may have negatively impacted LA reverse remodelling.  
 
5.5.2.4 Changes in valvular flow 
Quantitated MR (MR-Rvol/MR-RF) reduced in all patients (Figure 5-4). However, 
percutaneous mitral intervention had no effect on quantitated aortic, pulmonary or 
tricuspid regurgitant volumes/fraction. Significant changes in AR or PR after 
surgery/intervention for mitral regurgitation are not expected or previously reported. 
Conversely TR can improve post mitral valve repair, as described in an 
echocardiographic study by Desai at al (374). TR associated with MR can be 
multifactorial but is most often functional, where MR results in increased LA 
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pressure, causing increased pulmonary artery pressures, resultant RV 
dilatation/dysfunction and tricuspid annular dilatation causing functional TR. MR 
also causes LA dilatation, increasing the likelihood of AF, which in turn can cause 
RA dilatation, therefore tricuspid annular dilatation and resultant functional TR 
(375). Correction of MR can therefore theoretically reduce TR. However no such 
changes have been demonstrated post MitraClip in both echocardiographic (369, 
376) and CMR studies (364). Toyoyama et al investigated 102 MR patients 
(Primary MR 37%, secondary MR 63%) by TTE at baseline and 1-year post 
MitraClipTM; TR regressed in 26%, remained unchanged in 62% and worsened in 
16% of patients. The lack of a reduction in TR may also be due to incomplete 
resolution of MR and therefore less significant reductions in RV afterload/PASP 
that can occur post mitral valve surgery. However, it may also be a result of non-
significant baseline TR in the group, with mean quantitated TR-RF of 25%. 
 
5.5.3 Limitations 
The main limitation of this study is the small sample size. However, in the context 
of prior CMR studies assessing primary MR patients post percutaneous 
intervention the sample size is comparatively large. Lurz et al and Radunski et al 
only included 5 primary MR patients (363, 364). Only Krumm et al had a larger 
cohort of primary MR patients (n=13), but did not assess RV remodelling or 
quantitate MR changes (362). Therefore, to date, our study has the largest cohort 
of primary MR patients treated percutaneously in whom biventricular remodelling 
and changes in quantitated MR have been simultaneously assessed by CMR. 
Additionally, this is the first CMR study to focus solely on changes in primary MR 
patients post percutaneous mitral intervention, rather than perform pooled analysis 
and assess changes in right atrial size using CMR. However, clearly a larger cohort 
of patients would improve the generalisability of the results and may highlight 
statistically significant changes in cardiac parameters not visible at this cohort size. 
Indeed, left atrial volumes decreased, but were not statistically significant, which 
may be altered by a larger sample size. Recruitment in the study is ongoing to 
address this issue.   
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One patient dropped out after suffering partial MitraClipTM detachment and declined 
follow up imaging, excluding them from analysis. Such occurrences could result in 
survivor bias, as negative clinical outcomes resulted in exclusion and this patient 
may have demonstrated different remodelling to those with positive clinical 
outcomes. Therefore the results must be carefully interpreted as demonstrating a 
positive cardiac reverse remodelling in patients successfully treated with 
percutaneous mitral valve interventions.    
 
5.5.4 Clinical implications 
The study demonstrated positive LV reverse remodelling and MR reduction in all 
patients, which is a positive result for expanding the routine use of percutaneous 
interventions in primary MR patients not suitable for surgical intervention. Further 
research is required with additional patients to further study this cohort of patients, 
to allow in depth analysis of pre-procedural predictors of outcomes to further guide 
optimal patient selection. The study investigated patients that had either 
MitraClipTM or TMVI. With only one TMVI patient, comparisons between the two 
techniques could not be done. Future studies comparing varying percutaneous 
techniques to treat primary MR are required to further assess the differences and 
highlight which patients benefit greater from which technique.   
 
5.6 Conclusion 
Primary MR patients treated with percutaneous mitral valve intervention with good 
technical success benefit from left ventricular reverse remodelling, reduced MR, 
improved RV function and functional status. Larger studies using the reference 
standard (CMR) are now required to investigate if our positive results are repeated, 
allow more in-depth analysis and compare varying percutaneous techniques to 





Chapter 6 Overall Discussion 
Primary mitral regurgitation is a progressive disease, which left untreated can 
progress to significant morbidity and death (11). Surgical intervention is an 
effective treatment option. However, accurate imaging is pivotal to guide optimal 
management including patient selection and timing of surgical intervention or 
percutaneous intervention, if a patient’s surgical risk deemed too high (1, 37). TTE 
is a widely available first line investigation for MR assessment and exercise-TTE 
can provide additional prognostic information to assist decision making (85-90). 
However, TTE can be limited by poor acoustic windows and Doppler alignment 
issues to quantitate MR using geometric assumptions which reduce accuracy and 
reproducibility (38, 50). CMR is the reference standard for biventricular assessment 
(51, 52) and demonstrates superior reproducibility (59, 60, 62, 63) and prognostic 
ability of MR quantification compared with TTE (63, 64). Ex-CMR has been 
developing over the past 3 decades with recent advancements making clinical use 
more promising (93, 198). As such, CMR is a powerful tool for both clinical and 
research assessment of primary MR. The overarching aim of this thesis was to 
utilise existing CMR techniques and develop/validate new Ex-CMR techniques in 
the assessment of primary MR to improve the decision making tools available and 
assess the optimal treatment options available.  
 
6.1 Exercise CMR  
In Chapter 2 a novel free-breathing Ex-CMR protocol assessing biventricular 
function and great vessel flow was developed and validated in healthy volunteers, 
specifically using vendor provided sequences, a commercially available ergometer 
and standard analysis software to increase widespread attainability. The developed 
protocol was subsequently used in asymptomatic primary MR patients in Chapter 3 
and demonstrated the feasibility of the technique in this cohort and revealed 
decreasing MR severity as a mechanism to augment effective forward LVEF in 
asymptomatic patients. The healthy volunteers in Chapter 2 underwent a similar 
supine Ex-CMR protocol to the primary MR patients in Chapter 3. Therefore 
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comparisons can be made. However, there are some important caveats that 
prevent a direct comparison with statistical assessment and why the 2 cohorts are 
not presented in the same study: 1, the healthy volunteers are significantly younger 
and physically fitter, performing more regular exercise and 2, the healthy 
volunteers underwent a longer duration of exercise, as it was a protocol 
development study utilising more sequences and additionally assessing pulmonary 
flow. Both MR patients and healthy volunteers showed no change in LVEDVi with 
exercise. In contrast to healthy volunteers, the primary MR patients demonstrated 
no decrease in LVESVi, and no augmentation of LVSV or LVEF. The MR patients 
demonstrated no change in RVEDVi, whilst in healthy volunteers RVEDVi 
decreased. The differential findings in LV exercise haemodynamics are explainable 
by the variable LVCR found between primary MR patients (85, 86, 91). The 
explanation of an unchanged RVEDVi in MR patients compared with a decrease in 
healthy volunteers is less clear, but was similarly demonstrated by Chew et al (93) 
and potentially explainable by higher pulmonary pressures in MR patients. 
Pulmonary hypertension is a frequent consequence of significant MR which causes 
increased afterload on the RV (377) and can increase further during exercise (89, 
90). This could theoretically prevent RVEDV decreasing during moderate supine 
exercise. Indeed in prior supine Ex-CMR studies, patients with significant 
pulmonary hypertension demonstrate an increase in RVEDVi and decrease in 
RVEF during exercise, compared with a decrease in RVEDVi and increase in 
RVEF in healthy volunteers (244, 268). Thus patients with mild pulmonary 
hypertension may theoretically exhibit an intermediate exercise response, as 
demonstrated in our primary MR patients, where RVEF augments, but not as 
significantly as healthy volunteers and RVEDVi remains unchanged. The ability to 
assess biventricular function and quantitate MR and effective forward LVEF during 
continuous supine Ex-CMR in primary MR patients brings Ex-CMR a step closer to 
the clinical domain. Further research using the developed protocol is required to 
assess the techniques prognostic ability and whether performing CMR at low 
intensity exercise provides added value or whether it can be removed to reduce 




6.2 Mitral valve surgery/percutaneous intervention 
Mitral valve repair, when feasible, is advised over mitral valve replacement in the 
treatment of primary MR (1, 39). Unfortunately no randomised trial has been 
performed to reinforce this guidance. Recent studies suggest prior comparative 
studies in favour of MVr may be a result of intrinsic bias (123, 125). As MVR 
patients are often older with more comorbidities (123) and many studies predated 
the routine use of chordal preservation techniques (116-119), which improves 
cardiac reverse remodelling post MVR (112-115, 342). As such, in Chapter 4 a 
comparison of cardiac reverse remodelling post MVr/MVR with chordal 
preservation was performed using a watchful waiting control group for 
comprehensive comparison. The study demonstrated equivalent left ventricular 
reverse remodelling between the surgical groups, with a greater augmentation of 
RVEF post MVR vs controls and lower residual quantitated MR post MVR. The 
results reinforce the need for large multicentre studies and potentially a 
randomised trial, to further assess MVr vs MVR with chordal preservation. The use 
of CMR in which is pivotal to ensure accurate assessment of cardiac reverse 
remodelling and quantitate MR.  
Percutaneous interventions, such as the MitraClipTM, are a novel treatment for the 
numerous patients deemed too high risk for surgical treatment of primary MR. 
Accurately assessing outcomes post percutaneous intervention is important to 
guide optimal patient selection and CMR offers superior reproducibility in MR 
quantification pre (59, 60, 62, 63) and post-percutaneous intervention to TTE (361). 
As such, CMR studies have investigated cardiac reverse remodelling post 
percutaneous intervention (362-364). However, none have published analysis in 
primary MR alone and as outcomes post percutaneous intervention can be 
significantly affected by underlying aetiology (162, 357, 360, 365), in Chapter 5 a 
focussed study assessing remodelling in primary MR was presented. Impressively, 
the study demonstrated left ventricular reverse remodelling and MR reduction in all 
patients. Further research is now required, to recruit a larger cohort, to allow in 
depth analysis of pre-procedural predictors of outcomes and compare the various 
percutaneous techniques available to further guide optimal patient selection.  
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As the primary MR patients that underwent percutaneous intervention in Chapter 5 
had the identical CMR protocol performed to the control/MVr/MVR groups in 
Chapter 4, comparisons can be made. The caveats being the percutaneous group 
are significantly older, with more comorbidities that resulted in being declined 
surgical intervention, which may affect their cardiac reverse remodelling response 
and different statistical analysis was used in Chapter 4 & 5, therefore only cursory 
comparisons can be made. All intervention groups (MVr/MVR/percutaneous) 
demonstrated positive LV reverse remodelling with reductions in LVEDVi, whilst 
both surgical groups demonstrated reduced LVEF, the LVEF remained unchanged 
in the percutaneous group. This may be a result of less significant decreases in 
MR, with greater residual MR in the percutaneous group resulting in more 
offloading of LVSV into the left atrium. Indeed, left atrial reverse remodelling 
occurred in both surgical groups and not in the percutaneous group and may be, 
as described in Chapter 5.5.2.3, a result of greater residual MR, increased age and 
high incidence of AF blunting LA reverse remodelling in the percutaneous group. 
No intervention group (MVr/MVR/percutaneous) demonstrated statistically 
significant alterations in RV volumes. However, both surgical groups demonstrated 
a non-significant decreasing trend in RVEDVi, whilst mean RVEDVi of the 
percutaneous group remained exactly the same. Interestingly RVEF augmented in 
the MVR and percutaneous groups, but not the MVr group, despite lower residual 
MR in the MVr group. This may be a result of non-statistically significant increases 
in TR in the percutaneous group resulting in greater augmentation of RVEF, with 
more offloading into the RA, whilst both surgical groups demonstrated non-
statistically significant decreases in TR. Indeed, both surgical groups had a mean 
residual TR-RF of 13% whilst the percutaneous group had a mean residual TR-RF 
of 29%. The results of greater MR reduction after surgical vs percutaneous 
intervention are in keeping with the EVEREST II trial and reinforce that 
percutaneous treatments should be reserved for those too high risk for surgical 
intervention, but that LV remodelling and MR reductions can still be achieved by 





6.3 General thesis discussion 
The body of work presented in this thesis demonstrates a new method (Ex-CMR) 
via which primary MR patients can be investigated and challenges the current 
recommendation of MVr when feasible being universally superior to MVR. In 
addition to aspects discussed in Chapters 2 through 5 and sections 6.1 and 6.2, 
further insights are appreciated from this body of work when assessed as a whole 
and will be discussed below. 
Timing of surgery for patients with primary MR is important, specifically deciding 
which patients benefit from early intervention. This thesis demonstrates how both 
resting and Ex-CMR could assist this decision and act as a powerful research tool 
for comparing treatment techniques. 
As discussed in depth in section 1.1.3, CMR provides MR quantification with 
superior reproducibility and prognostic ability to TTE. Additionally, resting TTE 
utilises an integrated assessment of multiple measurements, as no single 
measurement is universally reliable in all patients/types of regurgitant jets. As such 
TTE assessment of MR is reliant on a subjective combination of each 
measurement, weighing up the caveats of each measurement in that individual, to 
determine severity. It is therefore not surprising that studies using CMR to assess 
outcomes could provide comparatively controversial results to TTE studies. The 
results highlighted in Chapter 4 pose a challenge to the current surgical 
recommendations, with MVR being deemed comparable to MVr as regards reverse 
remodelling but with greater residual MR post MVr. Indeed, these results are likely 
highlighted because of the greater accuracy of CMR to quantify MR than TTE. It is 
therefore arguable that future studies assessing MR patients should utilise CMR for 
the optimal assessment of MR severity and remodelling pre and post an 
intervention. Indeed, for research studies to accurately compare different 
percutaneous interventions for treatment of primary MR, the greater 
reproducibility/accuracy of MR quantification by CMR is likely essential due to the 
smaller decreases in MR often achieved, often smaller sample sizes and greater 
confounding variables due to being performed in an older population with more 
comorbidity. As regards routine clinical use of CMR, as previously discussed by 
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Uretsky et al (59, 72), it is reasonable to predict after further research, CMR be 
indicated to assess MR severity in cases where TTE/TOE assessment does not 
unequivocally define MR as severe before surgical intervention.  
Theoretically an accurate exercise cardiac imaging modality should highlight 
predictors of asymptomatic MR patients more prone to deteriorate earlier than 
resting imaging and therefore assist patient selection for early surgical intervention. 
As presented, exercise echocardiography provides additional prognostic insight to 
resting TTE (1, 37, 85-90) but does not currently feature in international guideline 
decision to treat cascade pathways. This is partly a result of limitations regarding 
acoustic windows and reproducibility in clinical patients (92). As such a clinically 
viable Ex-CMR protocol is inviting. The first step towards a clinically viable Ex-CMR 
protocol for use in MR patients has been developed within this body of work. 
Further research is needed to build upon this work to move Ex-CMR into the 
clinical realm of primary MR assessment. The identification of effective forward 
LVEF as a highly reproducible measurement during Ex-CMR may help this 
become a reality. As discussed, effective forward LVEF takes into account 
changes in MR and LVEF, providing a single indices depicting ‘true’ forward flow 
with prognostic ability demonstrated in resting CMR (325). Ex-CMR studies 
assessing the prognostic utility of this measurement are now required. The ability 
to reliably measure changes in both LVEF and MR with a single index during 
exercise may prove beneficial, especially given the caveats highlighted above with 
TTE resting and exercise assessment. 
In addition to recognising the importance of LV remodelling and changes in 
quantified MR, the results of this thesis highlight the importance of the right 
ventricle in patients with MR. As discussed in Chapter 6.1, one main difference 
between response to Ex-CMR between healthy volunteers in Chapter 2 and MR 
patients in Chapter 3 was changes in RVEDVi. Additionally, in Chapter 4 both 
surgical groups demonstrated significantly poorer baseline RVEF to the less 
symptomatic control group and post MVr patients demonstrated greater residual 
MR vs MVR patients and poorer follow-up RVEF (compared with controls). Yet 
comparable follow up RVEF was found between the MVR and control groups, 
additionally suggesting a causal link between MR severity and RVEF. Therefore 
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changes in RV size/function, as assessed by CMR, may be a precursor to 
symptom development/deterioration in primary MR patients. This is not a novel 
appreciation, with prior exercise TTE studies (87) demonstrating the prognostic 
importance of the right ventricle. Indeed, deterioration in RV size and function is 
partly mediated by pulmonary hypertension (377) and current guidelines advise 
considering early intervention in asymptomatic patients with PASP>50mmHg (1, 
39). Given CMR offers reference standard assessment of the right ventricle and 
TTE assessment of PASP is reliant on an accurate Doppler tracing not achievable 
in every patient, then CMR assessment of RV function could form an important role 
in future prognostic assessment of MR patients, alongside the assessment of LV 
size/function and MR quantification. Further research using CMR to accurately 
assess the prognostic insight that changes in right ventricular size/function 
provides over time and during Ex-CMR are now required. 




Chapter 7 Thesis conclusion 
Mitral regurgitation is a heterogeneous disease with multiple aetiologies and 
variables that effect prognosis and outcomes post-surgery/intervention. Accuracy 
of investigations guiding management decisions and assessing research outcomes 
is therefore essential. CMR is the reference standard for biventricular assessment 
and offers superior reproducibility of MR quantification to TTE and therefore ideal 
to supplement echocardiography to optimise decision making and assess cardiac 
reverse remodelling research outcomes. In borderline cases, performing exercise 
cardiac imaging can provide additional prognostic information. Ex-CMR has 
developed over the past 3 decades as an option to combine the superior image 
quality of CMR with the preferred method of stress. However, imaging during 
continuous Ex-CMR comes with numerous challenges. With increasing exercise 
intensity, physical motion, respiratory motion and ECG gating artefacts increase, 
making image acquisition and analysis more difficult. The use of un-gated real-time 
techniques overcomes this issue, but requires prolonged analysis time, specialist 
sequences and software, reducing routine clinical utility. Within this body of work, 
an Ex-CMR technique utilizing vendor provided C-SENSE pulse sequences with 
retrospective cardiac gating and respiratory navigation, commercially available 
equipment and software to assess biventricular volumes and great vessel flow was 
developed and validated in healthy volunteers. Feasibility of the developed Ex-
CMR protocol was subsequently proven in primary MR patients, demonstrating 
good/excellent reproducibility and that decreasing MR in this cohort allowed 
augmentation of effective forward LVEF. The technique now warrants further 
research to assess its prognostic ability in primary MR patients and feasibility in 
other valve diseases and congenital heart disease.  
In primary MR patients, on sequential CMR, no significant difference in LV reverse 
remodelling was found post MVr vs MVR with chordal preservation. However, MVR 
resulted in superior RVEF (compared with controls) and less residual MR. 
Therefore, MVR may offer comparable cardiac reverse remodelling to MVr. Given 
MVr is advised first line whenever feasible, larger, multicentre research is now 
warranted, to assess whether the guidance can be downgraded to allow direct 
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replacements of more complex pathologies, reducing surgical times, without 
necessarily adversely impacting reverse remodelling. When primary MR patients 
are deemed too high risk for surgery, percutaneous mitral valve intervention is a 
useful treatment option, where achieving good technical success offers a reduction 
in MR, left ventricular reverse remodelling, improved RV function and functional 
status.  
 
7.1 Future directions 
In addition to the future applications of the work presented throughout this thesis, 
further studies and developments are required to progress CMR and Ex-CMR as a 
clinical and research tool in the assessment of primary MR patients. These 
potential future developments will be discussed below and possible future studies 
indicated directly from the body of work in this thesis shall be discussed in section 
7.1.1. 
CMR has developed as a useful adjunct to assess MR severity in borderline cases 
or where there is uncertainty of MR severity after TTE assessment. Although MR 
quantification by CMR has demonstrated superior prognostic ability to TTE (63, 
64), limited studies determining how to accurately grade MR severity by CMR have 
been performed. Therefore, further studies to define MR severity by CMR MR 
quantification are required to improve the clinical utility of CMR across the entire 
MR severity spectrum. Once such studies have been completed and MR severity 
definitions by CMR are clearer a randomised TTE vs CMR guided 
surgery/intervention study may prove beneficial. Given the results highlighted in 
two studies by Urestky et al, demonstrated only 32-37% of patients undergoing 
mitral valve surgery for TTE defined significant MR had severe MR by CMR 
assessment (59, 72) and prior prospective observational studies demonstrated 
superior prognostic ability via CMR vs TTE (63, 64), then CMR MR severity 
assessment may better guide the need for surgical intervention. 
4D Flow CMR refers to PCMR with flow-encoding in all three spatial directions, 
resolved relative to all three dimensions of space and to the dimension of time 
along the cardiac cycle (378). It allows dynamic visualization of flow in multiple 
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orientations and accurate and reproducible quantification of MR using the 
retrospective valve tracking method. The technique potentially allows more 
accurate direct quantification of MR compared with 2D PCMR sequences, 
especially in MR jets that change direction and shape significantly during systole, 
which occur more commonly in primary MR (379). Further research is required to 
assess whether 4D-flow MR quantification provides additional/superior prognostic 
information to standard 2D PCMR techniques, but the technique demonstrates 
significant promise. The recent demonstration of feasibility of 4D flow assessment 
during supine Ex-CMR is exciting (300). Technological developments to hasten 
acquisition times and further research assessing feasibility in patients with MR are 
required to assess the potential clinical utility of the technique. 
 
7.1.1 Potential future studies 
Based on the body of work presented in this thesis, several future studies could 
progress the field of CMR and Ex-CMR in the optimal management of primary MR 
patients.  
Future Ex-CMR studies are required to build upon the feasibility studies presented 
in Chapters 2&3. The feasibility of accurate and reproducible assessment of other 
valve diseases and structural heart disease with the validated CS3 Ex-CMR 
protocol is indicated. Insights from Chapters 2&3 suggest the protocol should be 
widely applicable and useful in a wide range of valve diseases and structural heart 
disease. Larger studies to assess the prognostic utility of Ex-CMR in primary MR 
patients are indicated. The additional prognostic information exercise-TTE affords 
over resting TTE suggests Ex-CMR may become a useful prognostic tool in the 
future. Ex-CMR could potentially identify primary MR patients who benefit from 
early surgical intervention, thus justifying intervention before cardiac 
decompensation, reducing peri-operative risks and improving long term clinical 
outcomes. As such, future studies are indicated performed in the following order if 
positive results in the initial studies: 
1. Larger Ex-CMR studies assessing prognostic ability of the CS3 Ex-CMR 
protocol in primary MR patients, with the performance of baseline Ex-CMR 
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and observation for outcomes including development of symptoms or need 
for mitral valve surgery. 
2. Exercise-TTE vs Ex-CMR observational studies to compare prognostic 
ability and define any prognostic cut offs for clinical use in primary MR 
patients. 
The results presented in Chapter 4 demonstrating equivalent cardiac reverse 
remodelling between MVr and MVR with chordal preservation, but greater residual 
MR post MVr require further studies. If the results are replicated in larger 
multicentre studies, the current guidelines of repair whenever feasible could be 
relaxed, initially to allow direct MVR in elderly patients in whom a tissue MVR 
would last a lifetime or patients with a current indication for anticoagulation. This 
may allow for reduced surgical times, peri-operative risk and at least equivalent 
cardiac reverse remodelling and thus potentially clinical outcomes. As such, future 
studies are indicated to further question superiority between MVr and MVR with 
chordal preservation, performed in the following order if positive results in the initial 
studies: 
1. Multicentre studies comparing MVr vs MVR with chordal preservation in 
primary MR patients, using CMR to assess remodelling and prolonged 
follow up to assess clinical outcomes.  
2. Randomised control trials comparing MVr vs MVR with chordal preservation 
with recruitment criteria defined by prior multi-centre studies.   
Finally, the use and variety of percutaneous interventions to treat primary MR is 
increasing. As demonstrated in the differing results between MITRA-FR and 
COAPT trials, careful patient selection is vital to ensure optimal outcomes (145-
147). As shown in Chapter 5, percutaneous mitral valve intervention can result in a 
reduction in MR and positive cardiac reverse remodelling. Further research 
assessing predictors of favourable outcomes and compare the varying and 
emerging percutaneous interventions are required to help guide patient selection 
and optimal patient management. CMR is a vital tool in future studies due to the 
multiple benefits in MR and biventricular assessment presented throughout this 
thesis. As often smaller improvements are seen post percutaneous than surgical 
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intervention and are performed in older populations with greater co-morbidities and 
thus confounding variables. As such future comparative percutaneous studies 
require an imaging modality with excellent reproducibility/accuracy to highlight 
differences between treatments.  
With further research, CMR and Ex-CMR has the potential to significantly improve 
patient selection for early intervention, guide optimal surgical management 
strategies and therefore improve long term outcomes and quality of life in patients 
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